pmid
stringlengths 5
8
| title
stringlengths 17
342
| abstract
stringlengths 1
4.53k
| all_entity_list
listlengths 2
73
| label
sequencelengths 1
80
| intra-sentence
sequencelengths 1
80
| head_gene_entity
listlengths 1
80
| tail_diease_entity
listlengths 1
80
| head_name
sequencelengths 1
80
| tail_name
sequencelengths 1
80
|
|---|---|---|---|---|---|---|---|---|---|
10022417 | The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. | Detailed endocrinological studies were performed in the three affected kindred of a family carrying mutations of the GnRH receptor gene. All three were compound heterozygotes carrying on one allele the Arg262Gln mutation and on the other allele two mutations (Gln106Arg and Ser217Arg). When expressed in heterologous cells, both Gln106Arg and Ser217Arg mutations altered hormone binding, whereas the Arg262Gln mutation altered activation of phospholipase C. The propositus, a 30-yr-old man, displayed complete idiopathic hypogonadotropic hypogonadism with extremely low plasma levels of gonadotropins, absence of pulsatility of endogenous LH and alpha-subunit, absence of response to GnRH and GnRH agonist (triptorelin), and absence of effect of pulsatile administration of GnRH. The two sisters, 24 and 18 yr old, of the propositus displayed, on the contrary, only partial idiopathic hypogonadotropic hypogonadism. They both had primary amenorrhea, and the younger sister displayed retarded bone maturation and uterus development, but both sisters had normal breast development. Gonadotropin concentrations were normal or low, but in both cases were restored to normal levels by a single injection of GnRH. In the two sisters, there were no spontaneous pulses of LH, but pulsatile administration of GnRH provoked a pulsatile secretion of LH in the younger sister. The same mutations of the GnRH receptor gene may thus determine different degrees of alteration of gonadotropin function in affected kindred of the same family. | [
{
"begin_idx": "640",
"end_idx": "689",
"entity_id": "C562785",
"entity_type": "Disease",
"text_name": "complete idiopathic hypogonadotropic hypogonadism"
},
{
"begin_idx": "1013",
"end_idx": "1053",
"entity_id": "C562785",
"entity_type": "Disease",
"text_name": "idiopathic hypogonadotropic hypogonadism"
},
{
"begin_idx": "1077",
"end_idx": "1087",
"entity_id": "D000568",
"entity_type": "Disease",
"text_name": "amenorrhea"
},
{
"begin_idx": "105",
"end_idx": "117",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "hypogonadism"
},
{
"begin_idx": "34",
"end_idx": "73",
"entity_id": "2798",
"entity_type": "Gene",
"text_name": "gonadotropin-releasing hormone receptor"
},
{
"begin_idx": "256",
"end_idx": "269",
"entity_id": "2798",
"entity_type": "Gene",
"text_name": "GnRH receptor"
},
{
"begin_idx": "1530",
"end_idx": "1543",
"entity_id": "2798",
"entity_type": "Gene",
"text_name": "GnRH receptor"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "34",
"end_idx": "73",
"entity_id": "2798",
"entity_type": "Gene",
"text_name": "gonadotropin-releasing hormone receptor"
},
{
"begin_idx": "1530",
"end_idx": "1543",
"entity_id": "2798",
"entity_type": "Gene",
"text_name": "GnRH receptor"
}
] | [
{
"begin_idx": "640",
"end_idx": "689",
"entity_id": "C562785",
"entity_type": "Disease",
"text_name": "complete idiopathic hypogonadotropic hypogonadism"
},
{
"begin_idx": "105",
"end_idx": "117",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "hypogonadism"
}
] | [
"gonadotropin-releasing hormone receptor",
"GnRH receptor"
] | [
"complete idiopathic hypogonadotropic hypogonadism",
"hypogonadism"
] |
10022458 | Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively. | We have characterized two different mutations of the human androgen receptor (hAR) found in two unrelated subjects with androgen insensitivity syndrome (AIS): in one, the external genitalia were ambiguous (partial, PAIS); in the other, they were male, but small (mild, MAIS). Single base substitutions have been found in both individuals: E772A in the PAIS subject, and R871G in the MAIS patient. In COS-1 cells transfected with the E772A and R871G hARs, the apparent equilibrium dissociation constants (Kd) for mibolerone (MB) and methyltrienolone are normal. Nonetheless, the mutant hAR from the PAIS subject (E772A) has elevated nonequilibrium dissociation rate constants (k(diss)) for both androgens. In contrast, the MAIS subject's hAR (R871G) has k(diss) values that are apparently normal for MB and methyltrienolone; in addition, the R871G hAR's ability to bind MB resists thermal stress better than the hAR from the PAIS subject. The E772A and R871G hARs, therefore, confer the same pattern of discordant androgen-binding parameters in transfected COS-1 cells as observed previously in the subjects' genital skin fibroblasts. This proves their pathogenicity and correlates with the relative severity of the clinical phenotype. In COS-1 cells transfected with an androgen-responsive reporter gene, trans-activation was 50% of normal in cells containing either mutant hAR. However, mutant hAR-MB binding is unstable during prolonged incubation with MB, whereas normal hAR-MB binding increases. Thus, normal equilibrium dissociation constants alone, as determined by Scatchard analysis, may not be indicative of normal hAR function. An increased k(diss) despite a normal Kd for a given androgen suggests that it not only has increased egress from a mutant ligand-binding pocket, but also increased access to it. This hypothesis has certain implications in terms of the three-dimensional model of the ligand-binding domain of the nuclear receptor superfamily. | [
{
"begin_idx": "264",
"end_idx": "295",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
},
{
"begin_idx": "297",
"end_idx": "300",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "AIS"
},
{
"begin_idx": "222",
"end_idx": "225",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "729",
"end_idx": "732",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "881",
"end_idx": "884",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "991",
"end_idx": "994",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "1055",
"end_idx": "1058",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "1518",
"end_idx": "1521",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "1539",
"end_idx": "1542",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "1618",
"end_idx": "1621",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "1768",
"end_idx": "1771",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "203",
"end_idx": "220",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "593",
"end_idx": "597",
"entity_id": "6012",
"entity_type": "Gene",
"text_name": "hARs"
},
{
"begin_idx": "1102",
"end_idx": "1106",
"entity_id": "6012",
"entity_type": "Gene",
"text_name": "hARs"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "203",
"end_idx": "220",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "1768",
"end_idx": "1771",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
}
] | [
{
"begin_idx": "264",
"end_idx": "295",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
},
{
"begin_idx": "264",
"end_idx": "295",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
}
] | [
"androgen receptor",
"hAR"
] | [
"androgen insensitivity syndrome",
"androgen insensitivity syndrome"
] |
10022756 | The *NAT2 slow acetylator genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population. | [
{
"begin_idx": "54",
"end_idx": "68",
"entity_id": "D001749",
"entity_type": "Disease",
"text_name": "bladder cancer"
},
{
"begin_idx": "104",
"end_idx": "116",
"entity_id": "D005534",
"entity_type": "Disease",
"text_name": "Foot Disease"
},
{
"begin_idx": "4",
"end_idx": "8",
"entity_id": "10",
"entity_type": "Gene",
"text_name": "NAT2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "4",
"end_idx": "8",
"entity_id": "10",
"entity_type": "Gene",
"text_name": "NAT2"
},
{
"begin_idx": "4",
"end_idx": "8",
"entity_id": "10",
"entity_type": "Gene",
"text_name": "NAT2"
}
] | [
{
"begin_idx": "54",
"end_idx": "68",
"entity_id": "D001749",
"entity_type": "Disease",
"text_name": "bladder cancer"
},
{
"begin_idx": "104",
"end_idx": "116",
"entity_id": "D005534",
"entity_type": "Disease",
"text_name": "Foot Disease"
}
] | [
"NAT2",
"NAT2"
] | [
"bladder cancer",
"Foot Disease"
] |
|
10024302 | Genomic organization of the KCNQ1 K+ channel gene and identification of C-terminal mutations in the long-QT syndrome. | The voltage-gated K+ channel KVLQT1 is essential for the repolarization phase of the cardiac action potential and for K+ homeostasis in the inner ear. Mutations in the human KCNQ1 gene encoding the alpha subunit of the KVLQT1 channel cause the long-QT syndrome (LQTS). The autosomal dominant form of this cardiac disease, the Romano-Ward syndrome, is characterized by a prolongation of the QT interval, ventricular arrhythmias, and sudden death. The autosomal recessive form, the Jervell and Lange-Nielsen syndrome, also includes bilateral deafness. In the present study, we report the entire genomic structure of KCNQ1, which consists of 19 exons spanning 400 kb on chromosome 11p15.5. We describe the sequences of exon-intron boundaries and oligonucleotide primers that allow polymerase chain reaction (PCR) amplification of exons from genomic DNA. Two new (CA)n repeat microsatellites were found in introns 10 and 14. The present study provides helpful tools for the linkage analysis and mutation screening of the complete KCNQ1 gene. By use of these tools, five novel mutations were identified in LQTS patients by PCR-single-strand conformational polymorphism (SSCP) analysis in the C-terminal part of KCNQ1: two missense mutations, a 20-bp and 1-bp deletions, and a 1-bp insertion. Such mutations in the C-terminal domain of the gene may be more frequent than previously expected, because this region has not been analyzed so far. This could explain the low percentage of mutations found in large LQTS cohorts. | [
{
"begin_idx": "521",
"end_idx": "544",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "ventricular arrhythmias"
},
{
"begin_idx": "648",
"end_idx": "666",
"entity_id": "D003638",
"entity_type": "Disease",
"text_name": "bilateral deafness"
},
{
"begin_idx": "550",
"end_idx": "562",
"entity_id": "D003645",
"entity_type": "Disease",
"text_name": "sudden death"
},
{
"begin_idx": "423",
"end_idx": "438",
"entity_id": "D006331",
"entity_type": "Disease",
"text_name": "cardiac disease"
},
{
"begin_idx": "100",
"end_idx": "116",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long-QT syndrome"
},
{
"begin_idx": "362",
"end_idx": "378",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long-QT syndrome"
},
{
"begin_idx": "380",
"end_idx": "384",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "1219",
"end_idx": "1223",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "1620",
"end_idx": "1624",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "610",
"end_idx": "632",
"entity_id": "D029593",
"entity_type": "Disease",
"text_name": "Lange-Nielsen syndrome"
},
{
"begin_idx": "444",
"end_idx": "464",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "Romano-Ward syndrome"
},
{
"begin_idx": "122",
"end_idx": "146",
"entity_id": "3752",
"entity_type": "Gene",
"text_name": "voltage-gated K+ channel"
},
{
"begin_idx": "28",
"end_idx": "33",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
},
{
"begin_idx": "147",
"end_idx": "153",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "292",
"end_idx": "297",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
},
{
"begin_idx": "337",
"end_idx": "343",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "732",
"end_idx": "737",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
},
{
"begin_idx": "1144",
"end_idx": "1149",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
},
{
"begin_idx": "1324",
"end_idx": "1329",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "147",
"end_idx": "153",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "732",
"end_idx": "737",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
}
] | [
{
"begin_idx": "444",
"end_idx": "464",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "Romano-Ward syndrome"
},
{
"begin_idx": "100",
"end_idx": "116",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long-QT syndrome"
}
] | [
"KVLQT1",
"KCNQ1"
] | [
"Romano-Ward syndrome",
"long-QT syndrome"
] |
10025794 | Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. | OBJECTIVE: To investigate whether polymorphisms in the interleukin (IL)-1beta and IL-1 receptor antagonist (IL-1RA) genes are associated with both susceptibility to and clinical characteristics of MS. BACKGROUND: Genetic susceptibility to MS is determined by many partially identified genes. The genes encoding various cytokines are logical candidates for MS susceptibility and phenotype. METHODS: Genotypes were determined from 148 patients with clinically definite MS and 98 healthy controls. All the patients were unrelated, Dutch, and white. Patient files were reviewed for disease type, initial symptoms, age at onset of disease, and rate of disease progression. RESULTS: No significant differences in genotypes, allele frequencies, or carrier frequencies were found between MS patients and healthy controls. Stratification for disease type (relapsing-remitting, primary progressive, or secondary progressive) did not provide significant differences between patients and controls. However, a specific IL-1RA/IL-1beta combination was associated with disease severity. MS patients with the IL-1RA allele 2+/IL-1beta allele 2- combination had a higher rate of progression on the Expanded Disability Status Scale when compared with the other possible combinations (p = 0.007). CONCLUSIONS: IL-1RA and IL-1beta are disease severity genes rather than disease susceptibility genes. Furthermore, these gene polymorphisms may define subgroups of patients with a worse prognosis. | [
{
"begin_idx": "102",
"end_idx": "104",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "303",
"end_idx": "305",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "345",
"end_idx": "347",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "462",
"end_idx": "464",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "573",
"end_idx": "575",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "886",
"end_idx": "888",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1178",
"end_idx": "1180",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "15",
"end_idx": "32",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin-1beta"
},
{
"begin_idx": "161",
"end_idx": "183",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin (IL)-1beta"
},
{
"begin_idx": "1119",
"end_idx": "1127",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "IL-1beta"
},
{
"begin_idx": "1216",
"end_idx": "1224",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "IL-1beta"
},
{
"begin_idx": "1408",
"end_idx": "1416",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "IL-1beta"
},
{
"begin_idx": "188",
"end_idx": "212",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1 receptor antagonist"
},
{
"begin_idx": "214",
"end_idx": "220",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RA"
},
{
"begin_idx": "1112",
"end_idx": "1118",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RA"
},
{
"begin_idx": "1199",
"end_idx": "1205",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RA"
},
{
"begin_idx": "1397",
"end_idx": "1403",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RA"
}
] | [
"Yes",
"Yes"
] | [
true,
true
] | [
{
"begin_idx": "161",
"end_idx": "183",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin (IL)-1beta"
},
{
"begin_idx": "188",
"end_idx": "212",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1 receptor antagonist"
}
] | [
{
"begin_idx": "102",
"end_idx": "104",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "102",
"end_idx": "104",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
}
] | [
"interleukin (IL)-1beta",
"IL-1 receptor antagonist"
] | [
"MS",
"MS"
] |
10027593 | UKPDS 31: Hepatocyte nuclear factor-1alpha (the MODY3 gene) mutations in late onset Type II diabetic patients in the United Kingdom. United Kingdom prospective diabetes study. | [
{
"begin_idx": "160",
"end_idx": "168",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "84",
"end_idx": "100",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetic"
},
{
"begin_idx": "48",
"end_idx": "53",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "MODY3"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "48",
"end_idx": "53",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "MODY3"
},
{
"begin_idx": "48",
"end_idx": "53",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "MODY3"
}
] | [
{
"begin_idx": "84",
"end_idx": "100",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetic"
},
{
"begin_idx": "160",
"end_idx": "168",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
}
] | [
"MODY3",
"MODY3"
] | [
"Type II diabetic",
"diabetes"
] |
|
10027710 | Identification of a novel mutation in a non-Jewish factor XI deficient kindred. | The role of factor XI (FXI) in blood coagulation has been clarified in recent years by descriptions of FXI-deficient patients who are prone to excessive bleeding after haemostatic challenge. We have studied a large kindred of an Italian FXI-deficient patient with a previously undescribed mutation. The propositus, a 68-year-old woman, presented with a cerebral thromboembolic event but had no history of bleeding (FXI activity 1.6 U/dl). A sensitive ELISA failed to detect FXI antigen in the propositus. Sequence analysis of the entire FXI gene revealed a TGG to TGC transversion in codon 228 of exon 7 (FXI-W228C). This missense mutation results in a Trp to Cys substitution within the third apple domain of FXI. We conclude that this novel mutation occurred in a structurally conserved region and may therefore have interfered with either chain folding and secretion or stability of FXI and was responsible for the inherited abnormality seen in this kindred. It is unclear why this kindred does not exhibit a bleeding tendency but it may correlate with a FXI-like antigen and factor IX binding activity expressed on platelets. | [
{
"begin_idx": "111",
"end_idx": "128",
"entity_id": "D001778",
"entity_type": "Disease",
"text_name": "blood coagulation"
},
{
"begin_idx": "51",
"end_idx": "70",
"entity_id": "D005173",
"entity_type": "Disease",
"text_name": "factor XI deficient"
},
{
"begin_idx": "183",
"end_idx": "196",
"entity_id": "D005173",
"entity_type": "Disease",
"text_name": "FXI-deficient"
},
{
"begin_idx": "309",
"end_idx": "330",
"entity_id": "D005173",
"entity_type": "Disease",
"text_name": "Italian FXI-deficient"
},
{
"begin_idx": "233",
"end_idx": "241",
"entity_id": "D006470",
"entity_type": "Disease",
"text_name": "bleeding"
},
{
"begin_idx": "485",
"end_idx": "493",
"entity_id": "D006470",
"entity_type": "Disease",
"text_name": "bleeding"
},
{
"begin_idx": "1092",
"end_idx": "1100",
"entity_id": "D006470",
"entity_type": "Disease",
"text_name": "bleeding"
},
{
"begin_idx": "442",
"end_idx": "456",
"entity_id": "D013923",
"entity_type": "Disease",
"text_name": "thromboembolic"
},
{
"begin_idx": "998",
"end_idx": "1019",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited abnormality"
},
{
"begin_idx": "92",
"end_idx": "101",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "factor XI"
},
{
"begin_idx": "103",
"end_idx": "106",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "495",
"end_idx": "498",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "554",
"end_idx": "557",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "617",
"end_idx": "620",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "685",
"end_idx": "688",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "790",
"end_idx": "793",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "966",
"end_idx": "969",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
},
{
"begin_idx": "1138",
"end_idx": "1141",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "92",
"end_idx": "101",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "factor XI"
},
{
"begin_idx": "617",
"end_idx": "620",
"entity_id": "2160",
"entity_type": "Gene",
"text_name": "FXI"
}
] | [
{
"begin_idx": "309",
"end_idx": "330",
"entity_id": "D005173",
"entity_type": "Disease",
"text_name": "Italian FXI-deficient"
},
{
"begin_idx": "1092",
"end_idx": "1100",
"entity_id": "D006470",
"entity_type": "Disease",
"text_name": "bleeding"
}
] | [
"factor XI",
"FXI"
] | [
"Italian FXI-deficient",
"bleeding"
] |
10029606 | Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. | X-linked sideroblastic anemia (XLSA) in four unrelated male probands was caused by missense mutations in the erythroid-specific 5-aminolevulinate synthase gene (ALAS2). All were new mutations: T647C, C1283T, G1395A, and C1406T predicting amino acid substitutions Y199H, R411C, R448Q, and R452C. All probands were clinically pyridoxine-responsive. The mutation Y199H was shown to be the first de novo XLSA mutation and occurred in a gamete of the proband's maternal grandfather. There was a significantly higher frequency of coinheritance of the hereditary hemochromatosis (HH) HFE mutant allele C282Y in 18 unrelated XLSA hemizygotes than found in the normal population, indicating a role for coinheritance of HFE alleles in the expression of this disorder. One proband (Y199H) with severe and early iron loading coinherited HH as a C282Y homozygote. The clinical and hematologic histories of two XLSA probands suggest that iron overload suppresses pyridoxine responsiveness. Notably, reversal of the iron overload in the Y199H proband by phlebotomy resulted in higher hemoglobin concentrations during pyridoxine supplementation. The proband with the R452C mutation was symptom-free on occasional phlebotomy and daily pyridoxine. These studies indicate the value of combined phlebotomy and pyridoxine supplementation in the management of XLSA probands in order to prevent a downward spiral of iron toxicity and refractory anemia. | [
{
"begin_idx": "93",
"end_idx": "122",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "X-linked sideroblastic anemia"
},
{
"begin_idx": "254",
"end_idx": "283",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "X-linked sideroblastic anemia"
},
{
"begin_idx": "285",
"end_idx": "289",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "XLSA"
},
{
"begin_idx": "654",
"end_idx": "658",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "XLSA"
},
{
"begin_idx": "871",
"end_idx": "875",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "XLSA"
},
{
"begin_idx": "1151",
"end_idx": "1155",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "XLSA"
},
{
"begin_idx": "1592",
"end_idx": "1596",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "XLSA"
},
{
"begin_idx": "1665",
"end_idx": "1682",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "refractory anemia"
},
{
"begin_idx": "226",
"end_idx": "252",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "hereditary hemochromatosis"
},
{
"begin_idx": "799",
"end_idx": "825",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "hereditary hemochromatosis"
},
{
"begin_idx": "827",
"end_idx": "829",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "HH"
},
{
"begin_idx": "1079",
"end_idx": "1081",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "HH"
},
{
"begin_idx": "1647",
"end_idx": "1660",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "iron toxicity"
},
{
"begin_idx": "73",
"end_idx": "78",
"entity_id": "212",
"entity_type": "Gene",
"text_name": "ALAS2"
},
{
"begin_idx": "415",
"end_idx": "420",
"entity_id": "212",
"entity_type": "Gene",
"text_name": "ALAS2"
},
{
"begin_idx": "831",
"end_idx": "834",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
},
{
"begin_idx": "964",
"end_idx": "967",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "73",
"end_idx": "78",
"entity_id": "212",
"entity_type": "Gene",
"text_name": "ALAS2"
},
{
"begin_idx": "831",
"end_idx": "834",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
}
] | [
{
"begin_idx": "93",
"end_idx": "122",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "X-linked sideroblastic anemia"
},
{
"begin_idx": "871",
"end_idx": "875",
"entity_id": "C536761",
"entity_type": "Disease",
"text_name": "XLSA"
}
] | [
"ALAS2",
"HFE"
] | [
"X-linked sideroblastic anemia",
"XLSA"
] |
10036316 | Maroteaux-lamy syndrome: five novel mutations and their structural localization. | Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI, MPS VI) is an autosomal recessive disorder due to the deficiency of the lysosomal enzyme N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ASB). Mutation analysis in Maroteaux-Lamy syndrome resulted in the identification of approximately 40 molecular defects underlying a great genetic heterogeneity. Here we report five novel mutations in Italian subjects: S65F, P116H, R315Q, Q503X, P531R; each defect was confirmed by restriction enzyme or amplification refractory mutation system (ARMS) analysis. We also performed a three-dimensional (3-D) structure analysis of the alterations identified by us, and of an additional 22 point mutations reported by other groups, in an attempt to draw helpful information about their possible effects on protein conformation. | [
{
"begin_idx": "0",
"end_idx": "23",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "Maroteaux-lamy syndrome"
},
{
"begin_idx": "81",
"end_idx": "104",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "Maroteaux-Lamy syndrome"
},
{
"begin_idx": "106",
"end_idx": "135",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis type VI"
},
{
"begin_idx": "137",
"end_idx": "143",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "MPS VI"
},
{
"begin_idx": "305",
"end_idx": "328",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "Maroteaux-Lamy syndrome"
},
{
"begin_idx": "151",
"end_idx": "179",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "582",
"end_idx": "622",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "amplification refractory mutation system"
},
{
"begin_idx": "624",
"end_idx": "628",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "ARMS"
},
{
"begin_idx": "261",
"end_idx": "276",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "arylsulfatase B"
},
{
"begin_idx": "278",
"end_idx": "281",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "261",
"end_idx": "276",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "arylsulfatase B"
},
{
"begin_idx": "278",
"end_idx": "281",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
}
] | [
{
"begin_idx": "106",
"end_idx": "135",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis type VI"
},
{
"begin_idx": "151",
"end_idx": "179",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
}
] | [
"arylsulfatase B",
"ASB"
] | [
"mucopolysaccharidosis type VI",
"autosomal recessive disorder"
] |
10049523 | An interluekin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. | Induction of interleukin 1 activates vascular endothelial and kidney mesangial cells, and increases production of type IV (basement membrane) collagen. Hence, genes within the interleukin 1 gene cluster are potential candidates in the pathogenesis of diabetic nephropathy. In a previously validated case-control study from Northern Ireland, consisting of 95 patients with insulin-dependent (type 1) diabetes and nephropathy (cases) and 96 patients with insulin-dependent (type 1) diabetes without nephropathy (controls), the authors performed PCR-based genotyping of specific DNA polymorphisms within the interleukin 1A, interleukin 1B, interleukin 1 (type 1) receptor and interleukin 1 receptor antagonist genes. The groups were matched for age at onset and duration of diabetes. A statistically significant increase was found in the allele frequency of the interleukin 1B*2 allele in cases compared to controls (chi2=7. 19, df.=1; P=0.007, Pcorr=0.028). The results of this study suggest that the interleukin 1B*2 allele, or a susceptibility factor in linkage disequilibrium with this allele, is associated with diabetic nephropathy in the Northern Ireland population. | [
{
"begin_idx": "515",
"end_idx": "523",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "596",
"end_idx": "604",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "887",
"end_idx": "895",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "94",
"end_idx": "114",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "367",
"end_idx": "387",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "1230",
"end_idx": "1250",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "528",
"end_idx": "539",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "nephropathy"
},
{
"begin_idx": "613",
"end_idx": "624",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "nephropathy"
},
{
"begin_idx": "129",
"end_idx": "142",
"entity_id": "3552",
"entity_type": "Gene",
"text_name": "interleukin 1"
},
{
"begin_idx": "292",
"end_idx": "305",
"entity_id": "3552",
"entity_type": "Gene",
"text_name": "interleukin 1"
},
{
"begin_idx": "721",
"end_idx": "811",
"entity_id": "3552",
"entity_type": "Gene",
"text_name": "interleukin 1A, interleukin 1B, interleukin 1 (type 1) receptor and interleukin 1 receptor"
},
{
"begin_idx": "721",
"end_idx": "811",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin 1A, interleukin 1B, interleukin 1 (type 1) receptor and interleukin 1 receptor"
},
{
"begin_idx": "975",
"end_idx": "989",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin 1B"
},
{
"begin_idx": "1115",
"end_idx": "1129",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin 1B"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "721",
"end_idx": "811",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin 1A, interleukin 1B, interleukin 1 (type 1) receptor and interleukin 1 receptor"
},
{
"begin_idx": "292",
"end_idx": "305",
"entity_id": "3552",
"entity_type": "Gene",
"text_name": "interleukin 1"
}
] | [
{
"begin_idx": "94",
"end_idx": "114",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "515",
"end_idx": "523",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
}
] | [
"interleukin 1A, interleukin 1B, interleukin 1 (type 1) receptor and interleukin 1 receptor",
"interleukin 1"
] | [
"diabetic nephropathy",
"diabetes"
] |
10050867 | Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. | BACKGROUND: Most human female cells contain two X chromosomes, only one of which is active. The process of X-chromosome inactivation, which occurs early in development, is usually random, producing tissues with equal mixtures of cells having active X chromosomes of either maternal or paternal origin. However, nonrandom inactivation may occur in a subset of females. If a tumor suppressor gene were located on the X chromosome and if females with a germline mutation in one copy of that suppressor gene experienced nonrandom X-chromosome inactivation, then some or all of the tissues of such women might lack the wild-type suppressor gene function. This scenario could represent a previously unrecognized mechanism for development of hereditary cancers. We investigated whether such a mechanism might contribute to the development of hereditary ovarian cancers. METHODS: Patterns of X-chromosome inactivation were determined by means of polymerase chain reaction amplification of the CAG-nucleotide repeat of the androgen receptor (AR) gene after methylation-sensitive restriction endonuclease digestion of blood mononuclear cell DNA from patients with invasive (n = 213) or borderline (n = 44) ovarian cancer and control subjects without a personal or family history of cancer (n = 50). BRCA1 gene status was determined by means of single-strand conformational polymorphism analysis and DNA sequencing. All statistical tests were two-sided. RESULTS AND CONCLUSIONS: Among individuals informative for the AR locus, nonrandom X-chromosome inactivation was found in the DNA of 53% of those with invasive cancer versus 28% of those with borderline cancer (P = .005) and 33% of healthy control subjects (P = .016). Nonrandom X-chromosome inactivation can be a heritable trait. Nine of 11 AR-informative carriers of germline BRCA1 mutations demonstrated nonrandom X-chromosome inactivation (.0002 < P < .008, for simultaneous occurrence of both). IMPLICATIONS: Nonrandom X-chromosome inactivation may be a predisposing factor for the development of invasive, but not borderline, ovarian cancer. | [
{
"begin_idx": "1718",
"end_idx": "1733",
"entity_id": "D009362",
"entity_type": "Disease",
"text_name": "invasive cancer"
},
{
"begin_idx": "497",
"end_idx": "502",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1396",
"end_idx": "1402",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "1770",
"end_idx": "1776",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "859",
"end_idx": "877",
"entity_id": "D009386",
"entity_type": "Disease",
"text_name": "hereditary cancers"
},
{
"begin_idx": "108",
"end_idx": "122",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "959",
"end_idx": "985",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "hereditary ovarian cancers"
},
{
"begin_idx": "1320",
"end_idx": "1334",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "2199",
"end_idx": "2213",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "1138",
"end_idx": "1155",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "1157",
"end_idx": "1159",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1630",
"end_idx": "1632",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1909",
"end_idx": "1911",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "60",
"end_idx": "65",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1413",
"end_idx": "1418",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1945",
"end_idx": "1950",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "60",
"end_idx": "65",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1413",
"end_idx": "1418",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
}
] | [
{
"begin_idx": "959",
"end_idx": "985",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "hereditary ovarian cancers"
},
{
"begin_idx": "859",
"end_idx": "877",
"entity_id": "D009386",
"entity_type": "Disease",
"text_name": "hereditary cancers"
}
] | [
"BRCA1",
"BRCA1"
] | [
"hereditary ovarian cancers",
"hereditary cancers"
] |
10051017 | A mutation in the RIEG1 gene associated with Peters' anomaly. | Mutations within the RIEG1 homeobox gene on chromosome 4q25 have previously been reported in association with Rieger syndrome. We report a 3' splice site mutation within the 3rd intron of the RIEG1 gene which is associated with unilateral Peters' anomaly. The mutation is a single base substition of A to T at the invariant -2 site of the 3' splice site. Peters' anomaly, which is characterised by ocular anterior segment dysgenesis and central corneal opacification, is distinct from Rieger anomaly. This is the first description of a RIEG1 mutation associated with Peters' anomaly. | [
{
"begin_idx": "172",
"end_idx": "187",
"entity_id": "C535679",
"entity_type": "Disease",
"text_name": "Rieger syndrome"
},
{
"begin_idx": "547",
"end_idx": "561",
"entity_id": "C535679",
"entity_type": "Disease",
"text_name": "Rieger anomaly"
},
{
"begin_idx": "45",
"end_idx": "60",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters' anomaly"
},
{
"begin_idx": "301",
"end_idx": "316",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters' anomaly"
},
{
"begin_idx": "417",
"end_idx": "432",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters' anomaly"
},
{
"begin_idx": "629",
"end_idx": "644",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters' anomaly"
},
{
"begin_idx": "484",
"end_idx": "494",
"entity_id": "D050033",
"entity_type": "Disease",
"text_name": "dysgenesis"
},
{
"begin_idx": "18",
"end_idx": "23",
"entity_id": "5308",
"entity_type": "Gene",
"text_name": "RIEG1"
},
{
"begin_idx": "83",
"end_idx": "88",
"entity_id": "5308",
"entity_type": "Gene",
"text_name": "RIEG1"
},
{
"begin_idx": "254",
"end_idx": "259",
"entity_id": "5308",
"entity_type": "Gene",
"text_name": "RIEG1"
},
{
"begin_idx": "598",
"end_idx": "603",
"entity_id": "5308",
"entity_type": "Gene",
"text_name": "RIEG1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "18",
"end_idx": "23",
"entity_id": "5308",
"entity_type": "Gene",
"text_name": "RIEG1"
},
{
"begin_idx": "83",
"end_idx": "88",
"entity_id": "5308",
"entity_type": "Gene",
"text_name": "RIEG1"
}
] | [
{
"begin_idx": "45",
"end_idx": "60",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters' anomaly"
},
{
"begin_idx": "547",
"end_idx": "561",
"entity_id": "C535679",
"entity_type": "Disease",
"text_name": "Rieger anomaly"
}
] | [
"RIEG1",
"RIEG1"
] | [
"Peters' anomaly",
"Rieger anomaly"
] |
10051160 | Severe Lhermitte-Duclos disease with unique germline mutation of PTEN. | Germline mutations in the PTEN gene have recently been identified in some individuals with Cowden disease (CD), Lhermitte-Duclos disease (LDD), and Bannayan-Zonana syndrome. We report on a patient with CD and LDD in whom a unique de novo germline missense mutation is present in the PTEN gene. Direct sequence analysis detected a transitional change (T-->C) at nucleotide 335, resulting in substitution of the amino acid proline for leucine. The mutation is in exon 5, which has been proposed as a "hot-spot" for germline mutations. Comparison of this patient's clinical course with the previously reported cases of CD and LDD shows more extensive and more severe clinical findings than reported previously. Findings in this patient contribute to the current understanding of germline PTEN mutations and clinical outcome. | [
{
"begin_idx": "7",
"end_idx": "31",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Lhermitte-Duclos disease"
},
{
"begin_idx": "162",
"end_idx": "176",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Cowden disease"
},
{
"begin_idx": "178",
"end_idx": "180",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "183",
"end_idx": "207",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Lhermitte-Duclos disease"
},
{
"begin_idx": "209",
"end_idx": "212",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "LDD"
},
{
"begin_idx": "219",
"end_idx": "243",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Bannayan-Zonana syndrome"
},
{
"begin_idx": "273",
"end_idx": "275",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "280",
"end_idx": "283",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "LDD"
},
{
"begin_idx": "687",
"end_idx": "689",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "694",
"end_idx": "697",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "LDD"
},
{
"begin_idx": "65",
"end_idx": "69",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "97",
"end_idx": "101",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "354",
"end_idx": "358",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "856",
"end_idx": "860",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "65",
"end_idx": "69",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
}
] | [
{
"begin_idx": "7",
"end_idx": "31",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Lhermitte-Duclos disease"
}
] | [
"PTEN"
] | [
"Lhermitte-Duclos disease"
] |
10051604 | Human PEX19: cDNA cloning by functional complementation, mutation analysis in a patient with Zellweger syndrome, and potential role in peroxisomal membrane assembly. | At least 11 complementation groups (CGs) have been identified for the peroxisome biogenesis disorders (PBDs) such as Zellweger syndrome, for which seven pathogenic genes have been elucidated. We have isolated a human PEX19 cDNA (HsPEX19) by functional complementation of peroxisome deficiency of a mutant Chinese hamster ovary cell line, ZP119, defective in import of both matrix and membrane proteins. This cDNA encodes a hydrophilic protein (Pex19p) comprising 299 amino acids, with a prenylation motif, CAAX box, at the C terminus. Farnesylated Pex19p is partly, if not all, anchored in the peroxisomal membrane, exposing its N-terminal part to the cytosol. A stable transformant of ZP119 with HsPEX19 was morphologically and biochemically restored for peroxisome biogenesis. HsPEX19 expression also restored peroxisomal protein import in fibroblasts from a patient (PBDJ-01) with Zellweger syndrome of CG-J. This patient (PBDJ-01) possessed a homozygous, inactivating mutation: a 1-base insertion, A764, in a codon for Met255, resulted in a frameshift, inducing a 24-aa sequence entirely distinct from normal Pex19p. These results demonstrate that PEX19 is the causative gene for CG-J PBD and suggest that the C-terminal part, including the CAAX homology box, is required for the biological function of Pex19p. Moreover, Pex19p is apparently involved at the initial stage in peroxisome membrane assembly, before the import of matrix protein. | [
{
"begin_idx": "93",
"end_idx": "111",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "283",
"end_idx": "301",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "1050",
"end_idx": "1068",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "236",
"end_idx": "267",
"entity_id": "D018901",
"entity_type": "Disease",
"text_name": "peroxisome biogenesis disorders"
},
{
"begin_idx": "269",
"end_idx": "273",
"entity_id": "D018901",
"entity_type": "Disease",
"text_name": "PBDs"
},
{
"begin_idx": "437",
"end_idx": "458",
"entity_id": "D018901",
"entity_type": "Disease",
"text_name": "peroxisome deficiency"
},
{
"begin_idx": "6",
"end_idx": "11",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "PEX19"
},
{
"begin_idx": "383",
"end_idx": "388",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "PEX19"
},
{
"begin_idx": "610",
"end_idx": "616",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
},
{
"begin_idx": "714",
"end_idx": "720",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
},
{
"begin_idx": "1279",
"end_idx": "1285",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
},
{
"begin_idx": "1318",
"end_idx": "1323",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "PEX19"
},
{
"begin_idx": "1473",
"end_idx": "1479",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
},
{
"begin_idx": "1491",
"end_idx": "1497",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "610",
"end_idx": "616",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
},
{
"begin_idx": "1491",
"end_idx": "1497",
"entity_id": "5824",
"entity_type": "Gene",
"text_name": "Pex19p"
}
] | [
{
"begin_idx": "93",
"end_idx": "111",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "236",
"end_idx": "267",
"entity_id": "D018901",
"entity_type": "Disease",
"text_name": "peroxisome biogenesis disorders"
}
] | [
"Pex19p",
"Pex19p"
] | [
"Zellweger syndrome",
"peroxisome biogenesis disorders"
] |
10053004 | Human molybdopterin synthase gene: genomic structure and mutations in molybdenum cofactor deficiency type B. | Biosynthesis of the molybdenum cofactor (MoCo) can be divided into (1) the formation of a precursor and (2) the latter's subsequent conversion, by molybdopterin synthase, into the organic moiety of MoCo. These two steps are reflected by the complementation groups A and B and the two formally distinguished types of MoCo deficiency that have an identical phenotype. Both types of MoCo deficiency result in a pleiotropic loss of all molybdoenzyme activities and cause severe neurological damage. MOCS1 is defective in patients with group A deficiency and has been shown to encode two enzymes for early synthesis via a bicistronic transcript with two consecutive open reading frames (ORFs). MOCS2 encodes the small and large subunits of molybdopterin synthase via a single transcript with two overlapping reading frames. This gene was mapped to 5q and comprises seven exons. The coding sequence and all splice site-junction sequences were screened for mutations, in MoCo-deficient patients in whom a previous search for MOCS1 mutations had been negative. In seven of the eight patients whom we investigated, we identified MOCS2 mutations that, by their nature, are most likely responsible for the deficiency. Three different frameshift mutations were observed, with one of them found on 7 of 14 identified alleles. Furthermore, a start-codon mutation and a missense mutation of a highly conserved amino acid residue were found. The locations of the mutations confirm the functional role of both ORFs. One of the patients with identified MOCS2 mutations had been classified as type B, in complementation studies. These findings support the hypothetical mechanism, for both forms of MoCo deficiency, that formerly had been established by cell-culture experiments. | [
{
"begin_idx": "416",
"end_idx": "440",
"entity_id": "C535811",
"entity_type": "Disease",
"text_name": "types of MoCo deficiency"
},
{
"begin_idx": "480",
"end_idx": "504",
"entity_id": "C535811",
"entity_type": "Disease",
"text_name": "types of MoCo deficiency"
},
{
"begin_idx": "1073",
"end_idx": "1087",
"entity_id": "C535811",
"entity_type": "Disease",
"text_name": "MoCo-deficient"
},
{
"begin_idx": "1788",
"end_idx": "1803",
"entity_id": "C535811",
"entity_type": "Disease",
"text_name": "MoCo deficiency"
},
{
"begin_idx": "81",
"end_idx": "107",
"entity_id": "C565373",
"entity_type": "Disease",
"text_name": "cofactor deficiency type B"
},
{
"begin_idx": "583",
"end_idx": "602",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neurological damage"
},
{
"begin_idx": "604",
"end_idx": "609",
"entity_id": "4337",
"entity_type": "Gene",
"text_name": "MOCS1"
},
{
"begin_idx": "1127",
"end_idx": "1132",
"entity_id": "4337",
"entity_type": "Gene",
"text_name": "MOCS1"
},
{
"begin_idx": "798",
"end_idx": "803",
"entity_id": "4338",
"entity_type": "Gene",
"text_name": "MOCS2"
},
{
"begin_idx": "1229",
"end_idx": "1234",
"entity_id": "4338",
"entity_type": "Gene",
"text_name": "MOCS2"
},
{
"begin_idx": "1644",
"end_idx": "1649",
"entity_id": "4338",
"entity_type": "Gene",
"text_name": "MOCS2"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "798",
"end_idx": "803",
"entity_id": "4338",
"entity_type": "Gene",
"text_name": "MOCS2"
},
{
"begin_idx": "798",
"end_idx": "803",
"entity_id": "4338",
"entity_type": "Gene",
"text_name": "MOCS2"
}
] | [
{
"begin_idx": "81",
"end_idx": "107",
"entity_id": "C565373",
"entity_type": "Disease",
"text_name": "cofactor deficiency type B"
},
{
"begin_idx": "1073",
"end_idx": "1087",
"entity_id": "C535811",
"entity_type": "Disease",
"text_name": "MoCo-deficient"
}
] | [
"MOCS2",
"MOCS2"
] | [
"cofactor deficiency type B",
"MoCo-deficient"
] |
10053008 | Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. | Dubin-Johnson syndrome (DJS) is an autosomal recessive disease characterized by conjugated hyperbilirubinemia. Previous studies of the defects in the human canalicular multispecific organic anion transporter gene (MRP2/cMOAT) in patients with DJS have suggested that the gene defects are responsible for DJS. In this study, we determined the exon/intron structure of the human MRP2/cMOAT gene and further characterized mutations in patients with DJS. The human MRP2/cMOAT gene contains 32 exons, and it has a structure that is highly conserved with that of another ATP-binding-cassette gene, that for a multidrug resistance-associated protein. We then identified three mutations, including two novel ones. All mutations identified to date are in the cytoplasmic domain, which includes the two ATP-binding cassettes and the linker region, or adjacent putative transmembrane domain. Our results confirm that MRP2/cMOAT is the gene responsible for DJS. The finding that mutations are concentrated in the first ATP-binding-cassette domain strongly suggests that a disruption of this region is a critical route to loss of function. | [
{
"begin_idx": "262",
"end_idx": "280",
"entity_id": "D006932",
"entity_type": "Disease",
"text_name": "hyperbilirubinemia"
},
{
"begin_idx": "147",
"end_idx": "169",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "Dubin-Johnson syndrome"
},
{
"begin_idx": "171",
"end_idx": "193",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "Dubin-Johnson syndrome"
},
{
"begin_idx": "195",
"end_idx": "198",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "DJS"
},
{
"begin_idx": "414",
"end_idx": "417",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "DJS"
},
{
"begin_idx": "475",
"end_idx": "478",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "DJS"
},
{
"begin_idx": "617",
"end_idx": "620",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "DJS"
},
{
"begin_idx": "1116",
"end_idx": "1119",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "DJS"
},
{
"begin_idx": "206",
"end_idx": "233",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disease"
},
{
"begin_idx": "83",
"end_idx": "87",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "MRP2"
},
{
"begin_idx": "88",
"end_idx": "93",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
},
{
"begin_idx": "385",
"end_idx": "389",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "MRP2"
},
{
"begin_idx": "390",
"end_idx": "395",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
},
{
"begin_idx": "548",
"end_idx": "552",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "MRP2"
},
{
"begin_idx": "553",
"end_idx": "558",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
},
{
"begin_idx": "632",
"end_idx": "636",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "MRP2"
},
{
"begin_idx": "637",
"end_idx": "642",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
},
{
"begin_idx": "1077",
"end_idx": "1081",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "MRP2"
},
{
"begin_idx": "1082",
"end_idx": "1087",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
},
{
"begin_idx": "774",
"end_idx": "813",
"entity_id": "8714",
"entity_type": "Gene",
"text_name": "multidrug resistance-associated protein"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "88",
"end_idx": "93",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
},
{
"begin_idx": "553",
"end_idx": "558",
"entity_id": "1244",
"entity_type": "Gene",
"text_name": "cMOAT"
}
] | [
{
"begin_idx": "147",
"end_idx": "169",
"entity_id": "D007566",
"entity_type": "Disease",
"text_name": "Dubin-Johnson syndrome"
},
{
"begin_idx": "206",
"end_idx": "233",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disease"
}
] | [
"cMOAT",
"cMOAT"
] | [
"Dubin-Johnson syndrome",
"autosomal recessive disease"
] |
10069705 | Novel TSC2 mutation in a patient with pulmonary tuberous sclerosis: lack of loss of heterozygosity in a lung cyst. | A Japanese patient with tuberous sclerosis (TSC), who manifested with multiple lung cysts and pneumothorax, is described. All exons of two TSC genes, TSC1 and TSC2, in peripheral blood leukocytes from the patient were analyzed by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP). A novel T-to-G transition was found in exon 19 of TSC2 at nucleotide position 2168. This mutation caused an amino acid change, L717R. There was no such mutation in any other family members or in 100 normal Japanese. An automated sequencer-assisted quantitative analysis of normal and mutated SSCP-bands revealed no loss of heterozygosity (LOH) in the lung cyst tissue of the patient. | [
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "C566021",
"entity_type": "Disease",
"text_name": "TSC2"
},
{
"begin_idx": "274",
"end_idx": "278",
"entity_id": "C566021",
"entity_type": "Disease",
"text_name": "TSC2"
},
{
"begin_idx": "473",
"end_idx": "477",
"entity_id": "C566021",
"entity_type": "Disease",
"text_name": "TSC2"
},
{
"begin_idx": "104",
"end_idx": "113",
"entity_id": "D008171",
"entity_type": "Disease",
"text_name": "lung cyst"
},
{
"begin_idx": "185",
"end_idx": "204",
"entity_id": "D008171",
"entity_type": "Disease",
"text_name": "multiple lung cysts"
},
{
"begin_idx": "774",
"end_idx": "783",
"entity_id": "D008171",
"entity_type": "Disease",
"text_name": "lung cyst"
},
{
"begin_idx": "38",
"end_idx": "66",
"entity_id": "D014402",
"entity_type": "Disease",
"text_name": "pulmonary tuberous sclerosis"
},
{
"begin_idx": "139",
"end_idx": "157",
"entity_id": "D014402",
"entity_type": "Disease",
"text_name": "tuberous sclerosis"
},
{
"begin_idx": "159",
"end_idx": "162",
"entity_id": "D014402",
"entity_type": "Disease",
"text_name": "TSC"
},
{
"begin_idx": "254",
"end_idx": "257",
"entity_id": "D014402",
"entity_type": "Disease",
"text_name": "TSC"
},
{
"begin_idx": "265",
"end_idx": "269",
"entity_id": "7248",
"entity_type": "Gene",
"text_name": "TSC1"
},
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "7249",
"entity_type": "Gene",
"text_name": "TSC2"
},
{
"begin_idx": "274",
"end_idx": "278",
"entity_id": "7249",
"entity_type": "Gene",
"text_name": "TSC2"
},
{
"begin_idx": "473",
"end_idx": "477",
"entity_id": "7249",
"entity_type": "Gene",
"text_name": "TSC2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "7249",
"entity_type": "Gene",
"text_name": "TSC2"
},
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "7249",
"entity_type": "Gene",
"text_name": "TSC2"
}
] | [
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "C566021",
"entity_type": "Disease",
"text_name": "TSC2"
},
{
"begin_idx": "38",
"end_idx": "66",
"entity_id": "D014402",
"entity_type": "Disease",
"text_name": "pulmonary tuberous sclerosis"
}
] | [
"TSC2",
"TSC2"
] | [
"TSC2",
"pulmonary tuberous sclerosis"
] |
10071100 | Central visual, acoustic, and motor pathway involvement in a Charcot-Marie-Tooth family with an Asn205Ser mutation in the connexin 32 gene. | BACKGROUND: X linked dominant Charcot-Marie-Tooth disease (CMT1X) is an inherited motor and sensory neuropathy that mainly affects the peripheral nervous system. CMT1X is associated with mutations in the gap junction protein connexin 32 (Cx32). Cx32 is expressed in Schwann cells and oligodendrocytes in the peripheral (PNS) and in the (CNS) respectively. METHODS: A CMT1X family with a Cx32 mutation was examined clinically and electrophysiologically to determine whether PNS, or CNS, or both pathways were affected. RESULTS: In a CMT1X family a novel mutation (Asn205Ser) was found in the fourth transmembrane domain of Cx32. The patients showed typical clinical and electrophysiological abnormalities in the PNS, but in addition visual, acoustic, and motor pathways of the CNS were affected subclinically. This was indicated by pathological changes in visually evoked potentials (VEPs), brainstem auditory evoked potentials (BAEPs), and central motor evoked potentials (CMEPs). CONCLUSIONS: These findings underscore the necessity of a careful analysis of CNS pathways in patients with CMT and Cx32 mutations. Abnormal electrophysiological findings in CNS pathway examinations should raise the suspicion of CMTX and a search for gene mutations towards Cx32 should be considered. | [
{
"begin_idx": "1350",
"end_idx": "1354",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "CMTX"
},
{
"begin_idx": "61",
"end_idx": "80",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth"
},
{
"begin_idx": "170",
"end_idx": "197",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth disease"
},
{
"begin_idx": "212",
"end_idx": "250",
"entity_id": "D010523",
"entity_type": "Disease",
"text_name": "inherited motor and sensory neuropathy"
},
{
"begin_idx": "122",
"end_idx": "133",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "connexin 32"
},
{
"begin_idx": "365",
"end_idx": "376",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "connexin 32"
},
{
"begin_idx": "378",
"end_idx": "382",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "385",
"end_idx": "389",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "527",
"end_idx": "531",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "762",
"end_idx": "766",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "1237",
"end_idx": "1241",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "1395",
"end_idx": "1399",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "302",
"end_idx": "306",
"entity_id": "4359",
"entity_type": "Gene",
"text_name": "CMT1"
},
{
"begin_idx": "507",
"end_idx": "511",
"entity_id": "4359",
"entity_type": "Gene",
"text_name": "CMT1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "122",
"end_idx": "133",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "connexin 32"
},
{
"begin_idx": "762",
"end_idx": "766",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
}
] | [
{
"begin_idx": "1350",
"end_idx": "1354",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "CMTX"
},
{
"begin_idx": "212",
"end_idx": "250",
"entity_id": "D010523",
"entity_type": "Disease",
"text_name": "inherited motor and sensory neuropathy"
}
] | [
"connexin 32",
"Cx32"
] | [
"CMTX",
"inherited motor and sensory neuropathy"
] |
10072423 | A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. | Autosomal recessive juvenile parkinsonism (AR-JP, PARK2; OMIM 602544), one of the monogenic forms of Parkinson's disease (PD), was initially described in Japan. It is characterized by early onset (before age 40), marked response to levodopa treatment and levodopa-induced dyskinesias. The gene responsible for AR-JP was recently identified and designated parkin. We have analysed the 12 coding exons of the parkin gene in 35 mostly European families with early onset autosomal recessive parkinsonism. In one family, a homozygous deletion of exon 4 could be demonstrated. By direct sequencing of the exons in the index patients of the remaining 34 families, eight previously undescribed point mutations (homozygous or heterozygous) were detected in eight families that included 20 patients. The mutations segregated with the disease in the families and were not detected on 110-166 control chromosomes. Four mutations caused truncation of the parkin protein. Three were frameshifts (202-203delAG, 255delA and 321-322insGT) and one a nonsense mutation (Trp453Stop). The other four were missense mutations (Lys161Asn, Arg256Cys, Arg275Trp and Thr415Asn) that probably affect amino acids that are important for the function of the parkin protein, since they result in the same phenotype as truncating mutations or homozygous exon deletions. Mean age at onset was 38 +/- 12 years, but onset up to age 58 was observed. Mutations in the parkin gene are therefore not invariably associated with early onset parkinsonism. In many patients, the phenotype is indistinguishable from that of idiopathic PD. This study has shown that a wide variety of different mutations in the parkin gene are a common cause of autosomal recessive parkinsonism in Europe and that different types of point mutations seem to be more frequently responsible for the disease phenotype than are deletions. | [
{
"begin_idx": "509",
"end_idx": "520",
"entity_id": "D004409",
"entity_type": "Disease",
"text_name": "dyskinesias"
},
{
"begin_idx": "67",
"end_idx": "99",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "autosomal recessive parkinsonism"
},
{
"begin_idx": "118",
"end_idx": "137",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "Parkinson's Disease"
},
{
"begin_idx": "216",
"end_idx": "235",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "Parkinson's Disease"
},
{
"begin_idx": "338",
"end_idx": "357",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "Parkinson's disease"
},
{
"begin_idx": "359",
"end_idx": "361",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "PD"
},
{
"begin_idx": "704",
"end_idx": "736",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "autosomal recessive parkinsonism"
},
{
"begin_idx": "1827",
"end_idx": "1829",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "PD"
},
{
"begin_idx": "1936",
"end_idx": "1968",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "autosomal recessive parkinsonism"
},
{
"begin_idx": "1736",
"end_idx": "1748",
"entity_id": "D010302",
"entity_type": "Disease",
"text_name": "parkinsonism"
},
{
"begin_idx": "237",
"end_idx": "278",
"entity_id": "D020734",
"entity_type": "Disease",
"text_name": "Autosomal recessive juvenile parkinsonism"
},
{
"begin_idx": "280",
"end_idx": "285",
"entity_id": "D020734",
"entity_type": "Disease",
"text_name": "AR-JP"
},
{
"begin_idx": "547",
"end_idx": "552",
"entity_id": "D020734",
"entity_type": "Disease",
"text_name": "AR-JP"
},
{
"begin_idx": "280",
"end_idx": "285",
"entity_id": "5071",
"entity_type": "Gene",
"text_name": "AR-JP"
},
{
"begin_idx": "287",
"end_idx": "292",
"entity_id": "5071",
"entity_type": "Gene",
"text_name": "PARK2"
},
{
"begin_idx": "547",
"end_idx": "552",
"entity_id": "5071",
"entity_type": "Gene",
"text_name": "AR-JP"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "280",
"end_idx": "285",
"entity_id": "5071",
"entity_type": "Gene",
"text_name": "AR-JP"
},
{
"begin_idx": "547",
"end_idx": "552",
"entity_id": "5071",
"entity_type": "Gene",
"text_name": "AR-JP"
}
] | [
{
"begin_idx": "237",
"end_idx": "278",
"entity_id": "D020734",
"entity_type": "Disease",
"text_name": "Autosomal recessive juvenile parkinsonism"
},
{
"begin_idx": "1827",
"end_idx": "1829",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "PD"
}
] | [
"AR-JP",
"AR-JP"
] | [
"Autosomal recessive juvenile parkinsonism",
"PD"
] |
10072428 | Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. | Inherited mutations in the E-cadherin gene ( CDH1 ) were described recently in three Maori kindreds with familial gastric cancer. Familial gastric cancer is genetically heterogeneous and it is not clear what proportion of gastric cancer susceptibility in non-Maori populations is due to germline CDH1 mutations. Therefore, we screened eight familial gastric cancer kindreds of British and Irish origin for germline CDH1 mutations, by SSCP analysis of all 16 exons and flanking sequences. Each family contained: (i) two cases of gastric cancer in first degree relatives with one affected before age 50 years; or (ii) three or more cases of gastric cancer. Novel germline CDH1 mutations (a nonsense and a splice site) were detected in two families (25%). Both mutations were predicted to truncate the E-cadherin protein in the signal peptide domain. In one family there was evidence of non-penetrance and susceptibility to both gastric and colorectal cancer; thus, in addition to six cases of gastric cancer, a CDH1 mutation carrier developed colorectal cancer at age 30 years. We have confirmed that germline mutations in the CDH1 gene cause familial gastric cancer in non-Maori populations. However, only a minority of familial gastric cancers can be accounted for by CDH1 mutations. Loss of E-cadherin function has been implicated in the pathogenesis of sporadic colorectal and other cancers, and our findings provide evidence that germline CDH1 mutations predispose to early onset colorectal cancer. Thus, CDH1 should be investigated as a cause of inherited susceptibility to both gastric and colorectal cancers. | [
{
"begin_idx": "56",
"end_idx": "79",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancer"
},
{
"begin_idx": "208",
"end_idx": "231",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancer"
},
{
"begin_idx": "233",
"end_idx": "256",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "Familial gastric cancer"
},
{
"begin_idx": "325",
"end_idx": "339",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "444",
"end_idx": "467",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancer"
},
{
"begin_idx": "631",
"end_idx": "645",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "742",
"end_idx": "756",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1094",
"end_idx": "1108",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1244",
"end_idx": "1267",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancer"
},
{
"begin_idx": "1322",
"end_idx": "1346",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancers"
},
{
"begin_idx": "84",
"end_idx": "101",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "colorectal cancer"
},
{
"begin_idx": "1029",
"end_idx": "1058",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "gastric and colorectal cancer"
},
{
"begin_idx": "1144",
"end_idx": "1161",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "colorectal cancer"
},
{
"begin_idx": "1467",
"end_idx": "1495",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "colorectal and other cancers"
},
{
"begin_idx": "1586",
"end_idx": "1603",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "colorectal cancer"
},
{
"begin_idx": "1686",
"end_idx": "1716",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "gastric and colorectal cancers"
},
{
"begin_idx": "9",
"end_idx": "19",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "130",
"end_idx": "140",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "148",
"end_idx": "152",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "399",
"end_idx": "403",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "518",
"end_idx": "522",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "773",
"end_idx": "777",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "902",
"end_idx": "912",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "1112",
"end_idx": "1116",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "1228",
"end_idx": "1232",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "1371",
"end_idx": "1375",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "1395",
"end_idx": "1405",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "1545",
"end_idx": "1549",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
},
{
"begin_idx": "1611",
"end_idx": "1615",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "CDH1"
}
] | [
"Yes",
"Yes"
] | [
true,
true
] | [
{
"begin_idx": "9",
"end_idx": "19",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "9",
"end_idx": "19",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
}
] | [
{
"begin_idx": "1322",
"end_idx": "1346",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancers"
},
{
"begin_idx": "1686",
"end_idx": "1716",
"entity_id": "D015179",
"entity_type": "Disease",
"text_name": "gastric and colorectal cancers"
}
] | [
"E-cadherin",
"E-cadherin"
] | [
"familial gastric cancers",
"gastric and colorectal cancers"
] |
10075388 | Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. | In 30 patients with essential hypertension and 30 healthy control subjects, we evaluated blood concentrations of B cell leukemia-2 (bcl-2), a protooncogene that can reduce apoptosis. Bcl-2 concentrations were higher in hypertensive than in normotensive subjects. The increase in pressure due to a cold pressor test caused a further increase in blood bcl-2 concentrations, in both hypertensive and normotensive subjects. Treatment of hypertensive patients with hypotensive drugs caused a reduction in bcl-2 concentrations, which was more marked after administration of lisinopril than of nifedipine. The results suggest that concentrations of bcl-2 are increased in patients with hypertension, which could be an important factor in cell proliferation underlying posthypertensive vascular remodeling. Moreover, lisinopril and nifedipine appear to be capable of reducing bcl-2 concentrations, with potentially beneficial effects on vascular modifications in patients with hypertension. | [
{
"begin_idx": "32",
"end_idx": "44",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "131",
"end_idx": "143",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "320",
"end_idx": "332",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "481",
"end_idx": "493",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "534",
"end_idx": "546",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "780",
"end_idx": "792",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "1070",
"end_idx": "1082",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "561",
"end_idx": "572",
"entity_id": "D007022",
"entity_type": "Disease",
"text_name": "hypotensive"
},
{
"begin_idx": "8",
"end_idx": "13",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
},
{
"begin_idx": "214",
"end_idx": "231",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "B cell leukemia-2"
},
{
"begin_idx": "233",
"end_idx": "238",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
},
{
"begin_idx": "451",
"end_idx": "456",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
},
{
"begin_idx": "601",
"end_idx": "606",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
},
{
"begin_idx": "743",
"end_idx": "748",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
},
{
"begin_idx": "969",
"end_idx": "974",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
},
{
"begin_idx": "862",
"end_idx": "898",
"entity_id": "D066253",
"entity_type": "Disease",
"text_name": "posthypertensive vascular remodeling"
},
{
"begin_idx": "8",
"end_idx": "13",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
},
{
"begin_idx": "214",
"end_idx": "231",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "B cell leukemia-2"
},
{
"begin_idx": "233",
"end_idx": "238",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
},
{
"begin_idx": "284",
"end_idx": "289",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "451",
"end_idx": "456",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
},
{
"begin_idx": "601",
"end_idx": "606",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
},
{
"begin_idx": "743",
"end_idx": "748",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
},
{
"begin_idx": "969",
"end_idx": "974",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "214",
"end_idx": "231",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "B cell leukemia-2"
},
{
"begin_idx": "601",
"end_idx": "606",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "bcl-2"
}
] | [
{
"begin_idx": "32",
"end_idx": "44",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "743",
"end_idx": "748",
"entity_id": "D015448",
"entity_type": "Disease",
"text_name": "bcl-2"
}
] | [
"B cell leukemia-2",
"bcl-2"
] | [
"hypertensive",
"bcl-2"
] |
10077519 | Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome. | BACKGROUND: Long-QT (LQT) syndrome is a cardiac disorder that causes syncope, seizures, and sudden death from ventricular arrhythmias, specifically torsade de pointes. Both autosomal dominant LQT (Romano-Ward syndrome) and autosomal recessive LQT (Jervell and Lange-Nielsen syndrome, JLNS) have been reported. Heterozygous mutations in 3 potassium channel genes, KVLQT1, KCNE1 (minK), and HERG, and the cardiac sodium channel gene SCN5A cause autosomal dominant LQT. Autosomal recessive LQT, which is associated with deafness, has been found to occur with homozygous mutations in KVLQT1 and KCNE1 in JLNS families in which QTc prolongation was inherited as a dominant trait. METHODS AND RESULTS: An Amish family with clinical evidence of JLNS was analyzed for mutations by use of single-strand conformation polymorphism and DNA sequencing analyses for mutations in all known LQT genes. A novel homozygous 2-bp deletion in the S2 transmembrane segment of KVLQT1 was identified in affected members of this Amish family in which both QTc prolongation and deafness were inherited as recessive traits. This deletion represents a new JLNS-associated mutation in KVLQT1 and has deleterious effects on the KVLQT1 potassium channel, causing a frameshift and the truncation of the KVLQT1 protein. In contrast to previous reports in which LQT was inherited as a clear dominant trait, 2 parents in the JLNS family described here have normal QTc intervals (0.43 and 0.44 seconds, respectively). CONCLUSIONS: A novel homozygous KVLQT1 mutation causes JLNS in an Amish family with deafness that is inherited as an autosomal recessive trait. | [
{
"begin_idx": "192",
"end_idx": "215",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "ventricular arrhythmias"
},
{
"begin_idx": "599",
"end_idx": "607",
"entity_id": "D003638",
"entity_type": "Disease",
"text_name": "deafness"
},
{
"begin_idx": "1134",
"end_idx": "1142",
"entity_id": "D003638",
"entity_type": "Disease",
"text_name": "deafness"
},
{
"begin_idx": "1648",
"end_idx": "1656",
"entity_id": "D003638",
"entity_type": "Disease",
"text_name": "deafness"
},
{
"begin_idx": "174",
"end_idx": "186",
"entity_id": "D003645",
"entity_type": "Disease",
"text_name": "sudden death"
},
{
"begin_idx": "122",
"end_idx": "138",
"entity_id": "D006331",
"entity_type": "Disease",
"text_name": "cardiac disorder"
},
{
"begin_idx": "94",
"end_idx": "116",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "Long-QT (LQT) syndrome"
},
{
"begin_idx": "255",
"end_idx": "277",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "autosomal dominant LQT"
},
{
"begin_idx": "305",
"end_idx": "328",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "autosomal recessive LQT"
},
{
"begin_idx": "525",
"end_idx": "547",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "autosomal dominant LQT"
},
{
"begin_idx": "549",
"end_idx": "572",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "Autosomal recessive LQT"
},
{
"begin_idx": "705",
"end_idx": "721",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "QTc prolongation"
},
{
"begin_idx": "957",
"end_idx": "960",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQT"
},
{
"begin_idx": "1113",
"end_idx": "1129",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "QTc prolongation"
},
{
"begin_idx": "1410",
"end_idx": "1413",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQT"
},
{
"begin_idx": "160",
"end_idx": "168",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "151",
"end_idx": "158",
"entity_id": "D013575",
"entity_type": "Disease",
"text_name": "syncope"
},
{
"begin_idx": "230",
"end_idx": "248",
"entity_id": "D016171",
"entity_type": "Disease",
"text_name": "torsade de pointes"
},
{
"begin_idx": "58",
"end_idx": "80",
"entity_id": "D029593",
"entity_type": "Disease",
"text_name": "Lange-Nielsen syndrome"
},
{
"begin_idx": "342",
"end_idx": "364",
"entity_id": "D029593",
"entity_type": "Disease",
"text_name": "Lange-Nielsen syndrome"
},
{
"begin_idx": "279",
"end_idx": "299",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "Romano-Ward syndrome"
},
{
"begin_idx": "1148",
"end_idx": "1177",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited as recessive traits"
},
{
"begin_idx": "453",
"end_idx": "458",
"entity_id": "3753",
"entity_type": "Gene",
"text_name": "KCNE1"
},
{
"begin_idx": "460",
"end_idx": "464",
"entity_id": "3753",
"entity_type": "Gene",
"text_name": "minK"
},
{
"begin_idx": "673",
"end_idx": "678",
"entity_id": "3753",
"entity_type": "Gene",
"text_name": "KCNE1"
},
{
"begin_idx": "471",
"end_idx": "475",
"entity_id": "3757",
"entity_type": "Gene",
"text_name": "HERG"
},
{
"begin_idx": "23",
"end_idx": "29",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "445",
"end_idx": "451",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "662",
"end_idx": "668",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1036",
"end_idx": "1042",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1238",
"end_idx": "1244",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1280",
"end_idx": "1286",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1353",
"end_idx": "1359",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1596",
"end_idx": "1602",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "513",
"end_idx": "518",
"entity_id": "6331",
"entity_type": "Gene",
"text_name": "SCN5A"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "23",
"end_idx": "29",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1596",
"end_idx": "1602",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
}
] | [
{
"begin_idx": "58",
"end_idx": "80",
"entity_id": "D029593",
"entity_type": "Disease",
"text_name": "Lange-Nielsen syndrome"
},
{
"begin_idx": "1148",
"end_idx": "1177",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited as recessive traits"
}
] | [
"KVLQT1",
"KVLQT1"
] | [
"Lange-Nielsen syndrome",
"inherited as recessive traits"
] |
10079291 | Identification of the gene variations in human CD22. | CD22, a member of the immunoglobulin superfamily, is a B-cell transmembrane glycoprotein that acts as an accessory-signaling component of the B-cell antigen receptor (BCR). Recent evidence indicating the role of CD22 as a negative regulator of BCR signal transduction prompted us to test the possibility that genetic variations of human CD22 may be associated with autoimmune diseases. In this study, variation screening of the entire CD22 coding region was performed, and possible association with rheumatic diseases was tested, using the genomic DNA from 207 healthy Japanese individuals, 68 patients with systemic lupus erythematosus (SLE), and 119 patients with rheumatoid arthritis (RA). Through the variation screening, seven non-synonymous and four synonymous substitutions were identified. In addition, single base substitutions were found in two introns flanking exon-intron junctions. Among these variations, Q152E substitution within the second extracellular domain was observed with a marginally higher frequency in the patients with SLE (3/68, 4.4%) than that in healthy individuals (1/207, 0.5%) (P=0.048. SLE vs healthy individuals), although this difference was no longer significant after correction for the number of comparisons (Pc=0.62). No significant association was observed between any of the variations and RA. These findings indicate that a number of genetic variants are present in CD22, and suggest that CD22 could be considered a candidate for the susceptibility genes to autoimmune diseases. | [
{
"begin_idx": "719",
"end_idx": "739",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "741",
"end_idx": "743",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "1385",
"end_idx": "1387",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "418",
"end_idx": "437",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmune diseases"
},
{
"begin_idx": "1554",
"end_idx": "1573",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmune diseases"
},
{
"begin_idx": "661",
"end_idx": "689",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "691",
"end_idx": "694",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1099",
"end_idx": "1102",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1173",
"end_idx": "1176",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "552",
"end_idx": "570",
"entity_id": "D012216",
"entity_type": "Disease",
"text_name": "rheumatic diseases"
},
{
"begin_idx": "195",
"end_idx": "218",
"entity_id": "613",
"entity_type": "Gene",
"text_name": "B-cell antigen receptor"
},
{
"begin_idx": "220",
"end_idx": "223",
"entity_id": "613",
"entity_type": "Gene",
"text_name": "BCR"
},
{
"begin_idx": "297",
"end_idx": "300",
"entity_id": "613",
"entity_type": "Gene",
"text_name": "BCR"
},
{
"begin_idx": "47",
"end_idx": "51",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "53",
"end_idx": "57",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "265",
"end_idx": "269",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "390",
"end_idx": "394",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "488",
"end_idx": "492",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "1462",
"end_idx": "1466",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "1485",
"end_idx": "1489",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "47",
"end_idx": "51",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
},
{
"begin_idx": "53",
"end_idx": "57",
"entity_id": "933",
"entity_type": "Gene",
"text_name": "CD22"
}
] | [
{
"begin_idx": "661",
"end_idx": "689",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "1385",
"end_idx": "1387",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
}
] | [
"CD22",
"CD22"
] | [
"systemic lupus erythematosus",
"RA"
] |
10080178 | Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. | Darier disease (DD) is an autosomal-dominant skin disorder characterized by loss of adhesion between epidermal cells (acantholysis) and abnormal keratinization. Recently we constructed a 2.4-Mb, P1-derived artificial chromosome contig spanning the DD candidate region on chromosome 12q23-24.1. After screening several genes that mapped to this region, we identified mutations in the ATP2A2 gene, which encodes the sarco/endoplasmic reticulum Ca2(+)-ATPase type 2 isoform (SERCA2) and is highly expressed in keratinocytes. Thirteen mutations were identified, including frameshift deletions, in-frame deletions or insertions, splice-site mutations and non-conservative missense mutations in functional domains. Our results demonstrate that mutations in ATP2A2 cause DD and disclose a role for this pump in a Ca(2+)-signalling pathway regulating cell-to-cell adhesion and differentiation of the epidermis. | [
{
"begin_idx": "49",
"end_idx": "63",
"entity_id": "D007644",
"entity_type": "Disease",
"text_name": "Darier disease"
},
{
"begin_idx": "65",
"end_idx": "79",
"entity_id": "D007644",
"entity_type": "Disease",
"text_name": "Darier disease"
},
{
"begin_idx": "81",
"end_idx": "83",
"entity_id": "D007644",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "313",
"end_idx": "315",
"entity_id": "D007644",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "829",
"end_idx": "831",
"entity_id": "D007644",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "91",
"end_idx": "123",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal-dominant skin disorder"
},
{
"begin_idx": "13",
"end_idx": "19",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "ATP2A2"
},
{
"begin_idx": "448",
"end_idx": "454",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "ATP2A2"
},
{
"begin_idx": "479",
"end_idx": "535",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "sarco/endoplasmic reticulum Ca2(+)-ATPase type 2 isoform"
},
{
"begin_idx": "537",
"end_idx": "543",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "SERCA2"
},
{
"begin_idx": "816",
"end_idx": "822",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "ATP2A2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "479",
"end_idx": "535",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "sarco/endoplasmic reticulum Ca2(+)-ATPase type 2 isoform"
},
{
"begin_idx": "537",
"end_idx": "543",
"entity_id": "488",
"entity_type": "Gene",
"text_name": "SERCA2"
}
] | [
{
"begin_idx": "49",
"end_idx": "63",
"entity_id": "D007644",
"entity_type": "Disease",
"text_name": "Darier disease"
},
{
"begin_idx": "91",
"end_idx": "123",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal-dominant skin disorder"
}
] | [
"sarco/endoplasmic reticulum Ca2(+)-ATPase type 2 isoform",
"SERCA2"
] | [
"Darier disease",
"autosomal-dominant skin disorder"
] |
10080184 | Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. | The secreted polypeptide noggin (encoded by the Nog gene) binds and inactivates members of the transforming growth factor beta superfamily of signalling proteins (TGFbeta-FMs), such as BMP4 (ref. 1). By diffusing through extracellular matrices more efficiently than TGFbeta-FMs, noggin may have a principal role in creating morphogenic gradients. During mouse embryogenesis, Nog is expressed at multiple sites, including developing bones. Nog-/- mice die at birth from multiple defects that include bony fusion of the appendicular skeleton. We have identified five dominant human NOG mutations in unrelated families segregating proximal symphalangism (SYM1; OMIM 185800) and a de novo mutation in a patient with unaffected parents. We also found a dominant NOG mutation in a family segregating multiple synostoses syndrome (SYNS1; OMIM 186500); both SYM1 and SYNS1 have multiple joint fusion as their principal feature. All seven NOG mutations alter evolutionarily conserved amino acid residues. The findings reported here confirm that NOG is essential for joint formation and suggest that NOG requirements during skeletogenesis differ between species and between specific skeletal elements within species. | [
{
"begin_idx": "713",
"end_idx": "735",
"entity_id": "C536223",
"entity_type": "Disease",
"text_name": "proximal symphalangism"
},
{
"begin_idx": "879",
"end_idx": "907",
"entity_id": "C536943",
"entity_type": "Disease",
"text_name": "multiple synostoses syndrome"
},
{
"begin_idx": "180",
"end_idx": "246",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "transforming growth factor beta superfamily of signalling proteins"
},
{
"begin_idx": "248",
"end_idx": "259",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "TGFbeta-FMs"
},
{
"begin_idx": "351",
"end_idx": "362",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "TGFbeta-FMs"
},
{
"begin_idx": "955",
"end_idx": "976",
"entity_id": "D007592",
"entity_type": "Disease",
"text_name": "multiple joint fusion"
},
{
"begin_idx": "270",
"end_idx": "274",
"entity_id": "652",
"entity_type": "Gene",
"text_name": "BMP4"
},
{
"begin_idx": "44",
"end_idx": "50",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "noggin"
},
{
"begin_idx": "110",
"end_idx": "116",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "noggin"
},
{
"begin_idx": "133",
"end_idx": "136",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "Nog"
},
{
"begin_idx": "364",
"end_idx": "370",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "noggin"
},
{
"begin_idx": "460",
"end_idx": "463",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "Nog"
},
{
"begin_idx": "524",
"end_idx": "527",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "Nog"
},
{
"begin_idx": "665",
"end_idx": "668",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "NOG"
},
{
"begin_idx": "737",
"end_idx": "741",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "SYM1"
},
{
"begin_idx": "842",
"end_idx": "845",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "NOG"
},
{
"begin_idx": "909",
"end_idx": "914",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "SYNS1"
},
{
"begin_idx": "935",
"end_idx": "939",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "SYM1"
},
{
"begin_idx": "944",
"end_idx": "949",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "SYNS1"
},
{
"begin_idx": "1015",
"end_idx": "1018",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "NOG"
},
{
"begin_idx": "1121",
"end_idx": "1124",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "NOG"
},
{
"begin_idx": "1175",
"end_idx": "1178",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "NOG"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "44",
"end_idx": "50",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "noggin"
},
{
"begin_idx": "909",
"end_idx": "914",
"entity_id": "9241",
"entity_type": "Gene",
"text_name": "SYNS1"
}
] | [
{
"begin_idx": "879",
"end_idx": "907",
"entity_id": "C536943",
"entity_type": "Disease",
"text_name": "multiple synostoses syndrome"
},
{
"begin_idx": "351",
"end_idx": "362",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "TGFbeta-FMs"
}
] | [
"noggin",
"SYNS1"
] | [
"multiple synostoses syndrome",
"TGFbeta-FMs"
] |
10082481 | Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. | The natriuretic peptide (NP) system may play a crucial role in development of essential hypertension (EH). C-type NP dilates arteries and lowers blood pressure and inhibits proliferation of vascular smooth muscle cells via the type B NP receptor (NPR-B). However, the association of the human NPR-B gene with EH has not been studied, because little is known about the genomic organization of this gene. We designed oligonucleotide primers based on the cDNA sequence of the human NPR-B gene, and long-range polymerase chain reaction (PCR) was performed. The amplified fragments were sequenced directly, and the exon/intron organization of the human NPR-B gene was determined. The gene, which spans approximately 16.5 kbp, is composed of 22 exons, and the intron-exon junctions follow the GT-AG rule. Seven hundred fifty base pairs of the 5'-flanking region were sequenced using a thermal asymmetric interlaced-PCR (TAIL-PCR) method. This region contains 10 potential Sp1 binding sites and lacks a TATA box. Rapid amplification of cDNA ends (RACE) revealed the transcriptional start site at -14 bp. A CA/GT microsatellite repeat was identified with a hybridization-based method and was converted to a sequence-tagged site (STS). The GT microsatellite repeat was localized to intron 2 approximately 150 bp downstream of the exon-intron junction. Two alleles, (GT)10 and (GT)11, were detected in both EH patients and age-matched normotensive (NT) controls. Multiple logistic linear regression analysis indicated that the NPR-B genotype is associated significantly with EH (odds ratio 1.55; 95% confidence interval, 1.02 to 2.35). The (GT)11 frequency was 0.316 (65/206) for the EH group and 0.218 (44/202) for the NT group and differed significantly between the EH and NT groups (chi2=4.97, P=0.026). The structural organization of the human NPR-B gene was determined, and a novel GT repeat polymorphism, which associated with EH, was identified. These results suggest that one cause of EH is a mutation in this gene or a closely related gene or region. | [
{
"begin_idx": "124",
"end_idx": "146",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "essential hypertension"
},
{
"begin_idx": "226",
"end_idx": "248",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "essential hypertension"
},
{
"begin_idx": "250",
"end_idx": "252",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "457",
"end_idx": "459",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "1545",
"end_idx": "1547",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "1713",
"end_idx": "1715",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "1822",
"end_idx": "1824",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "1906",
"end_idx": "1908",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "2071",
"end_idx": "2073",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "2131",
"end_idx": "2133",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "EH"
},
{
"begin_idx": "935",
"end_idx": "937",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "1247",
"end_idx": "1267",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "CA/GT microsatellite"
},
{
"begin_idx": "1379",
"end_idx": "1381",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "1505",
"end_idx": "1507",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "1516",
"end_idx": "1518",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "1779",
"end_idx": "1781",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "2025",
"end_idx": "2027",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "395",
"end_idx": "400",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
},
{
"begin_idx": "441",
"end_idx": "446",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
},
{
"begin_idx": "627",
"end_idx": "632",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
},
{
"begin_idx": "796",
"end_idx": "801",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
},
{
"begin_idx": "1665",
"end_idx": "1670",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
},
{
"begin_idx": "1986",
"end_idx": "1991",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "395",
"end_idx": "400",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
},
{
"begin_idx": "395",
"end_idx": "400",
"entity_id": "4882",
"entity_type": "Gene",
"text_name": "NPR-B"
}
] | [
{
"begin_idx": "124",
"end_idx": "146",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "essential hypertension"
},
{
"begin_idx": "2025",
"end_idx": "2027",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
}
] | [
"NPR-B",
"NPR-B"
] | [
"essential hypertension",
"GT"
] |
10084318 | A novel mutation in the 1A domain of keratin 2e in ichthyosis bullosa of Siemens. | Ichthyosis bullosa of Siemens (IBS) is a rare autosomal dominant skin disorder with clinical features similar to epidermolytic hyperkeratosis (EHK). Both diseases have been linked to the type II keratin cluster on chromosome 12q. Hyperkeratosis and blister formation are relatively mild in IBS compared with EHK, and the lysis of keratinocytes is restricted to the upper spinous and granular layers of the epidermis of IBS patients, whereas in EHK lysis occurs in the lower spinous layer. Recently, mutations in the helix initiation and termination motifs of keratin 2e (K2e) have been described in IBS patients. The majority of the mutations reported to date lie in the 2B region. In this report, we have examined a large kindred in which the disease was originally diagnosed as EHK and mapped to the type II keratin cluster on chromosome 12q. Molecular analysis revealed a novel amino acid substitution at the beginning of the conserved 1A region of the rod domain (I4N) of K2e, resulting from a T to A transversion in codon 188. | [
{
"begin_idx": "331",
"end_idx": "338",
"entity_id": "D001768",
"entity_type": "Disease",
"text_name": "blister"
},
{
"begin_idx": "195",
"end_idx": "223",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic hyperkeratosis"
},
{
"begin_idx": "225",
"end_idx": "228",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "EHK"
},
{
"begin_idx": "312",
"end_idx": "326",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "Hyperkeratosis"
},
{
"begin_idx": "390",
"end_idx": "393",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "EHK"
},
{
"begin_idx": "526",
"end_idx": "529",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "EHK"
},
{
"begin_idx": "862",
"end_idx": "865",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "EHK"
},
{
"begin_idx": "128",
"end_idx": "160",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant skin disorder"
},
{
"begin_idx": "51",
"end_idx": "80",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "ichthyosis bullosa of Siemens"
},
{
"begin_idx": "82",
"end_idx": "111",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "Ichthyosis bullosa of Siemens"
},
{
"begin_idx": "113",
"end_idx": "116",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "372",
"end_idx": "375",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "501",
"end_idx": "504",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "681",
"end_idx": "684",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "37",
"end_idx": "47",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "641",
"end_idx": "651",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "653",
"end_idx": "656",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "K2e"
},
{
"begin_idx": "1058",
"end_idx": "1061",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "K2e"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "37",
"end_idx": "47",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "641",
"end_idx": "651",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
}
] | [
{
"begin_idx": "51",
"end_idx": "80",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "ichthyosis bullosa of Siemens"
},
{
"begin_idx": "312",
"end_idx": "326",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "Hyperkeratosis"
}
] | [
"keratin 2e",
"keratin 2e"
] | [
"ichthyosis bullosa of Siemens",
"Hyperkeratosis"
] |
10084598 | The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. | Mutations in the gene encoding hepatic nuclear factor-1alpha (HNF-1alpha) have been found in patients with maturity-onset diabetes of the young. We identified a new variant in the HNF-1alpha gene, namely G319S, in Ontario Oji-Cree with type 2 diabetes. G319S is within the proline II-rich domain of the trans-activation site of HNF-1alpha and alters a glycine residue that is conserved throughout evolution. S319 was absent from 990 alleles taken from subjects representing six other ethnic groups, suggesting that it is private for Oji-Cree. We found that 1) the S319 allele was significantly more prevalent in diabetic than nondiabetic Oji-Cree (0.209 vs. 0.087; P = 0.000001); 2) S319/S319 homozygotes and S319/G319 heterozygotes, respectively, had odds ratios for type 2 diabetes of 4.00 (95% confidence interval, 2.65-6.03) and 1.97 (95% confidence interval, 1.44-2.70) compared with G319/G319 homozygotes; 3) there was a significant difference in the mean age of onset of type 2 diabetes, with G319/G319, S319/G319, and S319/S319 subjects affected in the fifth, fourth, and third decades of life, respectively. In subjects with type 2 diabetes, we also found significantly lower body mass index and significantly higher post-challenge plasma glucose in S319/S319 and S319/G319 compared with G319/G319 subjects. Finally, among nondiabetic subjects, S319/G319 heterozygotes had significantly lower plasma insulin than G319/G319 homozygotes. The presence of the private HNF-1alpha G319S variant in a large number of Oji-Cree with type 2 diabetes and its strong association with type 2 diabetes susceptibility are unique among human populations. Also, G319S is associated with a distinct form of type 2 diabetes, characterized by onset at an earlier age, lower body mass, and a higher postchallenge plasma glucose. | [
{
"begin_idx": "86",
"end_idx": "94",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "239",
"end_idx": "260",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes of the young"
},
{
"begin_idx": "360",
"end_idx": "368",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "729",
"end_idx": "737",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
},
{
"begin_idx": "1102",
"end_idx": "1110",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "1258",
"end_idx": "1266",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "1657",
"end_idx": "1665",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "1705",
"end_idx": "1713",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "1822",
"end_idx": "1830",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "224",
"end_idx": "232",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "maturity"
},
{
"begin_idx": "885",
"end_idx": "905",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "type 2 diabetes of 4"
},
{
"begin_idx": "79",
"end_idx": "83",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "353",
"end_idx": "357",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "1095",
"end_idx": "1099",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "1251",
"end_idx": "1255",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "1650",
"end_idx": "1654",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "1698",
"end_idx": "1702",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "1815",
"end_idx": "1819",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
},
{
"begin_idx": "179",
"end_idx": "189",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "HNF-1alpha"
},
{
"begin_idx": "297",
"end_idx": "307",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "HNF-1alpha"
},
{
"begin_idx": "445",
"end_idx": "455",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "HNF-1alpha"
},
{
"begin_idx": "1590",
"end_idx": "1600",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "HNF-1alpha"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "179",
"end_idx": "189",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "HNF-1alpha"
},
{
"begin_idx": "179",
"end_idx": "189",
"entity_id": "6927",
"entity_type": "Gene",
"text_name": "HNF-1alpha"
}
] | [
{
"begin_idx": "885",
"end_idx": "905",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "type 2 diabetes of 4"
},
{
"begin_idx": "79",
"end_idx": "83",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "type"
}
] | [
"HNF-1alpha",
"HNF-1alpha"
] | [
"type 2 diabetes of 4",
"type"
] |
10089893 | Molecular characterization of two mutations in platelet glycoprotein (GP) Ib alpha in two Finnish Bernard-Soulier syndrome families. | Bernard-Soulier syndrome (BSS) is a rare hereditary bleeding disorder and macrothrombocytopenia which is caused by a defect in the platelet glycoprotein Ib/IX/V (GP Ib/IX/V) complex, the receptor for von Willebrand factor and thrombin. Here we report the molecular basis of the classical form of BSS in two unrelated Finnish patients, both with a life-long history of severe bleeding. Flow cytometry and immunoblotting showed no expression of GP Ib/IX, GP Ib alpha, GP Ib beta or GP IX (less than 10%) in the patients' platelets. No expression of GP V (< 10%) was observed in propositus 1, but a residual amount was found in propositus 2 (24%). DNA sequencing analysis revealed that propositus 1 was compound heterozygous for a two-base-pair deletion at Tyr505(TAT) and a point mutation Leu129(CTC)Pro(CCC) in the GP Ib alpha gene. Propositus 2 was homozygous for the Tyr505(TAT) deletion. The nine relatives who were heterozygous for either of the mutations also had low levels of GP Ib alpha (74-90%). Hence, Bernard-Soulier patients homozygous or compound heterozygous for Tyr505(TAT) are severely affected. Interestingly, both mutations have independently been found in three other families in previous reports, suggesting their ancient age or mutational 'hot spot'. | [
{
"begin_idx": "207",
"end_idx": "228",
"entity_id": "C564525",
"entity_type": "Disease",
"text_name": "macrothrombocytopenia"
},
{
"begin_idx": "98",
"end_idx": "122",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "Bernard-Soulier syndrome"
},
{
"begin_idx": "133",
"end_idx": "157",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "Bernard-Soulier syndrome"
},
{
"begin_idx": "159",
"end_idx": "162",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "BSS"
},
{
"begin_idx": "429",
"end_idx": "432",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "BSS"
},
{
"begin_idx": "1144",
"end_idx": "1159",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "Bernard-Soulier"
},
{
"begin_idx": "508",
"end_idx": "516",
"entity_id": "D006470",
"entity_type": "Disease",
"text_name": "bleeding"
},
{
"begin_idx": "333",
"end_idx": "347",
"entity_id": "D014842",
"entity_type": "Disease",
"text_name": "von Willebrand"
},
{
"begin_idx": "174",
"end_idx": "202",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary bleeding disorder"
},
{
"begin_idx": "56",
"end_idx": "82",
"entity_id": "2811",
"entity_type": "Gene",
"text_name": "glycoprotein (GP) Ib alpha"
},
{
"begin_idx": "586",
"end_idx": "597",
"entity_id": "2811",
"entity_type": "Gene",
"text_name": "GP Ib alpha"
},
{
"begin_idx": "947",
"end_idx": "958",
"entity_id": "2811",
"entity_type": "Gene",
"text_name": "GP Ib alpha"
},
{
"begin_idx": "1115",
"end_idx": "1126",
"entity_id": "2811",
"entity_type": "Gene",
"text_name": "GP Ib alpha"
},
{
"begin_idx": "599",
"end_idx": "609",
"entity_id": "2812",
"entity_type": "Gene",
"text_name": "GP Ib beta"
},
{
"begin_idx": "680",
"end_idx": "684",
"entity_id": "2814",
"entity_type": "Gene",
"text_name": "GP V"
},
{
"begin_idx": "613",
"end_idx": "618",
"entity_id": "2815",
"entity_type": "Gene",
"text_name": "GP IX"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "56",
"end_idx": "82",
"entity_id": "2811",
"entity_type": "Gene",
"text_name": "glycoprotein (GP) Ib alpha"
},
{
"begin_idx": "613",
"end_idx": "618",
"entity_id": "2815",
"entity_type": "Gene",
"text_name": "GP IX"
}
] | [
{
"begin_idx": "98",
"end_idx": "122",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "Bernard-Soulier syndrome"
},
{
"begin_idx": "1144",
"end_idx": "1159",
"entity_id": "D001606",
"entity_type": "Disease",
"text_name": "Bernard-Soulier"
}
] | [
"glycoprotein (GP) Ib alpha",
"GP IX"
] | [
"Bernard-Soulier syndrome",
"Bernard-Soulier"
] |
10090345 | Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. | The inducible nitric oxide synthase isoform (iNOS) is upregulated by cytokines and endotoxins in many types of cells, including cardiac myocytes. Nitric oxide (NO) induced by cytokines can be cytotoxic, and has been implicated in the pathophysiology of myocardial infarction, cardiomyopathy, and septic shock. To examine the role of iNOS in the ischemic myocardium, we studied: 1) the time course of expression of iNOS mRNA after myocardial infarction (MI) in male Sprague-Dawley rat hearts and expression of iNOS protein in the infarcted region; 2) whether hypoxia in vitro is a potential mediator of the induction of iNOS mRNA; and 3) whether inhibition of iNOS by two different selective inhibitors (aminoguanidine and S-methylisothiourea sulfate) in vivo influences infarct size. Myocardial infarction was induced by ligation of the left anterior descending coronary artery (LAD), and tissue was collected at selected times thereafter from both ligated and sham-operated rats. iNOS mRNA was induced in the infarcted region of the left ventricle for 7 days; iNOS protein was also detected in the infarcted area. We next tested whether hypoxia would induce iNOS in vitro. In cultured neonatal ventricular myocytes, iNOS mRNA was slightly induced by 6 to 24 h of hypoxia; however, iNOS protein was only detected when the cytokine interleukin-1beta was present. To study whether iNOS activity contributed to myocardial damage (eg, infarct size), we administered the first dose of the NOS inhibitors 24 h before LAD occlusion and then a second dose after surgery. Inhibition of iNOS activity with aminoguanidine reduced infarct size by 20% but had no effect on infiltration by neutrophils, whereas the more selective inhibitor S-methylisothiourea sulfate reduced infarct size by 41%. These data suggest that NO derived from the iNOS isoform contributes to some of the myocardial injury following MI, possibly by causing myocardial cell death in areas bordering the ischemic region of the heart. | [
{
"begin_idx": "645",
"end_idx": "652",
"entity_id": "D000860",
"entity_type": "Disease",
"text_name": "hypoxia"
},
{
"begin_idx": "1225",
"end_idx": "1232",
"entity_id": "D000860",
"entity_type": "Disease",
"text_name": "hypoxia"
},
{
"begin_idx": "1351",
"end_idx": "1358",
"entity_id": "D000860",
"entity_type": "Disease",
"text_name": "hypoxia"
},
{
"begin_idx": "857",
"end_idx": "864",
"entity_id": "D007238",
"entity_type": "Disease",
"text_name": "infarct"
},
{
"begin_idx": "1518",
"end_idx": "1525",
"entity_id": "D007238",
"entity_type": "Disease",
"text_name": "infarct"
},
{
"begin_idx": "1706",
"end_idx": "1713",
"entity_id": "D007238",
"entity_type": "Disease",
"text_name": "infarct"
},
{
"begin_idx": "1849",
"end_idx": "1856",
"entity_id": "D007238",
"entity_type": "Disease",
"text_name": "infarct"
},
{
"begin_idx": "432",
"end_idx": "440",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemic"
},
{
"begin_idx": "2051",
"end_idx": "2059",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemic"
},
{
"begin_idx": "363",
"end_idx": "377",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "cardiomyopathy"
},
{
"begin_idx": "1495",
"end_idx": "1512",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "myocardial damage"
},
{
"begin_idx": "1954",
"end_idx": "1971",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "myocardial injury"
},
{
"begin_idx": "13",
"end_idx": "31",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarct"
},
{
"begin_idx": "340",
"end_idx": "361",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "517",
"end_idx": "538",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "540",
"end_idx": "542",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "871",
"end_idx": "892",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "Myocardial infarction"
},
{
"begin_idx": "1982",
"end_idx": "1984",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "383",
"end_idx": "395",
"entity_id": "D012772",
"entity_type": "Disease",
"text_name": "septic shock"
},
{
"begin_idx": "1418",
"end_idx": "1435",
"entity_id": "3553",
"entity_type": "Gene",
"text_name": "interleukin-1beta"
},
{
"begin_idx": "132",
"end_idx": "136",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "420",
"end_idx": "424",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "501",
"end_idx": "505",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "596",
"end_idx": "600",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "706",
"end_idx": "710",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "746",
"end_idx": "750",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1068",
"end_idx": "1072",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1148",
"end_idx": "1152",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1246",
"end_idx": "1250",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1304",
"end_idx": "1308",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1369",
"end_idx": "1373",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1466",
"end_idx": "1470",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1664",
"end_idx": "1668",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1914",
"end_idx": "1918",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "132",
"end_idx": "136",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
},
{
"begin_idx": "1148",
"end_idx": "1152",
"entity_id": "4843",
"entity_type": "Gene",
"text_name": "iNOS"
}
] | [
{
"begin_idx": "340",
"end_idx": "361",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "363",
"end_idx": "377",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "cardiomyopathy"
}
] | [
"iNOS",
"iNOS"
] | [
"myocardial infarction",
"cardiomyopathy"
] |
10090472 | Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. | Multiple endocrine neoplasia type 1 (MEN 1) is a familial cancer syndrome characterized by parathyroid hyperplasia, pituitary adenomas, and neuroendocrine tumors of the pancreas and duodenum. In 1997, the MEN1 tumor suppressor gene was identified, and numerous germline mutations have been reported to be distributed throughout the gene. We used single strand conformational variant (SSCV) analysis to search for germline mutations in the members of 33 kindreds with a confirmed diagnosis of MEN 1. SSCV analysis revealed 25 conformational variants representing germline mutations that are predicted to result in loss of normal menin function. Twenty different disease-associated mutations were identified: five resulting in potential abnormal RNA splicing, two missense mutations, seven nonsense mutations, and six frameshift mutations. The aberrant splice products were identified and confirmed by RT-PCR and direct sequence analysis for two of the five splice mutations. Sixteen of the 20 (80%) mutations identified have not been previously reported. Mutations were not identified in eight kindreds with signs and symptoms consistent with MEN 1. The SSCV analysis revealed mutations in 76% (25 of 33) of the kindreds investigated, thus showing SSCV analysis to be a reliable mutation detection strategy. One-fifth of the mutations identified in this study involve intron sequences, therefore, highlighting the importance of including intron sequences in the search for germline mutations in the MEN1 gene. The need to investigate the entire gene when characterizing new MEN 1 families presents challenges in the translation of genetic studies to efficient clinical diagnostic tests. | [
{
"begin_idx": "157",
"end_idx": "181",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "familial cancer syndrome"
},
{
"begin_idx": "248",
"end_idx": "269",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neuroendocrine tumors"
},
{
"begin_idx": "313",
"end_idx": "323",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "MEN1 tumor"
},
{
"begin_idx": "199",
"end_idx": "222",
"entity_id": "D010282",
"entity_type": "Disease",
"text_name": "parathyroid hyperplasia"
},
{
"begin_idx": "224",
"end_idx": "242",
"entity_id": "D010911",
"entity_type": "Disease",
"text_name": "pituitary adenomas"
},
{
"begin_idx": "26",
"end_idx": "61",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "multiple endocrine neoplasia type 1"
},
{
"begin_idx": "108",
"end_idx": "143",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "Multiple endocrine neoplasia type 1"
},
{
"begin_idx": "145",
"end_idx": "150",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN 1"
},
{
"begin_idx": "600",
"end_idx": "605",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN 1"
},
{
"begin_idx": "1250",
"end_idx": "1255",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN 1"
},
{
"begin_idx": "1681",
"end_idx": "1686",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN 1"
},
{
"begin_idx": "26",
"end_idx": "61",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "multiple endocrine neoplasia type 1"
},
{
"begin_idx": "108",
"end_idx": "143",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "Multiple endocrine neoplasia type 1"
},
{
"begin_idx": "145",
"end_idx": "150",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN 1"
},
{
"begin_idx": "600",
"end_idx": "605",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN 1"
},
{
"begin_idx": "1250",
"end_idx": "1255",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN 1"
},
{
"begin_idx": "1606",
"end_idx": "1610",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
},
{
"begin_idx": "1681",
"end_idx": "1686",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN 1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "26",
"end_idx": "61",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "multiple endocrine neoplasia type 1"
},
{
"begin_idx": "600",
"end_idx": "605",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN 1"
}
] | [
{
"begin_idx": "26",
"end_idx": "61",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "multiple endocrine neoplasia type 1"
},
{
"begin_idx": "199",
"end_idx": "222",
"entity_id": "D010282",
"entity_type": "Disease",
"text_name": "parathyroid hyperplasia"
}
] | [
"multiple endocrine neoplasia type 1",
"MEN 1"
] | [
"multiple endocrine neoplasia type 1",
"parathyroid hyperplasia"
] |
10090474 | Mutation analysis in adenylosuccinate lyase deficiency: eight novel mutations in the re-evaluated full ADSL coding sequence. | The deficiency of adenylosuccinate lyase (ADSL, also termed adenylosuccinase) is an autosomal recessive disorder characterized by the accumulation in body fluids of succinylaminoimidazole-carboxamide riboside (SAICA-riboside) and succinyladenosine (S-Ado). Most ADSL-deficient children display marked psychomotor delay, often accompanied by epilepsy or autistic features, or both, although some patients may be less profoundly retarded. Occasionally, growth retardation and muscular wasting are also present. Up to now, nine missense mutations of the ADSL gene had been reported in six apparently unrelated sibships. In the present study of 10 additional patients with ADSL deficiency, nine point mutations, among which seven unreported missense mutations, and the first splicing error reported in this disorder, have been identified. These mutations have been characterized, taking into account the finding that the cDNA of human ADSL is 75 nucleotides longer at its 5'-end, and encodes a protein of 484 rather than 459 amino acids as previously reported. Five apparently unrelated patients were found to carry a R426H mutation. With the exceptions of the latter mutation, of a R190Q mutation that had been reported previously, and of a K246E mutation that was found in two unrelated patients, all other mutations were found only in a single family. | [
{
"begin_idx": "21",
"end_idx": "54",
"entity_id": "C538235",
"entity_type": "Disease",
"text_name": "adenylosuccinate lyase deficiency"
},
{
"begin_idx": "129",
"end_idx": "165",
"entity_id": "C538235",
"entity_type": "Disease",
"text_name": "deficiency of adenylosuccinate lyase"
},
{
"begin_idx": "387",
"end_idx": "401",
"entity_id": "C538235",
"entity_type": "Disease",
"text_name": "ADSL-deficient"
},
{
"begin_idx": "794",
"end_idx": "809",
"entity_id": "C538235",
"entity_type": "Disease",
"text_name": "ADSL deficiency"
},
{
"begin_idx": "478",
"end_idx": "486",
"entity_id": "D001321",
"entity_type": "Disease",
"text_name": "autistic"
},
{
"begin_idx": "466",
"end_idx": "474",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epilepsy"
},
{
"begin_idx": "576",
"end_idx": "594",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "growth retardation"
},
{
"begin_idx": "426",
"end_idx": "443",
"entity_id": "D011596",
"entity_type": "Disease",
"text_name": "psychomotor delay"
},
{
"begin_idx": "608",
"end_idx": "615",
"entity_id": "D019282",
"entity_type": "Disease",
"text_name": "wasting"
},
{
"begin_idx": "209",
"end_idx": "237",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "103",
"end_idx": "107",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "ADSL"
},
{
"begin_idx": "143",
"end_idx": "165",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "adenylosuccinate lyase"
},
{
"begin_idx": "167",
"end_idx": "171",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "ADSL"
},
{
"begin_idx": "185",
"end_idx": "201",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "adenylosuccinase"
},
{
"begin_idx": "676",
"end_idx": "680",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "ADSL"
},
{
"begin_idx": "1056",
"end_idx": "1060",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "ADSL"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "143",
"end_idx": "165",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "adenylosuccinate lyase"
},
{
"begin_idx": "103",
"end_idx": "107",
"entity_id": "158",
"entity_type": "Gene",
"text_name": "ADSL"
}
] | [
{
"begin_idx": "129",
"end_idx": "165",
"entity_id": "C538235",
"entity_type": "Disease",
"text_name": "deficiency of adenylosuccinate lyase"
},
{
"begin_idx": "478",
"end_idx": "486",
"entity_id": "D001321",
"entity_type": "Disease",
"text_name": "autistic"
}
] | [
"adenylosuccinate lyase",
"ADSL"
] | [
"deficiency of adenylosuccinate lyase",
"autistic"
] |
10090484 | Mutation analysis in 46 German families with familial hypercholesterolemia: identification of 8 new mutations. Mutations in brief no. 226. Online. | In order to obtain a survey of the mutations being prevalent in Northern Germany and to enable molecular genetic testing for families with clinically diagnosed familial hypercholesterolemia (FH), we screened 46 unrelated German individuals with elevated LDL levels for mutations in the 18 exons and their flanking intron sequences including the promotor region of the LDL receptor (LDLR) gene. In addition, we tested all patients for the presence of mutations in the gene coding for apolipoprotein B-100 (apoB-100). We detected 15 mutations affecting the LDLR gene, 8 of which, designated A29S, 195insAT, 313+1insG, 553insG, 680insGGACAAATCTG, D200N, E267K and L411V have not yet been reported. One patient is heterozygous for the double mutant N543H and 2393del9Bp. Two patients carried the mutation R3500Q (Arg-->Glu) within the apoB-100 gene. | [
{
"begin_idx": "45",
"end_idx": "74",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "307",
"end_idx": "336",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "338",
"end_idx": "340",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "FH"
},
{
"begin_idx": "630",
"end_idx": "650",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apolipoprotein B-100"
},
{
"begin_idx": "652",
"end_idx": "660",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB-100"
},
{
"begin_idx": "978",
"end_idx": "986",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB-100"
},
{
"begin_idx": "45",
"end_idx": "74",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "307",
"end_idx": "336",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "338",
"end_idx": "340",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "FH"
},
{
"begin_idx": "515",
"end_idx": "527",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
},
{
"begin_idx": "529",
"end_idx": "533",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDLR"
},
{
"begin_idx": "702",
"end_idx": "706",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDLR"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "45",
"end_idx": "74",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "652",
"end_idx": "660",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB-100"
}
] | [
{
"begin_idx": "45",
"end_idx": "74",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "338",
"end_idx": "340",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "FH"
}
] | [
"familial hypercholesterolemia",
"apoB-100"
] | [
"familial hypercholesterolemia",
"FH"
] |
10090526 | The multiple cases of Fabry disease in a Russian family caused by an E341K amino acid substitution in the alpha-galactosidase A. | A large Russian family with multiple cases of Fabry disease in several generations is presented. Fourteen family members were clinico-biochemically examined. Among 12 adult children (19-32 years old) of one couple, five sons manifested angiokeratotic skin lesions and other Fabry symptoms. Biochemical studies including an enzyme assay, the analysis of glycosphingolipid excretion and isoelectric focusing of a patient leukocyte extract allowed us to identify Fabry disease in four affected brothers and to establish the heterozygous status of their mother. The analysis of genomic DNA of four patients and their mother revealed a novel E341K missense mutation caused by a G to A transition (codon 341 GAA-AAA) in the alpha-galactosidase A gene. | [
{
"begin_idx": "22",
"end_idx": "35",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry disease"
},
{
"begin_idx": "175",
"end_idx": "188",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry disease"
},
{
"begin_idx": "403",
"end_idx": "417",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry symptoms"
},
{
"begin_idx": "589",
"end_idx": "602",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry disease"
},
{
"begin_idx": "482",
"end_idx": "509",
"entity_id": "D011507",
"entity_type": "Disease",
"text_name": "glycosphingolipid excretion"
},
{
"begin_idx": "380",
"end_idx": "392",
"entity_id": "D012871",
"entity_type": "Disease",
"text_name": "skin lesions"
},
{
"begin_idx": "106",
"end_idx": "127",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
},
{
"begin_idx": "847",
"end_idx": "868",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "106",
"end_idx": "127",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
},
{
"begin_idx": "106",
"end_idx": "127",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
}
] | [
{
"begin_idx": "403",
"end_idx": "417",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry symptoms"
},
{
"begin_idx": "380",
"end_idx": "392",
"entity_id": "D012871",
"entity_type": "Disease",
"text_name": "skin lesions"
}
] | [
"alpha-galactosidase A",
"alpha-galactosidase A"
] | [
"Fabry symptoms",
"skin lesions"
] |
10090529 | A single strand conformation polymorphism/heteroduplex (SSCP/HD) method for detection of mutations in 15 exons of the KVLQT1 gene, associated with long QT syndrome. | Congenital long QT syndrome (LQTS) is characterised by prolongation of the QT interval on ECG and cardiac arrhythmias, syncopes and sudden death. A rapid and reliable genetic diagnosis of the disease may be of great importance for diagnosis and treatment of LQTS. Mutations in the KVLQT1 gene, encoding a potassium-channel subunit of importance for the depolarisation of cardiac myocytes, is believed to be associated with 50% of all LQTS cases. Our data confirms that KvLQT1 isoform 1 is encoded by 16 exons, and not 15, as reported previously. We have used genomic DNA sequences to design intronic PCR primers for amplification of 15 exons of KVLQT1 and optimised a non-radioactive single stranded conformation polymorphism/heteroduplex (SSCP/HD) method for detection of mutations in KVLQT1. The sensitivity of the method was 100% when it was tested on 15 in vitro constructed mutants. By multiplexing the PCR amplification of KVLQT1, it is possible to cover all 15 exons in four PCR reactions. | [
{
"begin_idx": "263",
"end_idx": "282",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "cardiac arrhythmias"
},
{
"begin_idx": "297",
"end_idx": "309",
"entity_id": "D003645",
"entity_type": "Disease",
"text_name": "sudden death"
},
{
"begin_idx": "61",
"end_idx": "63",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
},
{
"begin_idx": "910",
"end_idx": "912",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
},
{
"begin_idx": "147",
"end_idx": "163",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long QT syndrome"
},
{
"begin_idx": "165",
"end_idx": "192",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "Congenital long QT syndrome"
},
{
"begin_idx": "194",
"end_idx": "198",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "423",
"end_idx": "427",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "599",
"end_idx": "603",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "284",
"end_idx": "292",
"entity_id": "D013575",
"entity_type": "Disease",
"text_name": "syncopes"
},
{
"begin_idx": "118",
"end_idx": "124",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "446",
"end_idx": "452",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "634",
"end_idx": "640",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KvLQT1"
},
{
"begin_idx": "810",
"end_idx": "816",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "951",
"end_idx": "957",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "1094",
"end_idx": "1100",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "118",
"end_idx": "124",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "634",
"end_idx": "640",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KvLQT1"
}
] | [
{
"begin_idx": "165",
"end_idx": "192",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "Congenital long QT syndrome"
},
{
"begin_idx": "61",
"end_idx": "63",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
}
] | [
"KVLQT1",
"KvLQT1"
] | [
"Congenital long QT syndrome",
"HD"
] |
10090885 | Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. | Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of lymphocyte homeostasis and immunological tolerance. Most patients have a heterozygous mutation in the APT1 gene, which encodes Fas (CD95, APO-1), mediator of an apoptotic pathway crucial to lymphocyte homeostasis. Of 17 unique APT1 mutations in unrelated ALPS probands, 12 (71%) occurred in exons 7-9, which encode the intracellular portion of Fas. In vitro, activated lymphocytes from all 17 patients showed apoptotic defects when exposed to an anti-Fas agonist monoclonal antibody. Similar defects were found in a Fas-negative cell line transfected with cDNAs bearing each of the mutations. In cotransfection experiments, Fas constructs with either intra- or extracellular mutations caused dominant inhibition of apoptosis mediated by wild-type Fas. Two missense Fas variants, not restricted to patients with ALPS, were identified. Variant A(-1)T at the Fas signal-sequence cleavage site, which mediates apoptosis less well than wild-type Fas and is partially inhibitory, was present in 13% of African American alleles. Among the ALPS-associated Fas mutants, dominant inhibition of apoptosis was much more pronounced in mutants affecting the intracellular, versus extracellular, portion of the Fas receptor. Mutations causing disruption of the intracellular Fas death domain also showed a higher penetrance of ALPS phenotype features in mutation-bearing relatives. Significant ALPS-related morbidity occurred in 44% of relatives with intracellular mutations, versus 0% of relatives with extracellular mutations. Thus, the location of mutations within APT1 strongly influences the development and the severity of ALPS. | [
{
"begin_idx": "144",
"end_idx": "206",
"entity_id": "D007154",
"entity_type": "Disease",
"text_name": "disorder of lymphocyte homeostasis and immunological tolerance"
},
{
"begin_idx": "0",
"end_idx": "39",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "Autoimmune lymphoproliferative syndrome"
},
{
"begin_idx": "92",
"end_idx": "131",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "Autoimmune lymphoproliferative syndrome"
},
{
"begin_idx": "133",
"end_idx": "137",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "411",
"end_idx": "415",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "967",
"end_idx": "971",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "1188",
"end_idx": "1192",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "1468",
"end_idx": "1472",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "1535",
"end_idx": "1539",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "1770",
"end_idx": "1774",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "ALPS"
},
{
"begin_idx": "258",
"end_idx": "262",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "APT1"
},
{
"begin_idx": "288",
"end_idx": "292",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "CD95"
},
{
"begin_idx": "294",
"end_idx": "299",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "APO-1"
},
{
"begin_idx": "383",
"end_idx": "387",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "APT1"
},
{
"begin_idx": "1709",
"end_idx": "1713",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "APT1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "294",
"end_idx": "299",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "APO-1"
},
{
"begin_idx": "1709",
"end_idx": "1713",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "APT1"
}
] | [
{
"begin_idx": "0",
"end_idx": "39",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "Autoimmune lymphoproliferative syndrome"
},
{
"begin_idx": "144",
"end_idx": "206",
"entity_id": "D007154",
"entity_type": "Disease",
"text_name": "disorder of lymphocyte homeostasis and immunological tolerance"
}
] | [
"APO-1",
"APT1"
] | [
"Autoimmune lymphoproliferative syndrome",
"disorder of lymphocyte homeostasis and immunological tolerance"
] |
10092513 | Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. | We isolated the human adipose-specific and most abundant gene transcript, apM1 (Maeda, K., et al., Biochem. Biophys. Res. Commun. 221, 286-289, 1996). The apM1 gene product was a kind of soluble matrix protein, which we named adiponectin. To quantitate the plasma adiponectin concentration, we have produced monoclonal and polyclonal antibodies for human adiponectin and developed an enzyme-linked immunosorbent assay (ELISA) system. Adiponectin was abundantly present in the plasma of healthy volunteers in the range from 1.9 to 17.0 mg/ml. Plasma concentrations of adiponectin in obese subjects were significantly lower than those in non-obese subjects, although adiponectin is secreted only from adipose tissue. The ELISA system developed in this study will be useful for elucidating the physiological and pathophysiological role of adiponectin in humans. | [
{
"begin_idx": "69",
"end_idx": "76",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obesity"
},
{
"begin_idx": "53",
"end_idx": "64",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
},
{
"begin_idx": "152",
"end_idx": "156",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "apM1"
},
{
"begin_idx": "233",
"end_idx": "237",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "apM1"
},
{
"begin_idx": "304",
"end_idx": "315",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
},
{
"begin_idx": "342",
"end_idx": "353",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
},
{
"begin_idx": "433",
"end_idx": "444",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
},
{
"begin_idx": "512",
"end_idx": "523",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "Adiponectin"
},
{
"begin_idx": "645",
"end_idx": "656",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
},
{
"begin_idx": "743",
"end_idx": "754",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
},
{
"begin_idx": "914",
"end_idx": "925",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "53",
"end_idx": "64",
"entity_id": "9370",
"entity_type": "Gene",
"text_name": "adiponectin"
}
] | [
{
"begin_idx": "69",
"end_idx": "76",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obesity"
}
] | [
"adiponectin"
] | [
"obesity"
] |
10094187 | Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS). | Coffin-Lowry syndrome (CLS) is an X-linked disorder characterized by facial dysmorphism, digit abnormalities and severe psychomotor retardation. CLS had previously been mapped to Xp22.2. Recently, mutations in the ribosomal S6 kinase (Rsk-2) gene were shown to be associated with CLS. We have tested five unrelated individuals with CLS for mutations in nine exons of Rsk-2 using Single Strand Conformation Polymorphism (SSCP) analysis. Two patients had the same missense mutation (C340T), which causes an arginine to tryptophan change (R114W). This mutation falls just outside the N-terminal ATP-binding site in a highly conserved region of the protein and may lead to structural changes since tryptophan has an aromatic side chain whereas arginine is a 5 carbon basic amino acid. The third patient also had a missense mutation (G2186A) resulting in an arginine to glutamine change (R729Q). The fourth patient had a 2bp deletion (AG) of bases 451 and 452. This creates a frameshift that results in a stop codon 25 amino acids downstream, thereby producing a truncated protein. This deletion also falls within the highly conserved amino-catalytic domain of the protein. The fifth patient has a nonsense mutation (C2065T) which results in a premature stop codon, thereby producing a truncated protein. These mutations further confirm Rsk-2 as the gene involved in CLS and may help in understanding the structure and function of the protein. | [
{
"begin_idx": "137",
"end_idx": "155",
"entity_id": "D000013",
"entity_type": "Disease",
"text_name": "facial dysmorphism"
},
{
"begin_idx": "188",
"end_idx": "211",
"entity_id": "D011596",
"entity_type": "Disease",
"text_name": "psychomotor retardation"
},
{
"begin_idx": "39",
"end_idx": "60",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "Coffin-Lowry syndrome"
},
{
"begin_idx": "62",
"end_idx": "65",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "68",
"end_idx": "89",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "Coffin-Lowry syndrome"
},
{
"begin_idx": "91",
"end_idx": "94",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "213",
"end_idx": "216",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "348",
"end_idx": "351",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "400",
"end_idx": "403",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "1430",
"end_idx": "1433",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "102",
"end_idx": "119",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked disorder"
},
{
"begin_idx": "19",
"end_idx": "24",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "Rsk-2"
},
{
"begin_idx": "303",
"end_idx": "308",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "Rsk-2"
},
{
"begin_idx": "435",
"end_idx": "440",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "Rsk-2"
},
{
"begin_idx": "1400",
"end_idx": "1405",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "Rsk-2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "19",
"end_idx": "24",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "Rsk-2"
},
{
"begin_idx": "303",
"end_idx": "308",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "Rsk-2"
}
] | [
{
"begin_idx": "39",
"end_idx": "60",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "Coffin-Lowry syndrome"
},
{
"begin_idx": "137",
"end_idx": "155",
"entity_id": "D000013",
"entity_type": "Disease",
"text_name": "facial dysmorphism"
}
] | [
"Rsk-2",
"Rsk-2"
] | [
"Coffin-Lowry syndrome",
"facial dysmorphism"
] |
10094189 | Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. | Sanfilippo B syndrome (mucopolysaccharidosis IIIB, MPS IIIB) is caused by a deficiency of alpha-N-acetylglucosaminidase, a lysosomal enzyme involved in the degradation of heparan sulphate. Accumulation of the substrate in lysosomes leads to degeneration of the central nervous system with progressive dementia often combined with hyperactivity and aggressive behaviour. Age of onset and rate of progression vary considerably, whilst diagnosis is often delayed due to the absence of the pronounced skeletal changes observed in other mucopolysaccharidoses. Cloning of the gene and cDNA encoding alpha-N-acetylglucosaminidase enabled a study of the molecular basis of this syndrome. We were able to identify 31 mutations, 25 of them novel, and two polymorphisms in the 40 patients mostly of Australasian and Dutch origin included in this study. The observed allellic heterogeneity reflects the wide spectrum of clinical phenotypes reported for MPS IIIB patients. The majority of changes are missense mutations; also four nonsense and nine frameshift mutations caused by insertions or deletions were identified. Only five mutations were found in more than one patient and the observed frequencies are well below those observed for the common mutations in MPS IIIA. R643C and R297X each account for around 20% of MPS IIIB alleles in the Dutch patient group, whilst R297X, P521L, R565W and R626X each have a frequency of about 6% in Australasian patients. R643C seems to be a Dutch MPS IIIB allele and clearly confers the attenuated phenotype. One region of the gene shows a higher concentration of mutations, probably reflecting the instability of this area which contains a direct repeat. Several arginine residues seem to be 'hot-spots' for mutations, being affected by two or three individual base pair exchanges. | [
{
"begin_idx": "485",
"end_idx": "505",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "aggressive behaviour"
},
{
"begin_idx": "438",
"end_idx": "446",
"entity_id": "D003704",
"entity_type": "Disease",
"text_name": "dementia"
},
{
"begin_idx": "467",
"end_idx": "480",
"entity_id": "D006948",
"entity_type": "Disease",
"text_name": "hyperactivity"
},
{
"begin_idx": "28",
"end_idx": "55",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis III B"
},
{
"begin_idx": "137",
"end_idx": "158",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "Sanfilippo B syndrome"
},
{
"begin_idx": "160",
"end_idx": "186",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis IIIB"
},
{
"begin_idx": "188",
"end_idx": "196",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "MPS IIIB"
},
{
"begin_idx": "1078",
"end_idx": "1086",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "MPS IIIB"
},
{
"begin_idx": "1388",
"end_idx": "1396",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "MPS IIIA"
},
{
"begin_idx": "1445",
"end_idx": "1453",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "MPS IIIB"
},
{
"begin_idx": "1613",
"end_idx": "1621",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "MPS IIIB"
},
{
"begin_idx": "16",
"end_idx": "26",
"entity_id": "D016393",
"entity_type": "Disease",
"text_name": "B syndrome"
},
{
"begin_idx": "378",
"end_idx": "420",
"entity_id": "D020279",
"entity_type": "Disease",
"text_name": "degeneration of the central nervous system"
},
{
"begin_idx": "188",
"end_idx": "196",
"entity_id": "4669",
"entity_type": "Gene",
"text_name": "MPS IIIB"
},
{
"begin_idx": "1078",
"end_idx": "1086",
"entity_id": "4669",
"entity_type": "Gene",
"text_name": "MPS IIIB"
},
{
"begin_idx": "1445",
"end_idx": "1453",
"entity_id": "4669",
"entity_type": "Gene",
"text_name": "MPS IIIB"
},
{
"begin_idx": "1613",
"end_idx": "1621",
"entity_id": "4669",
"entity_type": "Gene",
"text_name": "MPS IIIB"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "188",
"end_idx": "196",
"entity_id": "4669",
"entity_type": "Gene",
"text_name": "MPS IIIB"
},
{
"begin_idx": "188",
"end_idx": "196",
"entity_id": "4669",
"entity_type": "Gene",
"text_name": "MPS IIIB"
}
] | [
{
"begin_idx": "28",
"end_idx": "55",
"entity_id": "D009084",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis III B"
},
{
"begin_idx": "438",
"end_idx": "446",
"entity_id": "D003704",
"entity_type": "Disease",
"text_name": "dementia"
}
] | [
"MPS IIIB",
"MPS IIIB"
] | [
"mucopolysaccharidosis III B",
"dementia"
] |
10099885 | The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. | BACKGROUND: The insertion-deletion (I/D) polymorphism of the angiotensin converting enzyme gene is a diallelic polymorphism that constitutes a genetic influence on the progression of renal diseases such as IgA nephropathy. Patients with the DD genotype have an accelerated progression towards end stage renal failure in these diseases. The role of the I/D polymorphism in the pathogenesis of diabetic nephropathy in IDDM is unresolved. PATIENTS AND METHODS: We therefore set out to study the contribution of the I/D polymorphism in 79 patients (age 39.5 +/- 7.6 years (mean +/- SD) with end stage renal failure due to diabetic nephropathy, who were recipients of a combined kidney-pancreas transplantation (n = 60), or who were on the waiting list for such a procedure (n = 19). The control series consisted of 82 patients (age 39.5 +/- 9.6 years) without microalbuminuria after fifteen years of IDDM. RESULTS: The ACE genotype distribution in patients was not in accordance with the Hardy-Weinberg equilibrium due to a significant overrepresentation of the DD genotype (X2 = 8.9, p = 0.01). This resulted in a significant increase of the D-allele frequency in the cases compared to controls (X2 = 4.9, p = 0.03). The presence of one D-allele did not increase the risk of end stage renal failure (odds ratio ID/II = 1.0, 95% CI 0.4-2.2). The presence of the DD genotype increased the risk of end stage renal failure twofold compared to the other genotypes (odds ratio 2.1, 95% CI 1.1-4.0). The risk estimate seemed slightly higher in patients with good metabolic control (odds ratio 2.6, 95% CI 1.0-7.1), than in patients with poor control (odds ratio 1.6, 95% CI 0.59-4.3). CONCLUSION: It is concluded that the risk of end-stage renal failure in patients with IDDM is twofold increased in patients with the DD genotype as compared to patients with other genotypes. | [
{
"begin_idx": "4",
"end_idx": "6",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "377",
"end_idx": "379",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1194",
"end_idx": "1196",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1494",
"end_idx": "1496",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1944",
"end_idx": "1946",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "130",
"end_idx": "134",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "552",
"end_idx": "556",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1032",
"end_idx": "1036",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1897",
"end_idx": "1901",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "79",
"end_idx": "99",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "528",
"end_idx": "548",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "754",
"end_idx": "774",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "319",
"end_idx": "333",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "renal diseases"
},
{
"begin_idx": "342",
"end_idx": "357",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "IgA nephropathy"
},
{
"begin_idx": "1856",
"end_idx": "1879",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "end-stage renal failure"
},
{
"begin_idx": "107",
"end_idx": "126",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "stage renal failure"
},
{
"begin_idx": "433",
"end_idx": "452",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "stage renal failure"
},
{
"begin_idx": "727",
"end_idx": "746",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "stage renal failure"
},
{
"begin_idx": "1412",
"end_idx": "1431",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "stage renal failure"
},
{
"begin_idx": "1532",
"end_idx": "1551",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "stage renal failure"
},
{
"begin_idx": "23",
"end_idx": "26",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "197",
"end_idx": "226",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "1051",
"end_idx": "1054",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
false,
true,
true
] | [
{
"begin_idx": "197",
"end_idx": "226",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "197",
"end_idx": "226",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "197",
"end_idx": "226",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "197",
"end_idx": "226",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
}
] | [
{
"begin_idx": "79",
"end_idx": "99",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "1856",
"end_idx": "1879",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "end-stage renal failure"
},
{
"begin_idx": "1532",
"end_idx": "1551",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "stage renal failure"
},
{
"begin_idx": "130",
"end_idx": "134",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
}
] | [
"angiotensin converting enzyme",
"angiotensin converting enzyme",
"angiotensin converting enzyme",
"angiotensin converting enzyme"
] | [
"diabetic nephropathy",
"end-stage renal failure",
"stage renal failure",
"IDDM"
] |
10102298 | Bothnia dystrophy caused by mutations in the cellular retinaldehyde-binding protein gene (RLBP1) on chromosome 15q26. | PURPOSE: To determine the chromosomal location and to identify the gene causing a type of retinitis punctata albescens, called Bothnia dystrophy, found in a restricted geographic area in northern Sweden. METHODS: Twenty patients from seven families originating from a restricted geographic area in northern Sweden were clinically examined. Microsatellite markers were analyzed in all affected and unaffected family members. Direct genomic sequencing of the gene encoding cellular retinaldehyde-binding protein was performed after the linkage analysis had been completed. RESULTS: Affected individuals showed night blindness from early childhood with features consistent with retinitis punctata albescens and macular degeneration. The responsible gene was mapped to 15q26, the same region to which the cellular retinaldehyde-binding protein gene has been assigned. Subsequent analysis showed all affected patients were homozygous for a C to T substitution in exon 7 of the same gene, leading to the missense mutation Arg234Trp. Analysis of marker haplotypes suggested that all cases had a common ancestor who carried the mutation. CONCLUSIONS: A missense mutation in the cellular retinaldehyde-binding protein gene is the cause of Bothnia dystrophy. The disease is a local variant of retinitis punctata albescens that is common in northern Sweden due to a founder mutation. | [
{
"begin_idx": "208",
"end_idx": "236",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "793",
"end_idx": "821",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "1401",
"end_idx": "1429",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "C564392",
"entity_type": "Disease",
"text_name": "Bothnia dystrophy"
},
{
"begin_idx": "245",
"end_idx": "262",
"entity_id": "C564392",
"entity_type": "Disease",
"text_name": "Bothnia dystrophy"
},
{
"begin_idx": "1348",
"end_idx": "1365",
"entity_id": "C564392",
"entity_type": "Disease",
"text_name": "Bothnia dystrophy"
},
{
"begin_idx": "826",
"end_idx": "846",
"entity_id": "D008268",
"entity_type": "Disease",
"text_name": "macular degeneration"
},
{
"begin_idx": "726",
"end_idx": "741",
"entity_id": "D009755",
"entity_type": "Disease",
"text_name": "night blindness"
},
{
"begin_idx": "45",
"end_idx": "83",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "90",
"end_idx": "95",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
},
{
"begin_idx": "589",
"end_idx": "627",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "919",
"end_idx": "957",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "1288",
"end_idx": "1326",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "45",
"end_idx": "83",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "90",
"end_idx": "95",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
}
] | [
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "C564392",
"entity_type": "Disease",
"text_name": "Bothnia dystrophy"
},
{
"begin_idx": "726",
"end_idx": "741",
"entity_id": "D009755",
"entity_type": "Disease",
"text_name": "night blindness"
}
] | [
"cellular retinaldehyde-binding protein",
"RLBP1"
] | [
"Bothnia dystrophy",
"night blindness"
] |
10102299 | Recessive mutations in the RLBP1 gene encoding cellular retinaldehyde-binding protein in a form of retinitis punctata albescens. | PURPOSE: To determine the frequency and spectrum of mutations in the RLBP1 gene encoding cellular retinaldehyde-binding protein (CRALBP) in patients with hereditary retinal degeneration. METHODS: The single-strand conformation polymorphism (SSCP) technique and a direct genomic sequencing technique were used to screen the coding exons of this gene (exons 2-8) for mutations in 324 unrelated patients with recessive or isolate retinitis pigmentosa, retinitis punctata albescens, Leber congenital amaurosis, or a related disease. Variant DNA fragments revealed by SSCP analysis were subsequently sequenced. Selected alleles that altered the coding region or intron splice sites were evaluated further through segregation analysis in the families of the index cases. RESULTS: Four novel mutations were identified in this gene among three unrelated patients with recessively inherited retinitis punctata albescens. Two of the mutations were missense: one was a frameshift, and one affected a canonical splice donor site. CONCLUSIONS: Recessive mutations in the RLBP1 gene are an uncommon cause of retinal degeneration in humans. The phenotype produced by RLBP1 mutations seems to be a form of retinitis punctata albescens. | [
{
"begin_idx": "99",
"end_idx": "127",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "578",
"end_idx": "606",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "1319",
"end_idx": "1347",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "283",
"end_idx": "314",
"entity_id": "D012162",
"entity_type": "Disease",
"text_name": "hereditary retinal degeneration"
},
{
"begin_idx": "1223",
"end_idx": "1243",
"entity_id": "D012162",
"entity_type": "Disease",
"text_name": "retinal degeneration"
},
{
"begin_idx": "556",
"end_idx": "576",
"entity_id": "D012174",
"entity_type": "Disease",
"text_name": "retinitis pigmentosa"
},
{
"begin_idx": "989",
"end_idx": "1039",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "recessively inherited retinitis punctata albescens"
},
{
"begin_idx": "608",
"end_idx": "634",
"entity_id": "D057130",
"entity_type": "Disease",
"text_name": "Leber congenital amaurosis"
},
{
"begin_idx": "27",
"end_idx": "32",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
},
{
"begin_idx": "47",
"end_idx": "85",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "198",
"end_idx": "203",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
},
{
"begin_idx": "218",
"end_idx": "256",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "258",
"end_idx": "264",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "CRALBP"
},
{
"begin_idx": "1187",
"end_idx": "1192",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
},
{
"begin_idx": "1281",
"end_idx": "1286",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "47",
"end_idx": "85",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "cellular retinaldehyde-binding protein"
},
{
"begin_idx": "1281",
"end_idx": "1286",
"entity_id": "6017",
"entity_type": "Gene",
"text_name": "RLBP1"
}
] | [
{
"begin_idx": "99",
"end_idx": "127",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "989",
"end_idx": "1039",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "recessively inherited retinitis punctata albescens"
}
] | [
"cellular retinaldehyde-binding protein",
"RLBP1"
] | [
"retinitis punctata albescens",
"recessively inherited retinitis punctata albescens"
] |
10190266 | Association of the 677C-->T mutation on the methylenetetrahydrofolate reductase gene in Turkish patients with neural tube defects. | We report the analysis of the 677C-->T mutation on the 5, 10-methylenetetrahydrofolate reductase gene in Turkish controls and cases of neural tube defects. Mutation analysis of 91 patients with neural tube defects, 72 mothers, 63 fathers, and 93 healthy controls has been made by polymerase chain reaction and allele specific restriction digestion with Hinf I. We did not find a significant difference in the 677C-->T allele and genotype distribution among the patients with neural tube defects, their parents, and the control group. This result suggests that another mutation in the folate-related enzyme genes could be responsible for neural tube defects in Turkey. None of the mothers of patients with neural tube defects was advised to use folic acid as recommended to prevent neural tube defects. An immediate attempt to establish an education program for healthcare providers and women of childbearing age is crucial in Turkey. Furthermore, fortification of foods with folate would be a better approach. | [
{
"begin_idx": "110",
"end_idx": "129",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "266",
"end_idx": "285",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "325",
"end_idx": "344",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "606",
"end_idx": "625",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "768",
"end_idx": "787",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "836",
"end_idx": "855",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "912",
"end_idx": "931",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
},
{
"begin_idx": "44",
"end_idx": "79",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
},
{
"begin_idx": "192",
"end_idx": "227",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "44",
"end_idx": "79",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
}
] | [
{
"begin_idx": "110",
"end_idx": "129",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "neural tube defects"
}
] | [
"methylenetetrahydrofolate reductase"
] | [
"neural tube defects"
] |
10190325 | Identification and characterization of mutations in patients with holocarboxylase synthetase deficiency. | Holocarboxylase synthetase deficiency (HCS) is an autosomal recessive disorder characterized by metabolic ketoacidosis, abnormal urine organic metabolites, and dermatitis. These symptoms are improved by pharmacological doses of biotin. In this study, we have analyzed seven patients with HCS deficiency found in European and Middle Eastern countries by using reverse transcription/polymerase chain reaction/single-stranded conformation polymorphism and a sequencing analysis. Although we had previously reported that two mutations were frequent in Japanese patients, no frequent mutations were found in the patients analyzed in this study. Seven novel mutations were identified in the cDNA of the patients; these included three missense mutations, two single-base deletions that resulted in a termination codon, a three-base in-frame deletion, and a 68-bp deletion. A new polymorphism C1121T was also identified in four alleles. A transient expression study demonstrated that the HCS activities of three missense mutations and one amino acid deletion were 1%-14% that of wild-type cDNA; in contrast, the activities of the two single-base deletions followed by a termination codon and Asp571Asn were nearly undetectable. These data suggest that a variety of mutations is responsible for decreasing HCS activity and that the aspartate residue at amino acid position 571 may be crucial for the catalytic activity of HCS. | [
{
"begin_idx": "265",
"end_idx": "275",
"entity_id": "D003872",
"entity_type": "Disease",
"text_name": "dermatitis"
},
{
"begin_idx": "201",
"end_idx": "223",
"entity_id": "D007662",
"entity_type": "Disease",
"text_name": "metabolic ketoacidosis"
},
{
"begin_idx": "66",
"end_idx": "103",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "holocarboxylase synthetase deficiency"
},
{
"begin_idx": "105",
"end_idx": "142",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "Holocarboxylase synthetase deficiency"
},
{
"begin_idx": "144",
"end_idx": "147",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "HCS"
},
{
"begin_idx": "393",
"end_idx": "407",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "HCS deficiency"
},
{
"begin_idx": "1085",
"end_idx": "1088",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "HCS"
},
{
"begin_idx": "1402",
"end_idx": "1405",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "HCS"
},
{
"begin_idx": "1518",
"end_idx": "1521",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "HCS"
},
{
"begin_idx": "155",
"end_idx": "183",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "144",
"end_idx": "147",
"entity_id": "3141",
"entity_type": "Gene",
"text_name": "HCS"
},
{
"begin_idx": "1085",
"end_idx": "1088",
"entity_id": "3141",
"entity_type": "Gene",
"text_name": "HCS"
},
{
"begin_idx": "1402",
"end_idx": "1405",
"entity_id": "3141",
"entity_type": "Gene",
"text_name": "HCS"
},
{
"begin_idx": "1518",
"end_idx": "1521",
"entity_id": "3141",
"entity_type": "Gene",
"text_name": "HCS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "144",
"end_idx": "147",
"entity_id": "3141",
"entity_type": "Gene",
"text_name": "HCS"
},
{
"begin_idx": "1518",
"end_idx": "1521",
"entity_id": "3141",
"entity_type": "Gene",
"text_name": "HCS"
}
] | [
{
"begin_idx": "66",
"end_idx": "103",
"entity_id": "D028922",
"entity_type": "Disease",
"text_name": "holocarboxylase synthetase deficiency"
},
{
"begin_idx": "155",
"end_idx": "183",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
}
] | [
"HCS",
"HCS"
] | [
"holocarboxylase synthetase deficiency",
"autosomal recessive disorder"
] |
10192380 | A mutation in NRL is associated with autosomal dominant retinitis pigmentosa. | [
{
"begin_idx": "37",
"end_idx": "76",
"entity_id": "D012174",
"entity_type": "Disease",
"text_name": "autosomal dominant retinitis pigmentosa"
},
{
"begin_idx": "14",
"end_idx": "17",
"entity_id": "4901",
"entity_type": "Gene",
"text_name": "NRL"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "14",
"end_idx": "17",
"entity_id": "4901",
"entity_type": "Gene",
"text_name": "NRL"
}
] | [
{
"begin_idx": "37",
"end_idx": "76",
"entity_id": "D012174",
"entity_type": "Disease",
"text_name": "autosomal dominant retinitis pigmentosa"
}
] | [
"NRL"
] | [
"autosomal dominant retinitis pigmentosa"
] |
|
10195814 | Association analysis of sequence variants of GABA(A) alpha6, beta2, and gamma2 gene cluster and alcohol dependence. | Quantitative trait analyses in mice suggest a vulnerability locus for physiological alcohol withdrawal severity on a chromosomal segment that harbors the genes encoding the alpha1, alpha6, beta2, and gamma2 subunits of the gamma-aminobutyric acid type-A receptor (GABR). We tested whether genetic variation at the human GABA(A) alpha6, beta2, and gamma2 gene cluster on chromosome 5q33 confers vulnerability to alcohol dependence. The genotypes of three nucleotide substitution polymorphisms of the GABRA6, GABRB2, and GABRG2 genes were assessed in 349 German alcohol-dependent subjects and in 182 ethnically matched controls. To eliminate some of the genetic variance, three more homogeneous subgroups of alcoholics were formed by: (1) a history of alcohol withdrawal seizure or delirium (n = 106); (2) a history of parental alcoholism (n = 120); and (3) a comorbidity of dissocial personality disorder (n = 57). We found no evidence that any of the investigated allelic variants confers vulnerability to either alcohol dependence or severe physiological alcohol withdrawal symptoms or familial alcoholism (p > 0.05). The frequency of the T allele of the GABRA6 polymorphism was significantly increased in dissocial alcoholics [f(T) = 0.799] compared with the controls [f(T) = 0.658; p = 0.002; OR(T+) = 7.26]. Taking into account the high a priori risk of false-positive association findings due to multiple testing, further replication studies are necessary to examine the tentative phenotype-genotype relationship of GABRA6 gene variants and dissocial alcoholism. | [
{
"begin_idx": "96",
"end_idx": "114",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "527",
"end_idx": "545",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "942",
"end_idx": "952",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1129",
"end_idx": "1147",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "1212",
"end_idx": "1222",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1672",
"end_idx": "1682",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "896",
"end_idx": "904",
"entity_id": "D003693",
"entity_type": "Disease",
"text_name": "delirium"
},
{
"begin_idx": "989",
"end_idx": "1019",
"entity_id": "D010554",
"entity_type": "Disease",
"text_name": "dissocial personality disorder"
},
{
"begin_idx": "885",
"end_idx": "892",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizure"
},
{
"begin_idx": "61",
"end_idx": "66",
"entity_id": "10242",
"entity_type": "Gene",
"text_name": "beta2"
},
{
"begin_idx": "452",
"end_idx": "457",
"entity_id": "10242",
"entity_type": "Gene",
"text_name": "beta2"
},
{
"begin_idx": "305",
"end_idx": "310",
"entity_id": "10242",
"entity_type": "Gene",
"text_name": "beta2"
},
{
"begin_idx": "615",
"end_idx": "621",
"entity_id": "2559",
"entity_type": "Gene",
"text_name": "GABRA6"
},
{
"begin_idx": "1272",
"end_idx": "1278",
"entity_id": "2559",
"entity_type": "Gene",
"text_name": "GABRA6"
},
{
"begin_idx": "1637",
"end_idx": "1643",
"entity_id": "2559",
"entity_type": "Gene",
"text_name": "GABRA6"
},
{
"begin_idx": "623",
"end_idx": "629",
"entity_id": "2561",
"entity_type": "Gene",
"text_name": "GABRB2"
},
{
"begin_idx": "635",
"end_idx": "641",
"entity_id": "2566",
"entity_type": "Gene",
"text_name": "GABRG2"
},
{
"begin_idx": "72",
"end_idx": "78",
"entity_id": "7453",
"entity_type": "Gene",
"text_name": "gamma2"
},
{
"begin_idx": "316",
"end_idx": "322",
"entity_id": "7453",
"entity_type": "Gene",
"text_name": "gamma2"
},
{
"begin_idx": "463",
"end_idx": "469",
"entity_id": "7453",
"entity_type": "Gene",
"text_name": "gamma2"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
false,
true,
false,
true
] | [
{
"begin_idx": "635",
"end_idx": "641",
"entity_id": "2566",
"entity_type": "Gene",
"text_name": "GABRG2"
},
{
"begin_idx": "615",
"end_idx": "621",
"entity_id": "2559",
"entity_type": "Gene",
"text_name": "GABRA6"
},
{
"begin_idx": "316",
"end_idx": "322",
"entity_id": "7453",
"entity_type": "Gene",
"text_name": "gamma2"
},
{
"begin_idx": "72",
"end_idx": "78",
"entity_id": "7453",
"entity_type": "Gene",
"text_name": "gamma2"
}
] | [
{
"begin_idx": "96",
"end_idx": "114",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "96",
"end_idx": "114",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "885",
"end_idx": "892",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizure"
},
{
"begin_idx": "527",
"end_idx": "545",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
}
] | [
"GABRG2",
"GABRA6",
"gamma2",
"gamma2"
] | [
"alcohol dependence",
"alcohol dependence",
"seizure",
"alcohol dependence"
] |
10196694 | An Asn > Lys substitution in saposin B involving a conserved amino acidic residue and leading to the loss of the single N-glycosylation site in a patient with metachromatic leukodystrophy and normal arylsulphatase A activity. | Sphingolipid activator proteins are small glycoproteins required for the degradation of sphingolipids by specific lysosomal hydrolases. Four of them, called saposins, are encoded by the prosaposin gene, the product of which is proteolytically cleaved into the four mature saposin proteins (saposins A, B, C, D). One of these, saposin B, is necessary in the hydrolysis of sulphatide by arylsulphatase A where it presents the solubilised substrate to the enzyme. As an alternative to arylsulphatase A deficiency, deficiency of saposin B causes metachromatic leukodystrophy. We identified a previously undescribed mutation (N215K) in the prosaposin gene of a patient with metachromatic leukodystrophy but with normal arylsulphatase A activity and elevated sulphatide in urine. The mutation involves a highly conserved amino acidic residue and abolishes the only N-glycosylation site of saposin B. | [
{
"begin_idx": "737",
"end_idx": "760",
"entity_id": "C562609",
"entity_type": "Disease",
"text_name": "deficiency of saposin B"
},
{
"begin_idx": "159",
"end_idx": "187",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
},
{
"begin_idx": "768",
"end_idx": "796",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
},
{
"begin_idx": "895",
"end_idx": "923",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
},
{
"begin_idx": "723",
"end_idx": "735",
"entity_id": "D013661",
"entity_type": "Disease",
"text_name": "A deficiency"
},
{
"begin_idx": "412",
"end_idx": "422",
"entity_id": "5660",
"entity_type": "Gene",
"text_name": "prosaposin"
},
{
"begin_idx": "861",
"end_idx": "871",
"entity_id": "5660",
"entity_type": "Gene",
"text_name": "prosaposin"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "412",
"end_idx": "422",
"entity_id": "5660",
"entity_type": "Gene",
"text_name": "prosaposin"
},
{
"begin_idx": "861",
"end_idx": "871",
"entity_id": "5660",
"entity_type": "Gene",
"text_name": "prosaposin"
}
] | [
{
"begin_idx": "737",
"end_idx": "760",
"entity_id": "C562609",
"entity_type": "Disease",
"text_name": "deficiency of saposin B"
},
{
"begin_idx": "895",
"end_idx": "923",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
}
] | [
"prosaposin",
"prosaposin"
] | [
"deficiency of saposin B",
"metachromatic leukodystrophy"
] |
10197076 | A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. | OBJECTIVE: Recent studies have demonstrated an association between a microsatellite polymorphism of the CTLA-4 gene, specifically a 106 base pair allele, and both Graves' disease and autoimmune hypothyroidism. The aim of the present study was to determine whether the same polymorphism of the CTLA-4 gene was associated with autoimmune Addison's disease. DESIGN AND PATIENTS: We analysed a microsatellite polymorphism (variant lengths of a dinucleotide (AT)n repeat) within exon 3 of the CTLA-4 gene in the following groups: 21 English patients with non-associated Addison's disease, 18 with autoimmune polyglandular syndrome type 2 (APS2) and 173 healthy control subjects; 26 Norwegian patients with non-associated Addison's disease, 9 with autoimmune polyglandular syndrome type 1 (APS1), 17 with APS2 and 100 controls; 3 Finnish patients with non-associated Addison's disease, 5 with APS2 and 71 controls; 10 Estonian patients with non-associated Addison's disease, 2 with APS2 and 45 controls. MEASUREMENTS: The CTLA-4 microsatellite gene polymorphisms were determined by polymerase chain reaction amplification of genomic DNA and resolution of the products on sequencing gels. RESULTS: The frequency of the 106 base pair allele was significantly increased in the groups of English patients with either non-associated Addison's disease or APS2 (P = 0.02 and 0.04, respectively), when compared to healthy controls with no clinical evidence or family history of either Addison's disease or any other autoimmune disorder. For Norwegian patients with either non-associated Addison's disease, APS1 or APS2, there was no association (P = 0.69, 0.62 and 0.97, respectively). This was also the case for Finnish patients with either non-associated Addison's disease or APS2 (P = 0.23 and 0.28, respectively) and for Estonian patients with either non-associated Addison's disease or APS2 (P = 0.34 and 0.29, respectively). CONCLUSIONS: These results indicate that differences exist in the frequency of the 106 base pair allele in different population groups and in only the English population was the 106 base pair allele associated with Addison's disease. | [
{
"begin_idx": "314",
"end_idx": "339",
"entity_id": "C562768",
"entity_type": "Disease",
"text_name": "autoimmune hypothyroidism"
},
{
"begin_idx": "81",
"end_idx": "109",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "autoimmune Addison's disease"
},
{
"begin_idx": "456",
"end_idx": "484",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "autoimmune Addison's disease"
},
{
"begin_idx": "696",
"end_idx": "713",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "847",
"end_idx": "864",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "992",
"end_idx": "1009",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "1081",
"end_idx": "1098",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "1453",
"end_idx": "1470",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "1602",
"end_idx": "1619",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "1704",
"end_idx": "1721",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "1874",
"end_idx": "1891",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "1987",
"end_idx": "2004",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "2263",
"end_idx": "2280",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
},
{
"begin_idx": "585",
"end_idx": "587",
"entity_id": "D001260",
"entity_type": "Disease",
"text_name": "AT"
},
{
"begin_idx": "1633",
"end_idx": "1652",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmune disorder"
},
{
"begin_idx": "294",
"end_idx": "309",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "723",
"end_idx": "763",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "autoimmune polyglandular syndrome type 2"
},
{
"begin_idx": "765",
"end_idx": "769",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "873",
"end_idx": "913",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "autoimmune polyglandular syndrome type 1"
},
{
"begin_idx": "915",
"end_idx": "919",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS1"
},
{
"begin_idx": "930",
"end_idx": "934",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "1018",
"end_idx": "1022",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "1107",
"end_idx": "1111",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "1474",
"end_idx": "1478",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "1723",
"end_idx": "1735",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS1 or APS2"
},
{
"begin_idx": "1895",
"end_idx": "1899",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "2008",
"end_idx": "2012",
"entity_id": "D016884",
"entity_type": "Disease",
"text_name": "APS2"
},
{
"begin_idx": "2",
"end_idx": "34",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "cytotoxic T lymphocyte antigen-4"
},
{
"begin_idx": "36",
"end_idx": "42",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "235",
"end_idx": "241",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "424",
"end_idx": "430",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "619",
"end_idx": "625",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "1147",
"end_idx": "1153",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "723",
"end_idx": "763",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "autoimmune polyglandular syndrome type 2"
},
{
"begin_idx": "765",
"end_idx": "769",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "930",
"end_idx": "934",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "1018",
"end_idx": "1022",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "1107",
"end_idx": "1111",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "1474",
"end_idx": "1478",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "1731",
"end_idx": "1735",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "1895",
"end_idx": "1899",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "2008",
"end_idx": "2012",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
},
{
"begin_idx": "873",
"end_idx": "913",
"entity_id": "326",
"entity_type": "Gene",
"text_name": "autoimmune polyglandular syndrome type 1"
},
{
"begin_idx": "915",
"end_idx": "919",
"entity_id": "326",
"entity_type": "Gene",
"text_name": "APS1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "2",
"end_idx": "34",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "cytotoxic T lymphocyte antigen-4"
},
{
"begin_idx": "765",
"end_idx": "769",
"entity_id": "170685",
"entity_type": "Gene",
"text_name": "APS2"
}
] | [
{
"begin_idx": "81",
"end_idx": "109",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "autoimmune Addison's disease"
},
{
"begin_idx": "696",
"end_idx": "713",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "Addison's disease"
}
] | [
"cytotoxic T lymphocyte antigen-4",
"APS2"
] | [
"autoimmune Addison's disease",
"Addison's disease"
] |
10198369 | Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. | There is no pharmacological treatment to increase the glomerular filtration rate in end-stage renal disease (ESRD). The administration of 100 microgram/kg of insulin-like growth factor (IGF) I twice a day to patients with ESRD increases inulin clearance. However, its effect is short-lived and IGF-I has major side effects when given this way. To assess whether the use of a lower intermittent dose of IGF-I would effect sustained improved function with tolerable side effects we performed 1) a prospective open-labeled 24-day trial in which we enrolled five patients and 2) a 31-day randomized, double-blinded, placebo-controlled trial in which we enrolled 10 patients. Patients with ESRD [creatinine clearance of <15 ml. min-1. (1.73 m2)-1] and scheduled to initiate renal replacement therapy received subcutaneous IGF-I, 50 microgram. kg-1. day-1, or vehicle. Treatment with IGF I resulted in significantly increased glomerular filtration rates (inulin clearances) during the 3rd and 4th wk of therapy in both prospective and double-blinded studies. Vehicle had no effect. No patient required discontinuation of drug secondary to side effects. We conclude that IGF-I effects sustained improvement of renal function (clearances comparable to those generally achieved by dialysis) in patients with ESRD and is well tolerated. | [
{
"begin_idx": "187",
"end_idx": "210",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "end-stage renal disease"
},
{
"begin_idx": "212",
"end_idx": "216",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "ESRD"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "ESRD"
},
{
"begin_idx": "788",
"end_idx": "792",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "ESRD"
},
{
"begin_idx": "1402",
"end_idx": "1406",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "ESRD"
},
{
"begin_idx": "80",
"end_idx": "101",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "chronic renal failure"
},
{
"begin_idx": "261",
"end_idx": "295",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "insulin-like growth factor (IGF) I"
},
{
"begin_idx": "397",
"end_idx": "402",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "505",
"end_idx": "510",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "920",
"end_idx": "925",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "981",
"end_idx": "986",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF I"
},
{
"begin_idx": "1267",
"end_idx": "1272",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "826",
"end_idx": "831",
"entity_id": "966",
"entity_type": "Gene",
"text_name": "min-1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "261",
"end_idx": "295",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "insulin-like growth factor (IGF) I"
},
{
"begin_idx": "397",
"end_idx": "402",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
}
] | [
{
"begin_idx": "187",
"end_idx": "210",
"entity_id": "D007676",
"entity_type": "Disease",
"text_name": "end-stage renal disease"
},
{
"begin_idx": "80",
"end_idx": "101",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "chronic renal failure"
}
] | [
"insulin-like growth factor (IGF) I",
"IGF-I"
] | [
"end-stage renal disease",
"chronic renal failure"
] |
10201536 | A novel substitution in keratin 10 in epidermolytic hyperkeratosis. | Epidermolytic hyperkeratosis is characterized by tonofilament clumping, cytolysis, and blister formation in suprabasal keratinocytes. It has been shown that the tonofilament aggregates in these areas are composed of keratin 1 (K1) and keratin 10 (K10), and several K1 and K10 point mutations have been identified as the molecular basis of epidermolytic hyperkeratosis. In this report we identify a novel, single base pair substitution resulting in an amino acid exchange from tyrosine to serine at residue 14 within the conserved 1A region of K10 (Y14S). This A to C transversion in codon 160 was only present in the affected individual and was associated with a very severe disease phenotype. Our observations are in agreement with previous reports documenting that this tyrosine residue, located at the beginning of the rod domain of type I keratins, is particularly sensitive to amino acid substitutions, and that alterations in this residue can have deleterious effects on filament assembly and stability. | [
{
"begin_idx": "155",
"end_idx": "162",
"entity_id": "D001768",
"entity_type": "Disease",
"text_name": "blister"
},
{
"begin_idx": "38",
"end_idx": "66",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic hyperkeratosis"
},
{
"begin_idx": "68",
"end_idx": "96",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "Epidermolytic hyperkeratosis"
},
{
"begin_idx": "407",
"end_idx": "435",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic hyperkeratosis"
},
{
"begin_idx": "284",
"end_idx": "293",
"entity_id": "3848",
"entity_type": "Gene",
"text_name": "keratin 1"
},
{
"begin_idx": "295",
"end_idx": "297",
"entity_id": "3848",
"entity_type": "Gene",
"text_name": "K1"
},
{
"begin_idx": "333",
"end_idx": "335",
"entity_id": "3848",
"entity_type": "Gene",
"text_name": "K1"
},
{
"begin_idx": "24",
"end_idx": "34",
"entity_id": "3858",
"entity_type": "Gene",
"text_name": "keratin 10"
},
{
"begin_idx": "303",
"end_idx": "313",
"entity_id": "3858",
"entity_type": "Gene",
"text_name": "keratin 10"
},
{
"begin_idx": "315",
"end_idx": "318",
"entity_id": "3858",
"entity_type": "Gene",
"text_name": "K10"
},
{
"begin_idx": "340",
"end_idx": "343",
"entity_id": "3858",
"entity_type": "Gene",
"text_name": "K10"
},
{
"begin_idx": "611",
"end_idx": "614",
"entity_id": "3858",
"entity_type": "Gene",
"text_name": "K10"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "24",
"end_idx": "34",
"entity_id": "3858",
"entity_type": "Gene",
"text_name": "keratin 10"
},
{
"begin_idx": "284",
"end_idx": "293",
"entity_id": "3848",
"entity_type": "Gene",
"text_name": "keratin 1"
}
] | [
{
"begin_idx": "38",
"end_idx": "66",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic hyperkeratosis"
},
{
"begin_idx": "155",
"end_idx": "162",
"entity_id": "D001768",
"entity_type": "Disease",
"text_name": "blister"
}
] | [
"keratin 10",
"keratin 1"
] | [
"epidermolytic hyperkeratosis",
"blister"
] |
10203975 | [Gerstmann-Str ussler-Scheinker syndrome with a Pro102Leu mutation in the prion protein gene and atypical MRI findings, hyperthermia, tachycardia, and hyperhidrosis]. | A 64-year-old Japanese woman with Gerstmann-Str ussler-Scheinker syndrome (GSS) is reported. She was admitted to our hospital for progressive amnesia, twitching of the right upper limb, and difficulty in speaking and walking for 5 months. Physical examination revealed a fever, tachycardia, and hyperhidrosis without any evidence of inflammation or infection. Neurological examinations demonstrated dementia, frontal lobe signs, and spontaneous myoclonus. She developed akinetic mutism 4 months later. The levels of neuron-specific enolase and 14-3-3 protein were elevated in the cerebrospinal fluid, and serial EEG showed periodic synchronous discharges. DNA analysis of the prion protein gene revealed a Pro102Leu mutation and therefore she was diagnosed as GSS102. Head MRI showed abnormal high signal intensity by T2 weighted image in bilateral caudate nuclei, putamen, frontal lobes, and white matter around the posterior horn of lateral ventricles at admission, and extension to global cerebral cortex and diffuse deep white matter with marked atrophy of bilateral frontal and cerebellar cortices 4 months later. In 123I-IMP SPECT study, uptake of RI decreased slightly only in left frontal region at admission, but decreased markedly in bilateral frontal region 4 months later. Analysis of autonomic function (analysis of noradrenarine in plasma and urine, coefficient of variation of R-R intervals before and after giving atenolol, Aschner's eyeball pressure test, intracutaneous atropine and adrenaline injection test) revealed sympathetic hyperactivity but normal parasympathetic activity. This is a very rare case of GSS102 with atypical MRI findings and clinical features like Creutzfeldt-Jakob disease rather than GSS102, presenting hyperthermia, tachycardia, and hyperhidrosis caused presumably by sympathetic hyperactivity as well as fatal familial insomnia. Therefore it is suggested that some factors besides the codon mutation in the prion protein gene may influence clinical symptoms in prion disease. | [
{
"begin_idx": "311",
"end_idx": "318",
"entity_id": "D000647",
"entity_type": "Disease",
"text_name": "amnesia"
},
{
"begin_idx": "1219",
"end_idx": "1226",
"entity_id": "D001284",
"entity_type": "Disease",
"text_name": "atrophy"
},
{
"begin_idx": "568",
"end_idx": "576",
"entity_id": "D003704",
"entity_type": "Disease",
"text_name": "dementia"
},
{
"begin_idx": "121",
"end_idx": "133",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "hyperthermia"
},
{
"begin_idx": "440",
"end_idx": "445",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "fever"
},
{
"begin_idx": "1915",
"end_idx": "1927",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "hyperthermia"
},
{
"begin_idx": "152",
"end_idx": "165",
"entity_id": "D006945",
"entity_type": "Disease",
"text_name": "hyperhidrosis"
},
{
"begin_idx": "464",
"end_idx": "477",
"entity_id": "D006945",
"entity_type": "Disease",
"text_name": "hyperhidrosis"
},
{
"begin_idx": "1946",
"end_idx": "1959",
"entity_id": "D006945",
"entity_type": "Disease",
"text_name": "hyperhidrosis"
},
{
"begin_idx": "502",
"end_idx": "527",
"entity_id": "D007249",
"entity_type": "Disease",
"text_name": "inflammation or infection"
},
{
"begin_idx": "1858",
"end_idx": "1883",
"entity_id": "D007562",
"entity_type": "Disease",
"text_name": "Creutzfeldt-Jakob disease"
},
{
"begin_idx": "614",
"end_idx": "623",
"entity_id": "D009207",
"entity_type": "Disease",
"text_name": "myoclonus"
},
{
"begin_idx": "135",
"end_idx": "146",
"entity_id": "D013610",
"entity_type": "Disease",
"text_name": "tachycardia"
},
{
"begin_idx": "447",
"end_idx": "458",
"entity_id": "D013610",
"entity_type": "Disease",
"text_name": "tachycardia"
},
{
"begin_idx": "1929",
"end_idx": "1940",
"entity_id": "D013610",
"entity_type": "Disease",
"text_name": "tachycardia"
},
{
"begin_idx": "1",
"end_idx": "41",
"entity_id": "D016098",
"entity_type": "Disease",
"text_name": "Gerstmann-Str ussler-Scheinker syndrome"
},
{
"begin_idx": "202",
"end_idx": "242",
"entity_id": "D016098",
"entity_type": "Disease",
"text_name": "Gerstmann-Str ussler-Scheinker syndrome"
},
{
"begin_idx": "244",
"end_idx": "247",
"entity_id": "D016098",
"entity_type": "Disease",
"text_name": "GSS"
},
{
"begin_idx": "2175",
"end_idx": "2188",
"entity_id": "D017096",
"entity_type": "Disease",
"text_name": "prion disease"
},
{
"begin_idx": "639",
"end_idx": "647",
"entity_id": "D018476",
"entity_type": "Disease",
"text_name": "akinetic"
},
{
"begin_idx": "2018",
"end_idx": "2041",
"entity_id": "D034062",
"entity_type": "Disease",
"text_name": "fatal familial insomnia"
},
{
"begin_idx": "1141",
"end_idx": "1206",
"entity_id": "D056784",
"entity_type": "Disease",
"text_name": "extension to global cerebral cortex and diffuse deep white matter"
},
{
"begin_idx": "75",
"end_idx": "88",
"entity_id": "5621",
"entity_type": "Gene",
"text_name": "prion protein"
},
{
"begin_idx": "845",
"end_idx": "858",
"entity_id": "5621",
"entity_type": "Gene",
"text_name": "prion protein"
},
{
"begin_idx": "2121",
"end_idx": "2134",
"entity_id": "5621",
"entity_type": "Gene",
"text_name": "prion protein"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "75",
"end_idx": "88",
"entity_id": "5621",
"entity_type": "Gene",
"text_name": "prion protein"
},
{
"begin_idx": "2121",
"end_idx": "2134",
"entity_id": "5621",
"entity_type": "Gene",
"text_name": "prion protein"
}
] | [
{
"begin_idx": "1",
"end_idx": "41",
"entity_id": "D016098",
"entity_type": "Disease",
"text_name": "Gerstmann-Str ussler-Scheinker syndrome"
},
{
"begin_idx": "1219",
"end_idx": "1226",
"entity_id": "D001284",
"entity_type": "Disease",
"text_name": "atrophy"
}
] | [
"prion protein",
"prion protein"
] | [
"Gerstmann-Str ussler-Scheinker syndrome",
"atrophy"
] |
10204114 | Molecular biology of adenosine triphosphate-sensitive potassium channels. | KATP channels are a newly defined class of potassium channels based on the physical association of an ABC protein, the sulfonylurea receptor, and a K+ inward rectifier subunit. The beta-cell KATP channel is composed of SUR1, the high-affinity sulfonylurea receptor with multiple TMDs and two NBFs, and KIR6.2, a weak inward rectifier, in a 1:1 stoichiometry. The pore of the channel is formed by KIR6.2 in a tetrameric arrangement; the overall stoichiometry of active channels is (SUR1/KIR6.2)4. The two subunits form a tightly integrated whole. KIR6.2 can be expressed in the plasma membrane either by deletion of an ER retention signal at its C-terminal end or by high-level expression to overwhelm the retention mechanism. The single-channel conductance of the homomeric KIR6.2 channels is equivalent to SUR/KIR6.2 channels, but they differ in all other respects, including bursting behavior, pharmacological properties, sensitivity to ATP and ADP, and trafficking to the plasma membrane. Coexpression with SUR restores the normal channel properties. The key role KATP channel play in the regulation of insulin secretion in response to changes in glucose metabolism is underscored by the finding that a recessive form of persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is caused by mutations in KATP channel subunits that result in the loss of channel activity. KATP channels set the resting membrane potential of beta-cells, and their loss results in a constitutive depolarization that allows voltage-gated Ca2+ channels to open spontaneously, increasing the cytosolic Ca2+ levels enough to trigger continuous release of insulin. The loss of KATP channels, in effect, uncouples the electrical activity of beta-cells from their metabolic activity. PHHI mutations have been informative on the function of SUR1 and regulation of KATP channels by adenine nucleotides. The results indicate that SUR1 is important in sensing nucleotide changes, as implied by its sequence similarity to other ABC proteins, in addition to being the drug sensor. An unexpected finding is that the inhibitory action of ATP appears to be through a site located on KIR6.2, whose affinity for ATP is modified by SUR1. A PHHI mutation, G1479R, in the second NBF of SUR1 forms active KATP channels that respond normally to ATP, but fail to activate with MgADP. The result implies that ATP tonically inhibits KATP channels, but that the ADP level in a fasting beta-cell antagonizes this inhibition. Decreases in the ADP level as glucose is metabolized result in KATP channel closure. Although KATP channels are the target for sulfonylureas used in the treatment of NIDDM, the available data suggest that the identified KATP channel mutations do not play a major role in diabetes. Understanding how KATP channels fit into the overall scheme of glucose homeostasis, on the other hand, promises insight into diabetes and other disorders of glucose metabolism, while understanding the structure and regulation of these channels offers potential for development of novel compounds to regulate cellular electrical activity. | [
{
"begin_idx": "2827",
"end_idx": "2835",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "2962",
"end_idx": "2970",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "2722",
"end_idx": "2727",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "2981",
"end_idx": "3012",
"entity_id": "D044882",
"entity_type": "Disease",
"text_name": "disorders of glucose metabolism"
},
{
"begin_idx": "1298",
"end_idx": "1349",
"entity_id": "D044903",
"entity_type": "Disease",
"text_name": "persistent hyperinsulinemic hypoglycemia of infancy"
},
{
"begin_idx": "1351",
"end_idx": "1355",
"entity_id": "D044903",
"entity_type": "Disease",
"text_name": "PHHI"
},
{
"begin_idx": "1836",
"end_idx": "1840",
"entity_id": "D044903",
"entity_type": "Disease",
"text_name": "PHHI"
},
{
"begin_idx": "2280",
"end_idx": "2284",
"entity_id": "D044903",
"entity_type": "Disease",
"text_name": "PHHI"
},
{
"begin_idx": "376",
"end_idx": "382",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "470",
"end_idx": "476",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "560",
"end_idx": "566",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "620",
"end_idx": "626",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "848",
"end_idx": "854",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "885",
"end_idx": "891",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "2226",
"end_idx": "2232",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "293",
"end_idx": "297",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "555",
"end_idx": "559",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "1892",
"end_idx": "1896",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "1979",
"end_idx": "1983",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "2272",
"end_idx": "2276",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "2324",
"end_idx": "2328",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "376",
"end_idx": "382",
"entity_id": "3767",
"entity_type": "Gene",
"text_name": "KIR6.2"
},
{
"begin_idx": "293",
"end_idx": "297",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
}
] | [
{
"begin_idx": "1298",
"end_idx": "1349",
"entity_id": "D044903",
"entity_type": "Disease",
"text_name": "persistent hyperinsulinemic hypoglycemia of infancy"
},
{
"begin_idx": "1298",
"end_idx": "1349",
"entity_id": "D044903",
"entity_type": "Disease",
"text_name": "persistent hyperinsulinemic hypoglycemia of infancy"
}
] | [
"KIR6.2",
"SUR1"
] | [
"persistent hyperinsulinemic hypoglycemia of infancy",
"persistent hyperinsulinemic hypoglycemia of infancy"
] |
10204841 | Evaluation of a mutation screening strategy for sporadic cases of ATR-X syndrome. | We report on the evaluation of a strategy for screening for XNP/ATR-X mutations in males with mental retardation and associated dysmorphology. Because nearly half of the mutations in this gene reported to date fall into a short 300 bp region of the transcript, we decided to focus in this region and to extend the mutation analysis to cases with a negative family history. This study includes 21 mentally retarded male patients selected because they had severe mental retardation and a typical facial appearance. The presence of haemoglobin H or urogenital abnormalities was not considered critical for inclusion in this study. We have identified six mutations which represents a mutation detection rate of 28%. This figure is high enough for us to propose this strategy as a valid first level of screening in a selected subset of males with mental retardation. This approach is simple, does not require RNA preparation, does not involve time consuming mutation detection methods, and can thus be applied to a large number of patients at a low cost in any given laboratory. | [
{
"begin_idx": "66",
"end_idx": "80",
"entity_id": "C538258",
"entity_type": "Disease",
"text_name": "ATR-X syndrome"
},
{
"begin_idx": "176",
"end_idx": "194",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "478",
"end_idx": "495",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mentally retarded"
},
{
"begin_idx": "543",
"end_idx": "561",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "924",
"end_idx": "942",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "628",
"end_idx": "652",
"entity_id": "D014564",
"entity_type": "Disease",
"text_name": "urogenital abnormalities"
},
{
"begin_idx": "142",
"end_idx": "151",
"entity_id": "546",
"entity_type": "Gene",
"text_name": "XNP/ATR-X"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "142",
"end_idx": "151",
"entity_id": "546",
"entity_type": "Gene",
"text_name": "XNP/ATR-X"
},
{
"begin_idx": "142",
"end_idx": "151",
"entity_id": "546",
"entity_type": "Gene",
"text_name": "XNP/ATR-X"
}
] | [
{
"begin_idx": "66",
"end_idx": "80",
"entity_id": "C538258",
"entity_type": "Disease",
"text_name": "ATR-X syndrome"
},
{
"begin_idx": "543",
"end_idx": "561",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
}
] | [
"XNP/ATR-X",
"XNP/ATR-X"
] | [
"ATR-X syndrome",
"mental retardation"
] |
10205247 | Association of an apolipoprotein B gene marker with essential hypertension. | We designed an association (retrospective, case control) study aimed at evaluating associations between genetic variations of the human apolipoprotein B (apoB) gene and clinical diagnosis of essential hypertension. Our approach was to compare the distribution of the alleles of a highly polymorphic variable number of tandem repeats localized 3' to the human apoB gene, the apoB 3' hypervariable region (HVR), in a group of normotensive and a group of hypertensive individuals. We collected DNA samples from 437 unrelated nationals (215 normotensives and 222 hypertensives) from the United Arab Emirates (UAEs), and we determined their apoB 3' HVR allele and genotype status with a polymerase chain reaction-based assay. In the UAE population, we found 18 alleles underlying a total of 51 genotypes. The distribution of these alleles was significantly different between normotensive and hypertensive UAE nationals. The main peak of the distributions occurred at 35 repeats among hypertensives (with a relative frequency of 25.7% versus 19.6% in normotensives) and at 37 repeats among normotensives (28.8% versus 20.3% in hypertensives). Alleles with 21, 23, 25, 49, and 55 repeats were found in hypertensives only (with a combined relative frequency of 7.6%). We conclude that variations of the apoB gene, or of a nearby gene, that may be in linkage disequilibrium with these alleles play a role in the development of essential hypertension in the UAEs. | [
{
"begin_idx": "62",
"end_idx": "74",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "277",
"end_idx": "289",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "528",
"end_idx": "540",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "635",
"end_idx": "648",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
},
{
"begin_idx": "963",
"end_idx": "975",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "1055",
"end_idx": "1068",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
},
{
"begin_idx": "1197",
"end_idx": "1210",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
},
{
"begin_idx": "1271",
"end_idx": "1284",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
},
{
"begin_idx": "1504",
"end_idx": "1516",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "18",
"end_idx": "34",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apolipoprotein B"
},
{
"begin_idx": "212",
"end_idx": "228",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apolipoprotein B"
},
{
"begin_idx": "230",
"end_idx": "234",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB"
},
{
"begin_idx": "435",
"end_idx": "439",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB"
},
{
"begin_idx": "450",
"end_idx": "454",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB"
},
{
"begin_idx": "712",
"end_idx": "716",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB"
},
{
"begin_idx": "1371",
"end_idx": "1375",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apoB"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "18",
"end_idx": "34",
"entity_id": "338",
"entity_type": "Gene",
"text_name": "apolipoprotein B"
}
] | [
{
"begin_idx": "635",
"end_idx": "648",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
}
] | [
"apolipoprotein B"
] | [
"hypertensives"
] |
10205262 | Analysis of alkaptonuria (AKU) mutations and polymorphisms reveals that the CCC sequence motif is a mutational hot spot in the homogentisate 1,2 dioxygenase gene (HGO). | We recently showed that alkaptonuria (AKU) is caused by loss-of-function mutations in the homogentisate 1,2 dioxygenase gene (HGO). Herein we describe haplotype and mutational analyses of HGO in seven new AKU pedigrees. These analyses identified two novel single-nucleotide polymorphisms (INV4+31A-->G and INV11+18A-->G) and six novel AKU mutations (INV1-1G-->A, W60G, Y62C, A122D, P230T, and D291E), which further illustrates the remarkable allelic heterogeneity found in AKU. Reexamination of all 29 mutations and polymorphisms thus far described in HGO shows that these nucleotide changes are not randomly distributed; the CCC sequence motif and its inverted complement, GGG, are preferentially mutated. These analyses also demonstrated that the nucleotide substitutions in HGO do not involve CpG dinucleotides, which illustrates important differences between HGO and other genes for the occurrence of mutation at specific short-sequence motifs. Because the CCC sequence motifs comprise a significant proportion (34.5%) of all mutated bases that have been observed in HGO, we conclude that the CCC triplet is a mutational hot spot in HGO. | [
{
"begin_idx": "12",
"end_idx": "24",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "alkaptonuria"
},
{
"begin_idx": "26",
"end_idx": "29",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "AKU"
},
{
"begin_idx": "193",
"end_idx": "205",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "alkaptonuria"
},
{
"begin_idx": "207",
"end_idx": "210",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "AKU"
},
{
"begin_idx": "374",
"end_idx": "377",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "AKU"
},
{
"begin_idx": "504",
"end_idx": "507",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "AKU"
},
{
"begin_idx": "642",
"end_idx": "645",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "AKU"
},
{
"begin_idx": "127",
"end_idx": "156",
"entity_id": "3081",
"entity_type": "Gene",
"text_name": "homogentisate 1,2 dioxygenase"
},
{
"begin_idx": "259",
"end_idx": "288",
"entity_id": "3081",
"entity_type": "Gene",
"text_name": "homogentisate 1,2 dioxygenase"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "127",
"end_idx": "156",
"entity_id": "3081",
"entity_type": "Gene",
"text_name": "homogentisate 1,2 dioxygenase"
}
] | [
{
"begin_idx": "12",
"end_idx": "24",
"entity_id": "D000474",
"entity_type": "Disease",
"text_name": "alkaptonuria"
}
] | [
"homogentisate 1,2 dioxygenase"
] | [
"alkaptonuria"
] |
10205266 | Connexin46 mutations in autosomal dominant congenital cataract. | Loci for autosomal dominant "zonular pulverulent" cataract have been mapped to chromosomes 1q (CZP1) and 13q (CZP3). Here we report genetic refinement of the CZP3 locus and identify underlying mutations in the gene for gap-junction protein alpha-3 (GJA3), or connexin46 (Cx46). Linkage analysis gave a significantly positive two-point LOD score (Z) at marker D13S175 (maximum Z [Zmax]=>7.0; maximum recombination frequency [thetamax] =0). Haplotyping indicated that CZP3 probably lies in the genetic interval D13S1236-D13S175-D13S1316-cen-13pter, close to GJA3. Sequencing of a genomic clone isolated from the CZP3 candidate region identified an open reading frame coding for a protein of 435 amino acids (47,435 D) that shared approximately 88% homology with rat Cx46. Mutation analysis of GJA3 in two families with CZP3 detected distinct sequence changes that were not present in a panel of 105 normal, unrelated individuals. In family B, an A-->G transition resulted in an asparagine-to-serine substitution at codon 63 (N63S) and introduced a novel MwoI restriction site. In family E, insertion of a C at nucleotide 1137 (1137insC) introduced a novel BstXI site, causing a frameshift at codon 380. Restriction analysis confirmed that the novel MwoI and BstXI sites cosegregated with the disease in families B and E, respectively. This study identifies GJA3 as the sixth member of the connexin gene family to be implicated in human disease, and it highlights the physiological importance of gap-junction communication in the development of a transparent eye lens. | [
{
"begin_idx": "174",
"end_idx": "178",
"entity_id": "C566608",
"entity_type": "Disease",
"text_name": "CZP3"
},
{
"begin_idx": "222",
"end_idx": "226",
"entity_id": "C566608",
"entity_type": "Disease",
"text_name": "CZP3"
},
{
"begin_idx": "530",
"end_idx": "534",
"entity_id": "C566608",
"entity_type": "Disease",
"text_name": "CZP3"
},
{
"begin_idx": "674",
"end_idx": "678",
"entity_id": "C566608",
"entity_type": "Disease",
"text_name": "CZP3"
},
{
"begin_idx": "881",
"end_idx": "885",
"entity_id": "C566608",
"entity_type": "Disease",
"text_name": "CZP3"
},
{
"begin_idx": "24",
"end_idx": "62",
"entity_id": "D002386",
"entity_type": "Disease",
"text_name": "autosomal dominant congenital cataract"
},
{
"begin_idx": "114",
"end_idx": "122",
"entity_id": "D002386",
"entity_type": "Disease",
"text_name": "cataract"
},
{
"begin_idx": "0",
"end_idx": "10",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "Connexin46"
},
{
"begin_idx": "174",
"end_idx": "178",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "CZP3"
},
{
"begin_idx": "222",
"end_idx": "226",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "CZP3"
},
{
"begin_idx": "283",
"end_idx": "311",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "gap-junction protein alpha-3"
},
{
"begin_idx": "313",
"end_idx": "317",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "GJA3"
},
{
"begin_idx": "323",
"end_idx": "333",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "connexin46"
},
{
"begin_idx": "335",
"end_idx": "339",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "Cx46"
},
{
"begin_idx": "530",
"end_idx": "534",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "CZP3"
},
{
"begin_idx": "620",
"end_idx": "624",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "GJA3"
},
{
"begin_idx": "674",
"end_idx": "678",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "CZP3"
},
{
"begin_idx": "828",
"end_idx": "832",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "Cx46"
},
{
"begin_idx": "855",
"end_idx": "859",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "GJA3"
},
{
"begin_idx": "881",
"end_idx": "885",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "CZP3"
},
{
"begin_idx": "1419",
"end_idx": "1423",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "GJA3"
},
{
"begin_idx": "159",
"end_idx": "163",
"entity_id": "2703",
"entity_type": "Gene",
"text_name": "CZP1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "283",
"end_idx": "311",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "gap-junction protein alpha-3"
},
{
"begin_idx": "313",
"end_idx": "317",
"entity_id": "2700",
"entity_type": "Gene",
"text_name": "GJA3"
}
] | [
{
"begin_idx": "174",
"end_idx": "178",
"entity_id": "C566608",
"entity_type": "Disease",
"text_name": "CZP3"
},
{
"begin_idx": "114",
"end_idx": "122",
"entity_id": "D002386",
"entity_type": "Disease",
"text_name": "cataract"
}
] | [
"gap-junction protein alpha-3",
"GJA3"
] | [
"CZP3",
"cataract"
] |
10205268 | Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. | Compared with the general population, women who have inherited a germline mutation in the BRCA1 gene have a greatly increased risk of developing breast cancer. However, there is also substantial interindividual variability in the occurrence of breast cancer among BRCA1 mutation carriers. We hypothesize that other genes, particularly those involved in endocrine signaling, may modify the BRCA1-associated age-specific breast cancer risk. We studied the effect of the CAG repeat-length polymorphism found in exon 1 of the androgen-receptor (AR) gene (AR-CAG). AR alleles containing longer CAG repeat lengths are associated with a decreased ability to activate androgen-responsive genes. Using a sample of women who inherited germline BRCA1 mutations, we compared AR-CAG repeat length in 165 women with and 139 women without breast cancer. We found that women were at significantly increased risk of breast cancer if they carried at least one AR allele with >/=28 CAG repeats. Women who carried an AR-CAG allele of >/=28, >/=29, or >/=30 repeats were given a diagnosis 0.8, 1.8, or 6.3 years earlier than women who did not carry at least one such allele. All 11 women in our sample who carried at least one AR-CAG allele with >/=29 repeats had breast cancer. Our results support the hypothesis that age at breast cancer diagnosis is earlier among BRCA1 mutation carriers who carry very long AR-CAG repeats. These results suggest that pathways involving androgen signaling may affect the risk of BRCA1-associated breast cancer. | [
{
"begin_idx": "33",
"end_idx": "46",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "246",
"end_idx": "259",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "345",
"end_idx": "358",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "520",
"end_idx": "533",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "925",
"end_idx": "938",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1000",
"end_idx": "1013",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1344",
"end_idx": "1357",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1406",
"end_idx": "1419",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1612",
"end_idx": "1625",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "816",
"end_idx": "840",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited germline BRCA1"
},
{
"begin_idx": "71",
"end_idx": "88",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen-receptor"
},
{
"begin_idx": "623",
"end_idx": "640",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen-receptor"
},
{
"begin_idx": "642",
"end_idx": "644",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "661",
"end_idx": "663",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "864",
"end_idx": "866",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1043",
"end_idx": "1045",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1098",
"end_idx": "1100",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1307",
"end_idx": "1309",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "16",
"end_idx": "21",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "191",
"end_idx": "196",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "365",
"end_idx": "370",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "490",
"end_idx": "495",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "835",
"end_idx": "840",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1447",
"end_idx": "1452",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1595",
"end_idx": "1600",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "71",
"end_idx": "88",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen-receptor"
},
{
"begin_idx": "1595",
"end_idx": "1600",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
}
] | [
{
"begin_idx": "33",
"end_idx": "46",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1000",
"end_idx": "1013",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
}
] | [
"androgen-receptor",
"BRCA1"
] | [
"breast cancer",
"breast cancer"
] |
10206080 | CYP2D6 polymorphism in systemic lupus erythematosus patients. | OBJECTIVES: To determine whether patients with idiopathic systemic lupus erythematosus (SLE) are associated with impaired CYP2D6 activity and to gain insight into whether there is an association between particular CYP2D6 genotypes and susceptibility to SLE, and whether CYP2D6 polymorphism is linked to any specific clinical features of SLE. METHODS: Debrisoquine sulfate (10 mg p.o.) was given to 159 healthy volunteers and 39 idiopathic SLE patients. Genotypic assay was carried out in 80 healthy volunteers and 32 patients. A 10-ml blood sample was drawn for genotypic assay. Debrisoquine and 4-hydroxydebrisoquine were determined in 8-h urine samples. Blood samples were analysed for the presence of mutations in the CYP2D6 gene, by using polymerase chain reaction (PCR) specific for CYP2D6*3 and CYP2D6*4 alleles. RESULTS: The metabolic ratio of debrisoquine to 4-hydroxydebrisoquine ranged from 0.01 to 86.98 in healthy subjects and from 0.02 to 96 in SLE patients. We observed the poor metabolizer(PM) debrisoquine phenotype in three of 39 patients with idiopathic SLE (7.6%) and five of 159 healthy subjects (3.1%). There was no significant difference in the frequency of PM phenotypes between idiopathic SLE and healthy subjects (Fisher's exact test, P = 0.19). No significant difference in the distribution of overall genotypes and allele frequencies were observed between the two groups. No significant relationships were found between specific clinical features and the overall genotype. CONCLUSION: The results of this study confirm that CYP2D6 activity is not impaired in SLE and that there is no association between SLE and phenotypic CYP2D6 status. The results also showed that there was no difference in the frequency of CYP2D6A and CYP2D6B alleles between controls and patients with SLE. | [
{
"begin_idx": "23",
"end_idx": "51",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "120",
"end_idx": "148",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "150",
"end_idx": "153",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "315",
"end_idx": "318",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "399",
"end_idx": "402",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "501",
"end_idx": "504",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1020",
"end_idx": "1023",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1134",
"end_idx": "1137",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1275",
"end_idx": "1278",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1648",
"end_idx": "1651",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1693",
"end_idx": "1696",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1863",
"end_idx": "1866",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "0",
"end_idx": "6",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "184",
"end_idx": "190",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "276",
"end_idx": "282",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "332",
"end_idx": "338",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "783",
"end_idx": "789",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "850",
"end_idx": "856",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "863",
"end_idx": "869",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1613",
"end_idx": "1619",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1712",
"end_idx": "1718",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "0",
"end_idx": "6",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
}
] | [
{
"begin_idx": "23",
"end_idx": "51",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
}
] | [
"CYP2D6"
] | [
"systemic lupus erythematosus"
] |
10206233 | Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. | The epsilon-4 allele of apolipoprotein E (APOE) is associated with increased risk of Alzheimer's disease (AD), but the pathogenic mechanism is unknown. The 5-repeat allele of a CGG repeat polymorphism in the 5' untranslated region of the very low-density lipoprotein receptor (VLDL-R) gene, a receptor for apoE, has been found to be associated with increased risk of AD in a Japanese population. Other groups have been unable to replicate this in American Caucasian populations. A case-control study utilizing a clinically well-defined group of late-onset AD patients (n = 108) and age- and sex-matched control subjects (n = 108) from Northern Ireland was performed to test this association in a relatively homogeneous population. The 9,9 genotype of the VLDL-R was found to be significantly increased in patients compared to controls (P = 0.003; Pcorr = 0.035), leading to an increased risk of AD to subjects with this genotype (OR = 3.9; 95% CI, 1.52-11.25). In contrast to results from the Japanese study, the 5-repeat allele was found to be significantly reduced in the patient group when compared to controls (P = 0.008; Pcorr = 0.047). The results from this study suggest that individuals who have the 9,9 genotype of the VLDL-R gene are at increased risk of AD in Northern Ireland. | [
{
"begin_idx": "8",
"end_idx": "27",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "202",
"end_idx": "221",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "223",
"end_idx": "225",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "484",
"end_idx": "486",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "673",
"end_idx": "675",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1012",
"end_idx": "1014",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1382",
"end_idx": "1384",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "141",
"end_idx": "157",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "159",
"end_idx": "163",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "423",
"end_idx": "427",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apoE"
},
{
"begin_idx": "49",
"end_idx": "86",
"entity_id": "7436",
"entity_type": "Gene",
"text_name": "very low-density lipoprotein receptor"
},
{
"begin_idx": "355",
"end_idx": "392",
"entity_id": "7436",
"entity_type": "Gene",
"text_name": "very low-density lipoprotein receptor"
},
{
"begin_idx": "394",
"end_idx": "400",
"entity_id": "7436",
"entity_type": "Gene",
"text_name": "VLDL-R"
},
{
"begin_idx": "872",
"end_idx": "878",
"entity_id": "7436",
"entity_type": "Gene",
"text_name": "VLDL-R"
},
{
"begin_idx": "1345",
"end_idx": "1351",
"entity_id": "7436",
"entity_type": "Gene",
"text_name": "VLDL-R"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "49",
"end_idx": "86",
"entity_id": "7436",
"entity_type": "Gene",
"text_name": "very low-density lipoprotein receptor"
},
{
"begin_idx": "159",
"end_idx": "163",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
{
"begin_idx": "8",
"end_idx": "27",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "1382",
"end_idx": "1384",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
}
] | [
"very low-density lipoprotein receptor",
"APOE"
] | [
"Alzheimer's disease",
"AD"
] |
10206237 | 14-3-3 protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia. | Recent genetic analyses have suggested a linkage between schizophrenia and the chromosomal region 22q12-q13. 14-3-3 protein, abundant in the brain, mediates interactions between diverse molecules of biological activities; its gene was recently mapped to chromosome 22q12.1-q13.1. We therefore investigated allele frequencies of a variable number of tandem repeat (VNTR) in the 5'-noncoding region of the 14-3-3 eta chain gene in controls and schizophrenics. The frequencies of the two-repeat allele were significantly higher (P < 0.05) in the schizophrenics, and particularly in those with onset before age 22 (early-onset schizophrenics, P < 0.02), than in the controls. The odds ratio was significantly increased in the early-onset schizophrenics homozygous for the two-repeat allele (OR = 3.3, 95% CI = 1.1-9.7). The 14-3-3 eta chain gene is a potential susceptibility gene for schizophrenia, and particularly for early-onset schizophrenia. | [
{
"begin_idx": "84",
"end_idx": "97",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "156",
"end_idx": "169",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "541",
"end_idx": "555",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "642",
"end_idx": "656",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "722",
"end_idx": "736",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "833",
"end_idx": "847",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "980",
"end_idx": "993",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "1028",
"end_idx": "1041",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "15",
"end_idx": "18",
"entity_id": "1909",
"entity_type": "Gene",
"text_name": "eta"
},
{
"begin_idx": "31",
"end_idx": "36",
"entity_id": "7533",
"entity_type": "Gene",
"text_name": "YWHAH"
},
{
"begin_idx": "503",
"end_idx": "513",
"entity_id": "7533",
"entity_type": "Gene",
"text_name": "14-3-3 eta"
},
{
"begin_idx": "919",
"end_idx": "929",
"entity_id": "7533",
"entity_type": "Gene",
"text_name": "14-3-3 eta"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "503",
"end_idx": "513",
"entity_id": "7533",
"entity_type": "Gene",
"text_name": "14-3-3 eta"
},
{
"begin_idx": "15",
"end_idx": "18",
"entity_id": "1909",
"entity_type": "Gene",
"text_name": "eta"
}
] | [
{
"begin_idx": "541",
"end_idx": "555",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "642",
"end_idx": "656",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
}
] | [
"14-3-3 eta",
"eta"
] | [
"schizophrenics",
"schizophrenics"
] |
10206677 | Double mutation (A171T and D444H) is a common cause of profound biotinidase deficiency in children ascertained by newborn screening the the United States. Mutations in brief no. 128. Online. | Biotinidase deficiency is inherited as an antosomal recessive trait that, unless treated with pharmacologic doses of biotin, can result in neurologic and cutaneous symptoms. We have identified two new mutations in exon D of the biotinidase gene of children with profound biotinidase deficiency ascertained by newborn screening. Transition 511G->A near the 5' end of exon D results in a substitution of threonine for alanine 171 (A171T) and transversion 1330G->C occurs close to the 3' end of exon D causing a substitution of histidine for aspartic acid 444 (D444H). The D444H mutation was detected in four individuals from our normal population whose mean serum biotinidase activity is 5.25 nmol/min/ml, which is significantly lower than the mean normal activity (7.1 nmol/min/ml). We calculated that this mutation causes a 52% loss of activity in the aberrant enzyme. Twenty-three individuals with the D444H mutation were found by allele specific oligonucleotide analysis of DNA from 296 randomly-selected, anonymous dried-blood spots. We estimate the frequency of this allele in the general population to be 0.039. In contrast, no individuals in 376 have the A171T mutation. Fourteen children (eleven probands and three siblings) out of the 31 enzyme-deficient children have both the A171T and D444H mutations. Both mutations are inherited from a single parent as a double mutation allele. The nine families in which this allele was identified are of mostly European ancestry, although the mutation cannot be attributed to a specific nationality or ethnic group. The serum of a child who is homozygous for the double mutation allele has very little CRM and the aberrant enzyme has very low biotinylhydrolase activity and no botinyl-transferase activity. This double mutation allele (A171T and D444H) is a common cause of profound biotinidase deficience in children ascertained by newborn screening in the United States. | [
{
"begin_idx": "64",
"end_idx": "86",
"entity_id": "D028921",
"entity_type": "Disease",
"text_name": "biotinidase deficiency"
},
{
"begin_idx": "191",
"end_idx": "213",
"entity_id": "D028921",
"entity_type": "Disease",
"text_name": "Biotinidase deficiency"
},
{
"begin_idx": "462",
"end_idx": "484",
"entity_id": "D028921",
"entity_type": "Disease",
"text_name": "biotinidase deficiency"
},
{
"begin_idx": "419",
"end_idx": "430",
"entity_id": "686",
"entity_type": "Gene",
"text_name": "biotinidase"
},
{
"begin_idx": "853",
"end_idx": "864",
"entity_id": "686",
"entity_type": "Gene",
"text_name": "biotinidase"
},
{
"begin_idx": "2023",
"end_idx": "2034",
"entity_id": "686",
"entity_type": "Gene",
"text_name": "biotinidase"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "419",
"end_idx": "430",
"entity_id": "686",
"entity_type": "Gene",
"text_name": "biotinidase"
}
] | [
{
"begin_idx": "64",
"end_idx": "86",
"entity_id": "D028921",
"entity_type": "Disease",
"text_name": "biotinidase deficiency"
}
] | [
"biotinidase"
] | [
"biotinidase deficiency"
] |
10206678 | Two novel mutations of the arylsulfatase B gene in two Italian patients with severe form of mucopolysaccharidosis. Mutations in brief no. 127. Online. | Mucopolysaccharidosis type VI (MPS VI) or Maroteaux-Lamy syndrome, is a autosomal recessive disorder, due to the deficiency of the lysosomal enzyme N-acetylgalactosamine-4-sulfatase (arylsufatase B, ASB: EC 3.1.6.12). Three classical forms of the disease have been differentiated: severe, intermediate, mild. Mutational analysis of the ASB gene resulted in the identification of 30 ASB mutant alleles, each of which was found to be unique among unrelated patients, demonstrating a broad molecular heterogeneity of the disease. In this communication we present two novel mutant alleles in two severely affected subjects. Both alterations, the missense mutation G302R and the nonsense Q456X, were found in homozygosity and were confirmed by amplification refractory mutation system (ARMS) or restriction analysis. The missense G302R mutation concerns an amino acid which may be of special importance to the polypeptide, since 302 position is completely conserved in all the eukaryotic sulfatases aligned so far; the nonsense mutation Q456X leads to the translation of a putative mutant ASB protein lacking the last 78 amino acids with a loss of the 8 kD mature polypeptide, one of the two peptides generated by intralysosomal proteolytic processing of the 64kD precursor. | [
{
"begin_idx": "92",
"end_idx": "113",
"entity_id": "D009083",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis"
},
{
"begin_idx": "151",
"end_idx": "180",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "Mucopolysaccharidosis type VI"
},
{
"begin_idx": "182",
"end_idx": "188",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "MPS VI"
},
{
"begin_idx": "193",
"end_idx": "216",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "Maroteaux-Lamy syndrome"
},
{
"begin_idx": "223",
"end_idx": "251",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "890",
"end_idx": "930",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "amplification refractory mutation system"
},
{
"begin_idx": "932",
"end_idx": "936",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "ARMS"
},
{
"begin_idx": "27",
"end_idx": "42",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "arylsulfatase B"
},
{
"begin_idx": "350",
"end_idx": "353",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
},
{
"begin_idx": "487",
"end_idx": "490",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
},
{
"begin_idx": "533",
"end_idx": "536",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
},
{
"begin_idx": "1235",
"end_idx": "1238",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "27",
"end_idx": "42",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "arylsulfatase B"
},
{
"begin_idx": "350",
"end_idx": "353",
"entity_id": "411",
"entity_type": "Gene",
"text_name": "ASB"
}
] | [
{
"begin_idx": "151",
"end_idx": "180",
"entity_id": "D009087",
"entity_type": "Disease",
"text_name": "Mucopolysaccharidosis type VI"
},
{
"begin_idx": "92",
"end_idx": "113",
"entity_id": "D009083",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis"
}
] | [
"arylsulfatase B",
"ASB"
] | [
"Mucopolysaccharidosis type VI",
"mucopolysaccharidosis"
] |
10206679 | Novel allele of the insulin receptor substrate-1 bearing two non-conservative amino acid substitutions in a patient with noninsulin-dependent diabetes mellitus. Mutations in brief no. 130. Online. | We analyzed by SSCP the complete IRS-1 coding sequence in NIDDM patient #25 D. Unique conformers corresponding to a Ser to Tyr substitution at codon 1043 (S1043Y), and to a Cys to Tyr substitution at codon 1095 (C1095Y) were detected in this patient. The results of sequential digestion with restriction enzymes indicated that the novel sequence variants segregate on the same allele. Relatives of patient #25 D were not available for study, to confirm segregation of the novel allele with NIDDM in the family. Several lines of evidence suggest that the non-conservative amino acid substitutions detected in NIDDM patient #25 D have the potential to affect IRS-1 functions and could play a pathogenic role in this patient. Both S1043Y and C1095Y occur in a highly conserved sequence from human skeletal muscle, human hepatoma, mouse, and rat IRS-1. Protein subsequence analysis revealed that the S1043Y substitution abolishes a consensus sequence for glycogen synthase kinase 3 phosphorylation. Furthermore, S1043Y and C1095Y are not common IRS-1 polymorphisms as they were detected only in 1/136 choromosomes from NIDDM patients (allele frequency in NIDDM patients = 0.0007) and in 0/120 chromosomes from control subjects. | [
{
"begin_idx": "121",
"end_idx": "159",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "noninsulin-dependent diabetes mellitus"
},
{
"begin_idx": "255",
"end_idx": "260",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "687",
"end_idx": "692",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "805",
"end_idx": "810",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1312",
"end_idx": "1317",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1348",
"end_idx": "1353",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1014",
"end_idx": "1022",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "hepatoma"
},
{
"begin_idx": "230",
"end_idx": "235",
"entity_id": "3667",
"entity_type": "Gene",
"text_name": "IRS-1"
},
{
"begin_idx": "854",
"end_idx": "859",
"entity_id": "3667",
"entity_type": "Gene",
"text_name": "IRS-1"
},
{
"begin_idx": "1039",
"end_idx": "1044",
"entity_id": "3667",
"entity_type": "Gene",
"text_name": "IRS-1"
},
{
"begin_idx": "1238",
"end_idx": "1243",
"entity_id": "3667",
"entity_type": "Gene",
"text_name": "IRS-1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "230",
"end_idx": "235",
"entity_id": "3667",
"entity_type": "Gene",
"text_name": "IRS-1"
},
{
"begin_idx": "854",
"end_idx": "859",
"entity_id": "3667",
"entity_type": "Gene",
"text_name": "IRS-1"
}
] | [
{
"begin_idx": "121",
"end_idx": "159",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "noninsulin-dependent diabetes mellitus"
},
{
"begin_idx": "1014",
"end_idx": "1022",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "hepatoma"
}
] | [
"IRS-1",
"IRS-1"
] | [
"noninsulin-dependent diabetes mellitus",
"hepatoma"
] |
10206825 | Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy. | Portal-systemic encephalopathy (PSE) is a serious neuropsychiatric condition that results from chronic liver failure and portal-systemic shunting of venous blood. PSE is particularly prevalent following treatment of portal hypertension or ascites by the TIPS procedure. Recent studies both in autopsied brain tissue from PSE patients as well as in experimental animal models of PSE reveal that chronic liver failure results in altered expression of several genes coding for proteins having key roles in the control of neuronal excitability. Such alterations include increased expression of monoamine oxidase (MAO-A isoform), the "peripheral-type" benzodiazepine receptor (PTBR) as well as constitutive, neuronal nitric oxide synthase (nNOS). Such changes result in altered protein expression and in increased degradation of monoamine neurotransmitters, increased synthesis of neurosteroids with inhibitory properties and increased production of nitric oxide (respectively) in brain in chronic liver failure. In the case of PTBR and nNOS, increases in expression result from exposure to ammonia and/or manganese, two neurotoxic agents shown previously to be increased in brain in chronic liver failure. Further elucidation of the consequences of neurotransmitter-related gene expression could identify new pathophysiologic mechanisms and result in new approaches to the prevention of PSE in chronic liver disease in humans. | [
{
"begin_idx": "353",
"end_idx": "360",
"entity_id": "D001201",
"entity_type": "Disease",
"text_name": "ascites"
},
{
"begin_idx": "164",
"end_idx": "190",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "neuropsychiatric condition"
},
{
"begin_idx": "98",
"end_idx": "112",
"entity_id": "D001927",
"entity_type": "Disease",
"text_name": "encephalopathy"
},
{
"begin_idx": "235",
"end_idx": "275",
"entity_id": "D006402",
"entity_type": "Disease",
"text_name": "portal-systemic shunting of venous blood"
},
{
"begin_idx": "114",
"end_idx": "144",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "Portal-systemic encephalopathy"
},
{
"begin_idx": "146",
"end_idx": "149",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "PSE"
},
{
"begin_idx": "277",
"end_idx": "280",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "PSE"
},
{
"begin_idx": "435",
"end_idx": "438",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "PSE"
},
{
"begin_idx": "492",
"end_idx": "495",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "PSE"
},
{
"begin_idx": "337",
"end_idx": "349",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "1497",
"end_idx": "1525",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "PSE in chronic liver disease"
},
{
"begin_idx": "209",
"end_idx": "230",
"entity_id": "D017093",
"entity_type": "Disease",
"text_name": "chronic liver failure"
},
{
"begin_idx": "508",
"end_idx": "529",
"entity_id": "D017093",
"entity_type": "Disease",
"text_name": "chronic liver failure"
},
{
"begin_idx": "1099",
"end_idx": "1120",
"entity_id": "D017093",
"entity_type": "Disease",
"text_name": "chronic liver failure"
},
{
"begin_idx": "1293",
"end_idx": "1314",
"entity_id": "D017093",
"entity_type": "Disease",
"text_name": "chronic liver failure"
},
{
"begin_idx": "1230",
"end_idx": "1240",
"entity_id": "D020258",
"entity_type": "Disease",
"text_name": "neurotoxic"
},
{
"begin_idx": "723",
"end_idx": "728",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAO-A"
},
{
"begin_idx": "817",
"end_idx": "847",
"entity_id": "4842",
"entity_type": "Gene",
"text_name": "neuronal nitric oxide synthase"
},
{
"begin_idx": "849",
"end_idx": "853",
"entity_id": "4842",
"entity_type": "Gene",
"text_name": "nNOS"
},
{
"begin_idx": "1146",
"end_idx": "1150",
"entity_id": "4842",
"entity_type": "Gene",
"text_name": "nNOS"
},
{
"begin_idx": "743",
"end_idx": "784",
"entity_id": "706",
"entity_type": "Gene",
"text_name": "\"peripheral-type\" benzodiazepine receptor"
},
{
"begin_idx": "786",
"end_idx": "790",
"entity_id": "706",
"entity_type": "Gene",
"text_name": "PTBR"
},
{
"begin_idx": "1137",
"end_idx": "1141",
"entity_id": "706",
"entity_type": "Gene",
"text_name": "PTBR"
}
] | [
"Yes",
"Yes",
"Yes",
"No",
"No",
"No"
] | [
false,
false,
false,
true,
false,
true
] | [
{
"begin_idx": "743",
"end_idx": "784",
"entity_id": "706",
"entity_type": "Gene",
"text_name": "\"peripheral-type\" benzodiazepine receptor"
},
{
"begin_idx": "817",
"end_idx": "847",
"entity_id": "4842",
"entity_type": "Gene",
"text_name": "neuronal nitric oxide synthase"
},
{
"begin_idx": "723",
"end_idx": "728",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAO-A"
},
{
"begin_idx": "817",
"end_idx": "847",
"entity_id": "4842",
"entity_type": "Gene",
"text_name": "neuronal nitric oxide synthase"
},
{
"begin_idx": "1137",
"end_idx": "1141",
"entity_id": "706",
"entity_type": "Gene",
"text_name": "PTBR"
},
{
"begin_idx": "1137",
"end_idx": "1141",
"entity_id": "706",
"entity_type": "Gene",
"text_name": "PTBR"
}
] | [
{
"begin_idx": "114",
"end_idx": "144",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "Portal-systemic encephalopathy"
},
{
"begin_idx": "114",
"end_idx": "144",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "Portal-systemic encephalopathy"
},
{
"begin_idx": "114",
"end_idx": "144",
"entity_id": "D006501",
"entity_type": "Disease",
"text_name": "Portal-systemic encephalopathy"
},
{
"begin_idx": "1230",
"end_idx": "1240",
"entity_id": "D020258",
"entity_type": "Disease",
"text_name": "neurotoxic"
},
{
"begin_idx": "164",
"end_idx": "190",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "neuropsychiatric condition"
},
{
"begin_idx": "1293",
"end_idx": "1314",
"entity_id": "D017093",
"entity_type": "Disease",
"text_name": "chronic liver failure"
}
] | [
"\"peripheral-type\" benzodiazepine receptor",
"neuronal nitric oxide synthase",
"MAO-A",
"neuronal nitric oxide synthase",
"PTBR",
"PTBR"
] | [
"Portal-systemic encephalopathy",
"Portal-systemic encephalopathy",
"Portal-systemic encephalopathy",
"neurotoxic",
"neuropsychiatric condition",
"chronic liver failure"
] |
10208443 | Allelic association of the MTHFR gene with schizophrenia. | [
{
"begin_idx": "43",
"end_idx": "56",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "27",
"end_idx": "32",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "27",
"end_idx": "32",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
}
] | [
{
"begin_idx": "43",
"end_idx": "56",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
}
] | [
"MTHFR"
] | [
"schizophrenia"
] |
|
10208564 | The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. | Recent evidence suggests that a polymorphism in the regulatory region of the apolipoprotein E gene (APOE) is associated with an increased risk for developing Alzheimer's disease (AD) independent of that conveyed by the epsilon4 allele of APOE. Previous work by our group indicated that plasma apolipoprotein E (apoE) levels were elevated in AD, raising the possibility that the -491 genotype might modify AD risk by increasing expression of the APOE gene. In a total of 638 individuals the -491AA genotype was significantly associated with AD (P < 0.005) while the TT genotype was associated with controls (P < 0.005). In 138 individuals the AA genotype showed significantly higher plasma apoE levels, independent of epsilon4 and AD status (P < 0.01) as well as within control and AD groups (P < 0.05). Within the AD group the AA genotype showed increased apoE levels when compared to AA controls (P < 0.0001). These results suggest that the -491 AA genotype is associated with increased plasma apoE levels, providing a potential basis for elucidating how that genotype increases the risk for developing AD. | [
{
"begin_idx": "92",
"end_idx": "111",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "271",
"end_idx": "290",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "292",
"end_idx": "294",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "454",
"end_idx": "456",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "518",
"end_idx": "520",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "653",
"end_idx": "655",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "843",
"end_idx": "845",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "894",
"end_idx": "896",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "927",
"end_idx": "929",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1217",
"end_idx": "1219",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "31",
"end_idx": "35",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "77",
"end_idx": "81",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apoE"
},
{
"begin_idx": "190",
"end_idx": "206",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "213",
"end_idx": "217",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "351",
"end_idx": "355",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "406",
"end_idx": "422",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "424",
"end_idx": "428",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apoE"
},
{
"begin_idx": "558",
"end_idx": "562",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "802",
"end_idx": "806",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apoE"
},
{
"begin_idx": "969",
"end_idx": "973",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apoE"
},
{
"begin_idx": "1108",
"end_idx": "1112",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apoE"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "190",
"end_idx": "206",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
}
] | [
{
"begin_idx": "92",
"end_idx": "111",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
}
] | [
"apolipoprotein E"
] | [
"Alzheimer's disease"
] |
10208576 | A new GTP-cyclohydrolase I mutation in an unusual dopa-responsive dystonia, familial form. | We found a new mutation in the GTP cyclohydrolase gene involved in dopa-responsive dystonia. We sequenced the GTP cyclohydrolase gene in a family with four siblings affected by this disorder and identified an A-T mutation in exon 2, leading to a non conservative amino acid substitution at codon 135 of the protein (Ile135Lys), which may change the conformation of the binding site of this enzyme. The clinical evolution was heterogeneous among carriers of the same mutation, underlining the involvement of other determinants modulating the occurrence of the disease such as genetic or environmental susceptibility factors. | [
{
"begin_idx": "50",
"end_idx": "74",
"entity_id": "C538007",
"entity_type": "Disease",
"text_name": "dopa-responsive dystonia"
},
{
"begin_idx": "158",
"end_idx": "182",
"entity_id": "C538007",
"entity_type": "Disease",
"text_name": "dopa-responsive dystonia"
},
{
"begin_idx": "6",
"end_idx": "26",
"entity_id": "2643",
"entity_type": "Gene",
"text_name": "GTP-cyclohydrolase I"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "6",
"end_idx": "26",
"entity_id": "2643",
"entity_type": "Gene",
"text_name": "GTP-cyclohydrolase I"
}
] | [
{
"begin_idx": "50",
"end_idx": "74",
"entity_id": "C538007",
"entity_type": "Disease",
"text_name": "dopa-responsive dystonia"
}
] | [
"GTP-cyclohydrolase I"
] | [
"dopa-responsive dystonia"
] |
10208848 | Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. | Fabry disease (FD) (angiokeratoma corporis diffusum) is an X-linked inborn error of glycosphingolipid metabolism caused by defects in the lysosomal alpha-galactosidase A gene (GLA). The enzymatic defect leads to the systemic accumulation of neutral glycosphingolipids with terminal alpha-galactosyl moieties. Clinically, affected hemizygous males have angiokeratoma, severe acroparesthesia, renal failure, and vasculopathy of the heart and brain. While demonstration of alpha-galactosidase deficiency in leukocytes is diagnostic in affected males, enzymatic detection of female carriers is often inconclusive, due to random X-chromosomal inactivation, underlining the need of molecular investigations for accurate genetic counseling. By use of chemical cleavage of mismatches adapted to fluorescence-based detection systems, we have characterized the mutations underlying alpha-Gal A deficiency in 16 individuals from six unrelated families with FD. The mutational spectrum included five missense mutations (C202W, C223G, N224D, R301Q, and Q327K) and one splice-site mutation [IVS3 G(-1) --> C]. Studies at the mRNA level showed that the latter led to altered pre-mRNA splicing with consequent alteration of the mRNA translational reading frame and generation of a premature termination codon of translation. By use of this strategy, carrier status was accurately assessed in all seven at-risk females tested, whereas enzymatic dosages failed to diagnose or exclude heterozygosity. | [
{
"begin_idx": "525",
"end_idx": "547",
"entity_id": "C536711",
"entity_type": "Disease",
"text_name": "severe acroparesthesia"
},
{
"begin_idx": "510",
"end_idx": "523",
"entity_id": "D000794",
"entity_type": "Disease",
"text_name": "angiokeratoma"
},
{
"begin_idx": "0",
"end_idx": "13",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry disease"
},
{
"begin_idx": "158",
"end_idx": "171",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "Fabry disease"
},
{
"begin_idx": "173",
"end_idx": "175",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "FD"
},
{
"begin_idx": "178",
"end_idx": "209",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "angiokeratoma corporis diffusum"
},
{
"begin_idx": "628",
"end_idx": "658",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "alpha-galactosidase deficiency"
},
{
"begin_idx": "1030",
"end_idx": "1052",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "alpha-Gal A deficiency"
},
{
"begin_idx": "1104",
"end_idx": "1106",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "FD"
},
{
"begin_idx": "217",
"end_idx": "270",
"entity_id": "D008661",
"entity_type": "Disease",
"text_name": "X-linked inborn error of glycosphingolipid metabolism"
},
{
"begin_idx": "568",
"end_idx": "603",
"entity_id": "D014652",
"entity_type": "Disease",
"text_name": "vasculopathy of the heart and brain"
},
{
"begin_idx": "549",
"end_idx": "562",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "renal failure"
},
{
"begin_idx": "39",
"end_idx": "60",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
},
{
"begin_idx": "306",
"end_idx": "327",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
},
{
"begin_idx": "334",
"end_idx": "337",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "GLA"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "39",
"end_idx": "60",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
},
{
"begin_idx": "39",
"end_idx": "60",
"entity_id": "2717",
"entity_type": "Gene",
"text_name": "alpha-galactosidase A"
}
] | [
{
"begin_idx": "178",
"end_idx": "209",
"entity_id": "D000795",
"entity_type": "Disease",
"text_name": "angiokeratoma corporis diffusum"
},
{
"begin_idx": "549",
"end_idx": "562",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "renal failure"
}
] | [
"alpha-galactosidase A",
"alpha-galactosidase A"
] | [
"angiokeratoma corporis diffusum",
"renal failure"
] |
10211478 | Recessive inheritance of a new point mutation of the PMP22 gene in Dejerine-Sottas disease. | The existence of recessive transmission of Dejerine-Sottas disease, a severe demyelinating neuropathy of childhood, has been questioned, because only heterozygous mutations of the myelin proteins P0 or PMP22 genes have been identified in virtually all patients with this phenotype. We report on a family with 3 affected children with this phenotype, born to clinically and electrophysiologically unaffected parents. All 3 children carried a previously unknown homozygous missense point mutation (Arg157Trp) of the PMP22 gene. The parents were heterozygous for the same mutation. These findings demonstrate the occurrence of recessive transmission in this setting. | [
{
"begin_idx": "169",
"end_idx": "193",
"entity_id": "D003711",
"entity_type": "Disease",
"text_name": "demyelinating neuropathy"
},
{
"begin_idx": "67",
"end_idx": "90",
"entity_id": "D015417",
"entity_type": "Disease",
"text_name": "Dejerine-Sottas disease"
},
{
"begin_idx": "135",
"end_idx": "158",
"entity_id": "D015417",
"entity_type": "Disease",
"text_name": "Dejerine-Sottas disease"
},
{
"begin_idx": "508",
"end_idx": "513",
"entity_id": "5079",
"entity_type": "Gene",
"text_name": "All 3"
},
{
"begin_idx": "53",
"end_idx": "58",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "294",
"end_idx": "299",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "606",
"end_idx": "611",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "53",
"end_idx": "58",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "294",
"end_idx": "299",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
}
] | [
{
"begin_idx": "67",
"end_idx": "90",
"entity_id": "D015417",
"entity_type": "Disease",
"text_name": "Dejerine-Sottas disease"
},
{
"begin_idx": "169",
"end_idx": "193",
"entity_id": "D003711",
"entity_type": "Disease",
"text_name": "demyelinating neuropathy"
}
] | [
"PMP22",
"PMP22"
] | [
"Dejerine-Sottas disease",
"demyelinating neuropathy"
] |
10213152 | A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease. | Using a combination of polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP) and DNA sequencing techniques, we identified a unique missense mutation (T-->C) in exon 3 of the APOE gene which resulted in the substitution of pro-28 for leu-28. We screened 1118 White cases of late-onset (>60 years) Alzheimer's disease (AD) from three independent centers (Pittsburgh = 489, Indiana = 319, Mayo Clinic Rochester = 310) and 1123 controls (607 clinically assessed and 516 individuals randomly ascertained from the general population). Two of the 1123 control subjects had the pro-28 mutation (0.18%). However, this mutation was observed in heterozygous state in 2.66, 2.51 and 1.94% of the AD cases from Pittsburgh, Indiana and Mayo Clinic Rochester, respectively, with an overall frequency of 2.42%. All individuals with this mutation were carriers of the APOE*4 allele and hence the mutation was denoted as APOE*4 Pittsburgh (APOE*4P). Compared with the non-E*4P carriers, the E*4P carriers were associated with an increased risk of AD (odds ratio (OR) 13.2) and this risk remained significant even after adjusting for the known effect of APOE*4 (OR 5.4). The risk associated with the E*4P/E*4 combination was about five times (OR 29.1) the risk attributed to APOE*4 carriers alone (OR 5.7). Our data indicates that the new mutation most likely exists in cis-orientation with APOE*4 and is associated with increased risk of developing AD. | [
{
"begin_idx": "108",
"end_idx": "127",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "451",
"end_idx": "470",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "472",
"end_idx": "474",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "839",
"end_idx": "841",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1184",
"end_idx": "1186",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1586",
"end_idx": "1588",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "24",
"end_idx": "40",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "47",
"end_idx": "51",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "329",
"end_idx": "333",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1006",
"end_idx": "1012",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE*4"
},
{
"begin_idx": "1058",
"end_idx": "1064",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE*4"
},
{
"begin_idx": "1077",
"end_idx": "1081",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1290",
"end_idx": "1296",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE*4"
},
{
"begin_idx": "1411",
"end_idx": "1417",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE*4"
},
{
"begin_idx": "1527",
"end_idx": "1533",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE*4"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "24",
"end_idx": "40",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
}
] | [
{
"begin_idx": "108",
"end_idx": "127",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
}
] | [
"apolipoprotein E"
] | [
"Alzheimer's disease"
] |
10213175 | The -491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer's disease. | Several studies have attempted to confirm the association between the recently reported polymorphism located at position -491 in the transcriptional regulatory region of the Apolipoprotein E (ApoE) gene and Alzheimer's disease (AD). Results have been inconclusive, possibly due to the use of clinically diagnosed subjects and controls only. In this retrospective case-control study of 149 (96 AD and 53 controls) brain samples we show that homozygosity for the -491A variant is associated with an increased risk of development of AD. The genotype is also strongly associated with the presence of at least one epsilon4 allele (an established risk factor for AD) in women but not in men. | [
{
"begin_idx": "101",
"end_idx": "120",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "329",
"end_idx": "348",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "350",
"end_idx": "352",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "515",
"end_idx": "517",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "652",
"end_idx": "654",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "779",
"end_idx": "781",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "32",
"end_idx": "48",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "Apolipoprotein E"
},
{
"begin_idx": "296",
"end_idx": "312",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "Apolipoprotein E"
},
{
"begin_idx": "314",
"end_idx": "318",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "ApoE"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "32",
"end_idx": "48",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "Apolipoprotein E"
}
] | [
{
"begin_idx": "101",
"end_idx": "120",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
}
] | [
"Apolipoprotein E"
] | [
"Alzheimer's disease"
] |
10214944 | Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. | Tau is the major component of the neurofibrillar tangles that are a pathological hallmark of Alzheimers' disease. The identification of missense and splicing mutations in tau associated with the inherited frontotemporal dementia and Parkinsonism linked to chromosome 17 demonstrated that tau dysfunction can cause neurodegeneration. However, the mechanism by which tau dysfunction leads to neurodegeneration remains uncertain. Here, we present evidence that frontotemporal dementia and Parkinsonism linked to chromosome 17 missense mutations, P301L, V337M and R406W, cause an accelerated aggregation of tau into filaments. These results suggest one mechanism by which these mutations can cause neurodegeneration and frontotemporal dementia and Parkinsonism linked to chromosome 17. | [
{
"begin_idx": "183",
"end_idx": "202",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimers' disease"
},
{
"begin_idx": "323",
"end_idx": "335",
"entity_id": "D010302",
"entity_type": "Disease",
"text_name": "Parkinsonism"
},
{
"begin_idx": "576",
"end_idx": "588",
"entity_id": "D010302",
"entity_type": "Disease",
"text_name": "Parkinsonism"
},
{
"begin_idx": "834",
"end_idx": "846",
"entity_id": "D010302",
"entity_type": "Disease",
"text_name": "Parkinsonism"
},
{
"begin_idx": "404",
"end_idx": "421",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegeneration"
},
{
"begin_idx": "480",
"end_idx": "497",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegeneration"
},
{
"begin_idx": "784",
"end_idx": "829",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegeneration and frontotemporal dementia"
},
{
"begin_idx": "285",
"end_idx": "318",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited frontotemporal dementia"
},
{
"begin_idx": "548",
"end_idx": "571",
"entity_id": "D057180",
"entity_type": "Disease",
"text_name": "frontotemporal dementia"
},
{
"begin_idx": "62",
"end_idx": "69",
"entity_id": "4137",
"entity_type": "Gene",
"text_name": "FTDP-17"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "62",
"end_idx": "69",
"entity_id": "4137",
"entity_type": "Gene",
"text_name": "FTDP-17"
},
{
"begin_idx": "62",
"end_idx": "69",
"entity_id": "4137",
"entity_type": "Gene",
"text_name": "FTDP-17"
}
] | [
{
"begin_idx": "548",
"end_idx": "571",
"entity_id": "D057180",
"entity_type": "Disease",
"text_name": "frontotemporal dementia"
},
{
"begin_idx": "480",
"end_idx": "497",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegeneration"
}
] | [
"FTDP-17",
"FTDP-17"
] | [
"frontotemporal dementia",
"neurodegeneration"
] |
10215410 | A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. | Hypochondroplasia and achondroplasia are skeletal dysplasias, characterized by autosomal dominant inheritance and disproportionate short stature, which occurs mainly due to growth failure of the extremities. Both dysplasias have been mapped to fibroblast growth factor receptor 3 (FGFR3) gene. For hypochondroplasia, two point mutations, both responsible for the Asn540Lys substitution in the region coding the tyrosine kinase domain have been reported. Here we report an A to G transition at position 1651, predicting an Ile538Val substitution in the FGFR3, in hypochondroplasia. The substitution is found in a swedish family with three affected members. The criteria for hypochondroplasia were disproportionate short stature and radiological evidence of shortened long bones and decrease or absence of normal increase in interpedicular distances of the lumbar column. The mutation was detected by direct sequencing and restriction enzyme Tai I digestion. The base change was not found in the FGFR3 genes of unaffected members of the family nor in seventy-five unrelated unaffected individuals, suggesting that it was not a polymorphism. The Ile538Val substitution is a conservative amino acid change (a hydrophobic amino acid incorporated for another hydrophobic amino acid). Nevertheless, it is located in the stretch of nine amino acids, which is highly conserved among all the human fibroblast growth factor receptors. Considering the location of this substitution and the segregation with the phenotype in this family, we propose that it is a causative mutation of hypochondroplasia. It is difficult to establish whether the Ile538Val substitution is rare in hypochondroplasia patients or whether the individuals, who have a moderate degree of short stature, rarely seek medical help for the short stature and consequently are rarely diagnosed as affected by hypochondroplasia. | [
{
"begin_idx": "178",
"end_idx": "197",
"entity_id": "C535662",
"entity_type": "Disease",
"text_name": "skeletal dysplasias"
},
{
"begin_idx": "350",
"end_idx": "360",
"entity_id": "C535662",
"entity_type": "Disease",
"text_name": "dysplasias"
},
{
"begin_idx": "82",
"end_idx": "99",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "137",
"end_idx": "154",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "Hypochondroplasia"
},
{
"begin_idx": "435",
"end_idx": "452",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "699",
"end_idx": "716",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "810",
"end_idx": "827",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "1708",
"end_idx": "1725",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "1802",
"end_idx": "1819",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "2002",
"end_idx": "2019",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "159",
"end_idx": "173",
"entity_id": "D000130",
"entity_type": "Disease",
"text_name": "achondroplasia"
},
{
"begin_idx": "268",
"end_idx": "281",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
},
{
"begin_idx": "850",
"end_idx": "863",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
},
{
"begin_idx": "1887",
"end_idx": "1900",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
},
{
"begin_idx": "1935",
"end_idx": "1948",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
},
{
"begin_idx": "43",
"end_idx": "78",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "fibroblast growth factor receptor 3"
},
{
"begin_idx": "381",
"end_idx": "416",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "fibroblast growth factor receptor 3"
},
{
"begin_idx": "418",
"end_idx": "423",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "FGFR3"
},
{
"begin_idx": "689",
"end_idx": "694",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "FGFR3"
},
{
"begin_idx": "1131",
"end_idx": "1136",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "FGFR3"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "43",
"end_idx": "78",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "fibroblast growth factor receptor 3"
},
{
"begin_idx": "418",
"end_idx": "423",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "FGFR3"
}
] | [
{
"begin_idx": "82",
"end_idx": "99",
"entity_id": "C562937",
"entity_type": "Disease",
"text_name": "hypochondroplasia"
},
{
"begin_idx": "1887",
"end_idx": "1900",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
}
] | [
"fibroblast growth factor receptor 3",
"FGFR3"
] | [
"hypochondroplasia",
"short stature"
] |
10215411 | Detection of four novel mutations in the iduronate-2-sulfatase gene. Mutations in brief no. 123. Online. | Hunter disease (mucopolysaccharidosis type II or MPS II) is an X-linked recessive disorder caused by the deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS) (E.C.3.1.6.13.) involved in the catabolism of mucopolysaccharides dermatan sulfate and heparan sulfate. A large variety of alterations have been detected at the IDS locus. We report here the identification, in 7 unrelated Italian patients, of IDS gene mutations, four of which are novel and have been confirmed by amplification refractory system (ARMS) or restriction analysis. Our findings include: the missense mutation P86L found in a severe phenotype, the splicing mutation G374G and the nonsense mutation W475X, both associated with mild phenotypes. The four novel mutations were: the missense mutations R88P and R88H, associated with severe phenotypes, concerning a position found to be a mutational "hot-spot" for the IDS gene due to a mutation-prone CpG dinucleotide; mutations T1181 and P266H, both in mild patients. Interestingly, four of our mutations are located on exon III of IDS gene, confirming the high mutation frequency of this exon. After this manuscript was submitted, Rathman et al (Am. J.Hum.Genet.59,1202,1996) reported a total of 101 mutations including one R88H which is one of the novel mutations in this report. | [
{
"begin_idx": "105",
"end_idx": "119",
"entity_id": "D004194",
"entity_type": "Disease",
"text_name": "Hunter disease"
},
{
"begin_idx": "41",
"end_idx": "62",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "121",
"end_idx": "160",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis type II or MPS II"
},
{
"begin_idx": "245",
"end_idx": "266",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "268",
"end_idx": "271",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "IDS"
},
{
"begin_idx": "434",
"end_idx": "437",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "IDS"
},
{
"begin_idx": "516",
"end_idx": "519",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "IDS"
},
{
"begin_idx": "998",
"end_idx": "1001",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "IDS"
},
{
"begin_idx": "1163",
"end_idx": "1166",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "IDS"
},
{
"begin_idx": "560",
"end_idx": "618",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "and have been confirmed by amplification refractory system"
},
{
"begin_idx": "168",
"end_idx": "195",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked recessive disorder"
},
{
"begin_idx": "41",
"end_idx": "62",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "245",
"end_idx": "266",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "268",
"end_idx": "271",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
},
{
"begin_idx": "434",
"end_idx": "437",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
},
{
"begin_idx": "516",
"end_idx": "519",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
},
{
"begin_idx": "998",
"end_idx": "1001",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
},
{
"begin_idx": "1163",
"end_idx": "1166",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "41",
"end_idx": "62",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "245",
"end_idx": "266",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate-2-sulfatase"
}
] | [
{
"begin_idx": "121",
"end_idx": "160",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis type II or MPS II"
},
{
"begin_idx": "560",
"end_idx": "618",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "and have been confirmed by amplification refractory system"
}
] | [
"iduronate-2-sulfatase",
"iduronate-2-sulfatase"
] | [
"mucopolysaccharidosis type II or MPS II",
"and have been confirmed by amplification refractory system"
] |
10219239 | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | A novel potassium channel gene has been cloned, characterized, and associated with cardiac arrhythmia. The gene encodes MinK-related peptide 1 (MiRP1), a small integral membrane subunit that assembles with HERG, a pore-forming protein, to alter its function. Unlike channels formed only with HERG, mixed complexes resemble native cardiac IKr channels in their gating, unitary conductance, regulation by potassium, and distinctive biphasic inhibition by the class III antiarrhythmic E-4031. Three missense mutations associated with long QT syndrome and ventricular fibrillation are identified in the gene for MiRP1. Mutants form channels that open slowly and close rapidly, thereby diminishing potassium currents. One variant, associated with clarithromycin-induced arrhythmia, increases channel blockade by the antibiotic. A mechanism for acquired arrhythmia is revealed: genetically based reduction in potassium currents that remains clinically silent until combined with additional stressors. | [
{
"begin_idx": "68",
"end_idx": "86",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "cardiac arrhythmia"
},
{
"begin_idx": "171",
"end_idx": "189",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "cardiac arrhythmia"
},
{
"begin_idx": "853",
"end_idx": "863",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "arrhythmia"
},
{
"begin_idx": "936",
"end_idx": "946",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "arrhythmia"
},
{
"begin_idx": "619",
"end_idx": "635",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long QT syndrome"
},
{
"begin_idx": "640",
"end_idx": "664",
"entity_id": "D014693",
"entity_type": "Disease",
"text_name": "ventricular fibrillation"
},
{
"begin_idx": "40",
"end_idx": "44",
"entity_id": "3757",
"entity_type": "Gene",
"text_name": "HERG"
},
{
"begin_idx": "294",
"end_idx": "298",
"entity_id": "3757",
"entity_type": "Gene",
"text_name": "HERG"
},
{
"begin_idx": "380",
"end_idx": "384",
"entity_id": "3757",
"entity_type": "Gene",
"text_name": "HERG"
},
{
"begin_idx": "0",
"end_idx": "5",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MiRP1"
},
{
"begin_idx": "208",
"end_idx": "230",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MinK-related peptide 1"
},
{
"begin_idx": "232",
"end_idx": "237",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MiRP1"
},
{
"begin_idx": "696",
"end_idx": "701",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MiRP1"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
true,
true,
true
] | [
{
"begin_idx": "208",
"end_idx": "230",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MinK-related peptide 1"
},
{
"begin_idx": "208",
"end_idx": "230",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MinK-related peptide 1"
},
{
"begin_idx": "208",
"end_idx": "230",
"entity_id": "9992",
"entity_type": "Gene",
"text_name": "MinK-related peptide 1"
},
{
"begin_idx": "294",
"end_idx": "298",
"entity_id": "3757",
"entity_type": "Gene",
"text_name": "HERG"
}
] | [
{
"begin_idx": "640",
"end_idx": "664",
"entity_id": "D014693",
"entity_type": "Disease",
"text_name": "ventricular fibrillation"
},
{
"begin_idx": "619",
"end_idx": "635",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long QT syndrome"
},
{
"begin_idx": "853",
"end_idx": "863",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "arrhythmia"
},
{
"begin_idx": "68",
"end_idx": "86",
"entity_id": "D001145",
"entity_type": "Disease",
"text_name": "cardiac arrhythmia"
}
] | [
"MinK-related peptide 1",
"MinK-related peptide 1",
"MinK-related peptide 1",
"HERG"
] | [
"ventricular fibrillation",
"long QT syndrome",
"arrhythmia",
"cardiac arrhythmia"
] |
10220141 | Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. | Mutations in the 6-pyruvoyltetrahydropterin synthase (PTPS) gene result in persistent hyperphenylalaninemia and severe catecholamine and serotonin deficiencies. We investigated at the DNA level a family with a PTPS-deficient child presenting with an unusual form of transient hyperphenylalaninemia. The patient exhibited compound heterozygosity for the PTPS-mutant alleles N47D and D116G. Transfection studies with single PTPS alleles in COS-1 cells showed that the N47D allele was inactive, while D116G had around 66% of the wild-type activity. Upon co-transfection of two PTPS alleles into COS-1 cells, the N47D allele had a dominant negative effect on both the wild-type PTPS and the D116G mutant with relative reduction to about 20% of control values. Whereas the mother and the father had reduced enzyme activity in red blood cells (34.7% and 51.7%, respectively) and skin fibroblasts (2.8% and 15.4%, respectively), the clinically normal patient had in these cells activities at the detection limits, although PTPS-cross-reactive material was present in the fibroblasts. The specifically low PTPS activity in the mother's cells corroborated the evidence of a dominant negative effect of the maternal N47D allele on wild-type PTPS. | [
{
"begin_idx": "374",
"end_idx": "388",
"entity_id": "C535325",
"entity_type": "Disease",
"text_name": "PTPS-deficient"
},
{
"begin_idx": "131",
"end_idx": "162",
"entity_id": "D010661",
"entity_type": "Disease",
"text_name": "transient hyperphenylalaninemia"
},
{
"begin_idx": "250",
"end_idx": "271",
"entity_id": "D010661",
"entity_type": "Disease",
"text_name": "hyperphenylalaninemia"
},
{
"begin_idx": "430",
"end_idx": "461",
"entity_id": "D010661",
"entity_type": "Disease",
"text_name": "transient hyperphenylalaninemia"
},
{
"begin_idx": "301",
"end_idx": "323",
"entity_id": "D020230",
"entity_type": "Disease",
"text_name": "serotonin deficiencies"
},
{
"begin_idx": "76",
"end_idx": "111",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "6-pyruvoyltetrahydropterin synthase"
},
{
"begin_idx": "181",
"end_idx": "216",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "6-pyruvoyltetrahydropterin synthase"
},
{
"begin_idx": "218",
"end_idx": "222",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "517",
"end_idx": "521",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "586",
"end_idx": "590",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "738",
"end_idx": "742",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "838",
"end_idx": "842",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "1180",
"end_idx": "1184",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "1262",
"end_idx": "1266",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
},
{
"begin_idx": "1395",
"end_idx": "1399",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "76",
"end_idx": "111",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "6-pyruvoyltetrahydropterin synthase"
},
{
"begin_idx": "738",
"end_idx": "742",
"entity_id": "5805",
"entity_type": "Gene",
"text_name": "PTPS"
}
] | [
{
"begin_idx": "374",
"end_idx": "388",
"entity_id": "C535325",
"entity_type": "Disease",
"text_name": "PTPS-deficient"
},
{
"begin_idx": "430",
"end_idx": "461",
"entity_id": "D010661",
"entity_type": "Disease",
"text_name": "transient hyperphenylalaninemia"
}
] | [
"6-pyruvoyltetrahydropterin synthase",
"PTPS"
] | [
"PTPS-deficient",
"transient hyperphenylalaninemia"
] |
10220152 | Identification of 6 new mutations in the iduronate sulfatase gene. Mutation in brief no. 233. Online. | Mucopolysaccharidosis type II (Hunter syndrome) is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. We sequenced genomic DNA and RT-PCR products in the iduronate sulfatase (IDS) gene in 6 unrelated patients with Hunter syndrome to assess genotype/phenotype relationships and offer carrier testing where required. Six novel mutations were identified: four missense mutations, one four-base pair deletion (596-599delAACA) and a cryptic splice site mutation. Three of the missense mutations were significant amino acid substitutions (S143F, S491F, E341K) of which the latter two involve amino acids conserved amongst sulfatase enzymes. The patients identified with these mutations all had a severe clinical phenotype. One missense mutation with a minimal amino acid substitution (H342Y), in a non-conserved region of the gene, was associated with a mild clinical phenotype. We identified a novel cryptic splice site (IVS5+934G>A) with some normal (wild type) mRNA processing. We predict that the normal mRNA product confered some residual functional enzyme, resulting in a mild phenotype associated with the absence of overt central nervous system disease. | [
{
"begin_idx": "156",
"end_idx": "191",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "X-linked lysosomal storage disorder"
},
{
"begin_idx": "102",
"end_idx": "131",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Mucopolysaccharidosis type II"
},
{
"begin_idx": "133",
"end_idx": "148",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Hunter syndrome"
},
{
"begin_idx": "364",
"end_idx": "379",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Hunter syndrome"
},
{
"begin_idx": "1274",
"end_idx": "1304",
"entity_id": "D020279",
"entity_type": "Disease",
"text_name": "central nervous system disease"
},
{
"begin_idx": "41",
"end_idx": "60",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate sulfatase"
},
{
"begin_idx": "229",
"end_idx": "250",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "304",
"end_idx": "323",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate sulfatase"
},
{
"begin_idx": "325",
"end_idx": "328",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "229",
"end_idx": "250",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "iduronate-2-sulfatase"
},
{
"begin_idx": "325",
"end_idx": "328",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
}
] | [
{
"begin_idx": "102",
"end_idx": "131",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Mucopolysaccharidosis type II"
},
{
"begin_idx": "156",
"end_idx": "191",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "X-linked lysosomal storage disorder"
}
] | [
"iduronate-2-sulfatase",
"IDS"
] | [
"Mucopolysaccharidosis type II",
"X-linked lysosomal storage disorder"
] |
10220154 | Identification of mutations in the galactose-1-phosphate uridyltransferase (GALT) gene in 16 Turkish patients with galactosemia, including a novel mutation of F294Y. Mutation in brief no. 235. Online. | Classical galactosemia caused by deficiency of galactose-1-phosphate uridyltransferase (GALT) is a severe autosomal recessive disorder. We report here molecular analysis of 16 unrelated Turkish galactosemia index cases without GALT activity. Almost 84% of all mutant alleles were identified in this study. The most common molecular defect observed in the Turkish population was Q188R (replacement of glutamine-188 by arginine) (57%). In order to facilitate the determination of unknown mutations in the entire coding region of GALT, we established an approach based on GALT cDNA synthesis and direct sequencing. We have identified one novel candidate galactosemia mutation, a T-to-A transversion at the codon 294 (F294Y) in exon 9 in addition to previously reported three missense (M142K K285N, A320T), one stop codon (E340X), and one silent (L218L) mutations in galactosemia patients which reflect considerable genetic heterogeneity in the Turkish population. | [
{
"begin_idx": "115",
"end_idx": "127",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "galactosemia"
},
{
"begin_idx": "201",
"end_idx": "223",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "Classical galactosemia"
},
{
"begin_idx": "234",
"end_idx": "287",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "deficiency of galactose-1-phosphate uridyltransferase"
},
{
"begin_idx": "395",
"end_idx": "407",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "galactosemia"
},
{
"begin_idx": "852",
"end_idx": "864",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "galactosemia"
},
{
"begin_idx": "1064",
"end_idx": "1076",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "galactosemia"
},
{
"begin_idx": "307",
"end_idx": "335",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "35",
"end_idx": "74",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "galactose-1-phosphate uridyltransferase"
},
{
"begin_idx": "76",
"end_idx": "80",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "GALT"
},
{
"begin_idx": "248",
"end_idx": "287",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "galactose-1-phosphate uridyltransferase"
},
{
"begin_idx": "289",
"end_idx": "293",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "GALT"
},
{
"begin_idx": "428",
"end_idx": "432",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "GALT"
},
{
"begin_idx": "728",
"end_idx": "732",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "GALT"
},
{
"begin_idx": "770",
"end_idx": "774",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "GALT"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "35",
"end_idx": "74",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "galactose-1-phosphate uridyltransferase"
},
{
"begin_idx": "35",
"end_idx": "74",
"entity_id": "2592",
"entity_type": "Gene",
"text_name": "galactose-1-phosphate uridyltransferase"
}
] | [
{
"begin_idx": "234",
"end_idx": "287",
"entity_id": "D005693",
"entity_type": "Disease",
"text_name": "deficiency of galactose-1-phosphate uridyltransferase"
},
{
"begin_idx": "307",
"end_idx": "335",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
}
] | [
"galactose-1-phosphate uridyltransferase",
"galactose-1-phosphate uridyltransferase"
] | [
"deficiency of galactose-1-phosphate uridyltransferase",
"autosomal recessive disorder"
] |
10220155 | Three novel mutations in the gap junction beta 1 (GJB1) gene coding region identified in Charcot-Marie-Tooth patients of Greek origin: T55I, R164Q, V120E. Mutation in brief no 236. Online. | Charcot-Marie-Tooth (CMT) disease type CMTX has been linked with mutations in GJB1, a gene on chromosome X coding for a gap junction protein, Connexin 32. We screened the GJB1 gene for mutations by SSCP analysis and sequencing of candidate regions, in five unrelated CMT affected individuals, members of families presenting a mode of transmission and clinical findings compatible with CMTX. Mutations were detected in all five patients. Three not previously reported mutations were identified: C164T, G491A and T359A. Two patients shared the same mutation (C164T) while one had a reported mutation (C43T). Restriction enzyme digestion confirmed the sequencing results, as well as the co-segregation of the mutation with the disease. The same method was used to screen 150 control X chromosomes and the variations were not detected. | [
{
"begin_idx": "228",
"end_idx": "232",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "CMTX"
},
{
"begin_idx": "574",
"end_idx": "578",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "CMTX"
},
{
"begin_idx": "89",
"end_idx": "108",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth"
},
{
"begin_idx": "189",
"end_idx": "208",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth"
},
{
"begin_idx": "210",
"end_idx": "213",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "CMT"
},
{
"begin_idx": "456",
"end_idx": "459",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "CMT"
},
{
"begin_idx": "29",
"end_idx": "48",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "gap junction beta 1"
},
{
"begin_idx": "50",
"end_idx": "54",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "GJB1"
},
{
"begin_idx": "228",
"end_idx": "232",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "CMTX"
},
{
"begin_idx": "267",
"end_idx": "271",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "GJB1"
},
{
"begin_idx": "331",
"end_idx": "342",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Connexin 32"
},
{
"begin_idx": "360",
"end_idx": "364",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "GJB1"
},
{
"begin_idx": "574",
"end_idx": "578",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "CMTX"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "29",
"end_idx": "48",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "gap junction beta 1"
},
{
"begin_idx": "360",
"end_idx": "364",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "GJB1"
}
] | [
{
"begin_idx": "228",
"end_idx": "232",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "CMTX"
},
{
"begin_idx": "189",
"end_idx": "208",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth"
}
] | [
"gap junction beta 1",
"GJB1"
] | [
"CMTX",
"Charcot-Marie-Tooth"
] |
10220498 | Association of K-ras mutations with p16 methylation in human colon cancer. | BACKGROUND _ AIMS: K-ras mutations are early genetic changes in colon cancer. p16, a tumor-suppressor gene, is inactivated in neoplasms by mutation, deletion, or methylation. The aims of this study were to determine p16 methylation status and its possible association with K-ras mutations in human colon cancer. METHODS: DNA isolated from 8 colon cancer cell lines and 41 microdissected human colon tissue samples was analyzed. p16 methylation status was determined using two analytical methods. The level of p16 expression was determined by reverse-transcription polymerase chain reaction and Northern blot. K-ras mutations were determined by DNA sequence analysis. The DNA methyltransferase activity was determined by microassay. Parental and K-ras-transformed IEC-18 cells were used to determine the potential association between K-ras mutations and p16 methylation. RESULTS: Methylated p16 was found in 100% of colon cancer cell lines, 55% of colon cancers, 54% of adenomas, and 25% of transitional mucosa but not in normal colonic epithelium. Forty-five percent of cancers and 38% of adenomas showed both K-ras mutations and p16 methylation. Of 11 cancers and adenomas with K-ras mutation, 10 specimens showed methylated p16. In contrast, of 13 adenomas and cancers with wild-type K-ras, only 3 specimens showed methylated p16 (P = 0.001). Stable transformation of IEC-18 cells with K-ras increased the DNA methyltransferase activity, methylated the p16 gene, and suppressed the expression of p16. Treatment with a DNA methylation inhibitor (azadeoxycytidine) resulted in reexpression of p16 in K-ras-transformed IEC-18 cells, suggesting that the expression of p16 was suppressed by DNA methylation. CONCLUSIONS: p16 methylation occurs frequently in human colonic adenomas and cancers and is closely associated with K-ras mutations. | [
{
"begin_idx": "1044",
"end_idx": "1052",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "1164",
"end_idx": "1172",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "1240",
"end_idx": "1248",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "1325",
"end_idx": "1333",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "61",
"end_idx": "73",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancer"
},
{
"begin_idx": "139",
"end_idx": "151",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancer"
},
{
"begin_idx": "373",
"end_idx": "385",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancer"
},
{
"begin_idx": "416",
"end_idx": "428",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancer"
},
{
"begin_idx": "990",
"end_idx": "1002",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancer"
},
{
"begin_idx": "1022",
"end_idx": "1035",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancers"
},
{
"begin_idx": "1836",
"end_idx": "1852",
"entity_id": "D003111",
"entity_type": "Disease",
"text_name": "colonic adenomas"
},
{
"begin_idx": "160",
"end_idx": "165",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "201",
"end_idx": "210",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
},
{
"begin_idx": "1145",
"end_idx": "1152",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancers"
},
{
"begin_idx": "1228",
"end_idx": "1235",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancers"
},
{
"begin_idx": "1338",
"end_idx": "1345",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancers"
},
{
"begin_idx": "1857",
"end_idx": "1864",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancers"
},
{
"begin_idx": "36",
"end_idx": "39",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "153",
"end_idx": "156",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "291",
"end_idx": "294",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "503",
"end_idx": "506",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "584",
"end_idx": "587",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "928",
"end_idx": "931",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "965",
"end_idx": "968",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1205",
"end_idx": "1208",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1301",
"end_idx": "1304",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1403",
"end_idx": "1406",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1530",
"end_idx": "1533",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1573",
"end_idx": "1576",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1668",
"end_idx": "1671",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1741",
"end_idx": "1744",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "1793",
"end_idx": "1796",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
},
{
"begin_idx": "15",
"end_idx": "20",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "94",
"end_idx": "99",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "348",
"end_idx": "353",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "684",
"end_idx": "689",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "820",
"end_idx": "825",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "908",
"end_idx": "913",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1185",
"end_idx": "1190",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1254",
"end_idx": "1259",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1361",
"end_idx": "1366",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1463",
"end_idx": "1468",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1675",
"end_idx": "1680",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1896",
"end_idx": "1901",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "15",
"end_idx": "20",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "153",
"end_idx": "156",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16"
}
] | [
{
"begin_idx": "1022",
"end_idx": "1035",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon cancers"
},
{
"begin_idx": "160",
"end_idx": "165",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
}
] | [
"K-ras",
"p16"
] | [
"colon cancers",
"tumor"
] |
10220506 | Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. | BACKGROUNDS _ AIMS: Mutations in the JAGGED1 gene are responsible for the Alagille syndrome, an autosomal dominant disorder characterized by neonatal jaundice, intrahepatic cholestasis, and developmental disorders affecting the liver, heart, vertebrae, eyes, and face. We screened a large group of patients for mutations in JAGGED1 and studied transmission of the mutations. METHODS: The coding sequence of the JAGGED1 gene was searched by single-strand conformation polymorphism and sequence analysis for mutations in 109 unrelated patients with the Alagille syndrome and their family if available. RESULTS: Sixty-nine patients (63%) had intragenic mutations, including 14 nonsense mutations, 31 frameshifts, 11 splice site mutations, and 13 missense mutations. We identified 59 different types of mutation of which 54 were previously undescribed; 8 were observed more than once. Mutations were de novo in 40 of 57 probands. CONCLUSIONS: Most of the observed mutations other than the missense mutations in JAGGED1 are expected to give rise to truncated and unanchored proteins. All mutations mapped to the extracellular domain of the protein, and there appeared to be regional hot spots, although no clustering was observed. Thus, the sequencing of 7 exons of JAGGED1 would detect 51% of the mutations. Transmission analysis showed a high frequency of sporadic cases (70%). | [
{
"begin_idx": "265",
"end_idx": "288",
"entity_id": "D002658",
"entity_type": "Disease",
"text_name": "developmental disorders"
},
{
"begin_idx": "235",
"end_idx": "259",
"entity_id": "D002780",
"entity_type": "Disease",
"text_name": "intrahepatic cholestasis"
},
{
"begin_idx": "216",
"end_idx": "233",
"entity_id": "D007567",
"entity_type": "Disease",
"text_name": "neonatal jaundice"
},
{
"begin_idx": "56",
"end_idx": "73",
"entity_id": "D016738",
"entity_type": "Disease",
"text_name": "Alagille syndrome"
},
{
"begin_idx": "149",
"end_idx": "166",
"entity_id": "D016738",
"entity_type": "Disease",
"text_name": "Alagille syndrome"
},
{
"begin_idx": "626",
"end_idx": "643",
"entity_id": "D016738",
"entity_type": "Disease",
"text_name": "Alagille syndrome"
},
{
"begin_idx": "171",
"end_idx": "198",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant disorder"
},
{
"begin_idx": "13",
"end_idx": "20",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
},
{
"begin_idx": "112",
"end_idx": "119",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
},
{
"begin_idx": "399",
"end_idx": "406",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
},
{
"begin_idx": "486",
"end_idx": "493",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
},
{
"begin_idx": "1082",
"end_idx": "1089",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
},
{
"begin_idx": "1336",
"end_idx": "1343",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "13",
"end_idx": "20",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
},
{
"begin_idx": "1082",
"end_idx": "1089",
"entity_id": "182",
"entity_type": "Gene",
"text_name": "JAGGED1"
}
] | [
{
"begin_idx": "56",
"end_idx": "73",
"entity_id": "D016738",
"entity_type": "Disease",
"text_name": "Alagille syndrome"
},
{
"begin_idx": "235",
"end_idx": "259",
"entity_id": "D002780",
"entity_type": "Disease",
"text_name": "intrahepatic cholestasis"
}
] | [
"JAGGED1",
"JAGGED1"
] | [
"Alagille syndrome",
"intrahepatic cholestasis"
] |
10220507 | Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. | BACKGROUND _ AIMS: Transporter associated with antigen processing (TAP) has essential roles in the antigen-presenting systems, translocating antigenic peptides from the cytosol into the endoplasmic reticulum. The aim of this study was to clarify whether TAP polymorphisms are involved in hepatitis C virus (HCV) infection. METHODS: The 145 HCV-infected Japanese patients examined in this study were categorized into two groups: 36 carriers with persistently normal alanine transaminase (ALT) values and 109 patients with chronic liver disease (CLD). TAP2 gene phenotypes were determined by means of polymerase chain reaction-restriction fragment length polymorphism, and their frequencies were compared between the two groups. RESULTS: Frequencies of TAP2*0101, *0102, and *0201 were not different between the two groups. However, TAP2*0103 frequency in carriers with normal ALT levels was significantly higher than that in patients with CLD (44% vs. 16%; P = 0.00064, Pc < 0.005). Although the TAP2*0103 allele was tightly linked with class II DRB1*1302-DQB1*0604 haplotype in this study, the TAP2*0103 frequency in the normal ALT group was also significantly higher than that in the CLD group even in DRB1*1302-DQB1*0604-negative patients (31% vs. 10%; P = 0.0076, Pc < 0.05). CONCLUSIONS: These findings suggest that TAP2*0103 may be closely associated with low serum ALT activity in HCV-infected Japanese patients. | [
{
"begin_idx": "93",
"end_idx": "120",
"entity_id": "D006526",
"entity_type": "Disease",
"text_name": "hepatitis C virus infection"
},
{
"begin_idx": "410",
"end_idx": "443",
"entity_id": "D006526",
"entity_type": "Disease",
"text_name": "hepatitis C virus (HCV) infection"
},
{
"begin_idx": "643",
"end_idx": "664",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "chronic liver disease"
},
{
"begin_idx": "666",
"end_idx": "669",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "CLD"
},
{
"begin_idx": "1060",
"end_idx": "1063",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "CLD"
},
{
"begin_idx": "1307",
"end_idx": "1310",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "CLD"
},
{
"begin_idx": "1167",
"end_idx": "1171",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "1325",
"end_idx": "1329",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "65",
"end_idx": "69",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "672",
"end_idx": "676",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "873",
"end_idx": "877",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "953",
"end_idx": "957",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "1117",
"end_idx": "1121",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "1216",
"end_idx": "1220",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "1442",
"end_idx": "1446",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "65",
"end_idx": "69",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
},
{
"begin_idx": "1442",
"end_idx": "1446",
"entity_id": "6891",
"entity_type": "Gene",
"text_name": "TAP2"
}
] | [
{
"begin_idx": "410",
"end_idx": "443",
"entity_id": "D006526",
"entity_type": "Disease",
"text_name": "hepatitis C virus (HCV) infection"
},
{
"begin_idx": "1307",
"end_idx": "1310",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "CLD"
}
] | [
"TAP2",
"TAP2"
] | [
"hepatitis C virus (HCV) infection",
"CLD"
] |
10221692 | Androgen receptor gene mutations in 46,XY females with germ cell tumours. | We present clinical findings and molecular characterization in two patients previously diagnosed as 46,XY female gonadal dysgenesis with germ cell tumour. Both patients showed a female general phenotype with unambiguously female external genitalia and primary amenorrhoea compatible with complete androgen insensitivity syndrome. The first patient, at the age of 31 years, developed a dysgerminoma measuring 8 x 13 x 10 cm in one abdominal testis. Genetic analysis revealed a single nucleotide substitution on exon 4 in the hormone-binding domain of the androgen receptor (AR) gene, resulting in a change of codon 681 GAG (glutamic acid) to AAG (lysine). The second patient, at the age of 17 years, developed a dysgerminoma measuring 12 x 10 x 7 cm in one abdominal testis and gonadoblastoma in the other testis. Genetic analysis showed a point mutation on exon 3 in the DNA-binding domain of the AR gene resulting in a change of codon 607 CGA (arginine) to CAA (glutamine). Arg607-Gln and Arg608-Lys point mutations in the DNA-binding domain of the AR gene have been associated with male breast cancer in partial androgen insensitivity syndrome. A codon 607 mutation in the DNA-binding domain of the AR gene in our patient 2 is associated with early development of germ cell tumour. We suggest regular molecular genetic analysis of the AR gene in 46,XY females with germ cell tumour and androgen insensitivity syndrome to detect differences in the specific regions of AR gene involved in early progression toward oncogenesis of the dysgenetic gonads. | [
{
"begin_idx": "334",
"end_idx": "345",
"entity_id": "C537962",
"entity_type": "Disease",
"text_name": "amenorrhoea"
},
{
"begin_idx": "459",
"end_idx": "471",
"entity_id": "D004407",
"entity_type": "Disease",
"text_name": "dysgerminoma"
},
{
"begin_idx": "785",
"end_idx": "797",
"entity_id": "D004407",
"entity_type": "Disease",
"text_name": "dysgerminoma"
},
{
"begin_idx": "187",
"end_idx": "205",
"entity_id": "D006059",
"entity_type": "Disease",
"text_name": "gonadal dysgenesis"
},
{
"begin_idx": "65",
"end_idx": "72",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumours"
},
{
"begin_idx": "211",
"end_idx": "227",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "germ cell tumour"
},
{
"begin_idx": "1340",
"end_idx": "1356",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "germ cell tumour"
},
{
"begin_idx": "1441",
"end_idx": "1457",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "germ cell tumour"
},
{
"begin_idx": "362",
"end_idx": "402",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "complete androgen insensitivity syndrome"
},
{
"begin_idx": "1180",
"end_idx": "1219",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "partial androgen insensitivity syndrome"
},
{
"begin_idx": "1462",
"end_idx": "1493",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
},
{
"begin_idx": "851",
"end_idx": "865",
"entity_id": "D018238",
"entity_type": "Disease",
"text_name": "gonadoblastoma"
},
{
"begin_idx": "1158",
"end_idx": "1176",
"entity_id": "D018567",
"entity_type": "Disease",
"text_name": "male breast cancer"
},
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "Androgen receptor"
},
{
"begin_idx": "628",
"end_idx": "645",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "647",
"end_idx": "649",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "971",
"end_idx": "973",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1124",
"end_idx": "1126",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1275",
"end_idx": "1277",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1411",
"end_idx": "1413",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1543",
"end_idx": "1545",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "Androgen receptor"
},
{
"begin_idx": "1411",
"end_idx": "1413",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
}
] | [
{
"begin_idx": "362",
"end_idx": "402",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "complete androgen insensitivity syndrome"
},
{
"begin_idx": "1158",
"end_idx": "1176",
"entity_id": "D018567",
"entity_type": "Disease",
"text_name": "male breast cancer"
}
] | [
"Androgen receptor",
"AR"
] | [
"complete androgen insensitivity syndrome",
"male breast cancer"
] |
10221770 | An androgen receptor mutation in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core is associated with complete androgen insensitivity. | Subjects with androgen insensitivity syndromes (AIS) are characterized by a 46, XY karyotype, presence of testes, normal or elevated androgen levels in blood, and impairment of the usual response to androgens associated with various aberrations of male differentiation and virilization ranging from slightly undervirilized men to phenotypic females. Here we describe a novel proline to serine mutation in codon 892 (exon 8) of the androgen receptor in a patient with complete androgen insensitivity. The mutation is located in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core. Investigation of androgen binding in cultured testicular fibroblasts of the patient revealed a reduced AR binding capacity (11 fmol/mg protein) and a highly elevated Kd value (3.1 nM) in comparison to control genital skin fibroblasts. Cotransfection studies with an androgen-responsive reporter gene revealed a diminished transactivation property of the mutant androgen receptor. | [
{
"begin_idx": "201",
"end_idx": "232",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "complete androgen insensitivity"
},
{
"begin_idx": "248",
"end_idx": "280",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndromes"
},
{
"begin_idx": "282",
"end_idx": "285",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "AIS"
},
{
"begin_idx": "701",
"end_idx": "732",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "complete androgen insensitivity"
},
{
"begin_idx": "3",
"end_idx": "20",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "665",
"end_idx": "682",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "1272",
"end_idx": "1289",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "3",
"end_idx": "20",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
}
] | [
{
"begin_idx": "248",
"end_idx": "280",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndromes"
}
] | [
"androgen receptor"
] | [
"androgen insensitivity syndromes"
] |
10223192 | Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. | Non-steroidal anti-inflammatory drugs (NSAIDs) can cause regression of early intestinal tumors and although this is believed to involve cyclooxygenase-2 and apoptosis, the molecular mechanisms remain unclear. Cytoplasmic and nuclear beta-catenin are overexpressed in many of these lesions and Bcl-2, which inhibits apoptosis, may also be elevated during the course of intestinal tumorigenesis. We recently showed that sulindac causes regression of 70-80% of small intestinal tumors in Min/+ mice within 4 days, but does not have the same impact on colonic lesions; after 20 days of treatment the tumor load stabilizes at 10-20% of that in untreated animals. The aim of this study was to determine if NSAID-induced regression of intestinal adenomas might be associated with changes in beta-catenin or Bcl-2 expression. Intestinal tumors from Min/+ mice were harvested after treatment with sulindac for 2, 4 or 20 days and evaluated for expression of beta-catenin and Bcl-2 using immunohistochemistry. There was a > or = 50% decrease in beta-catenin (P = 0.001) and diminishing Bcl-2 (P = 0.019) in small intestinal tumors harvested between 2 and 4 days of treatment when compared with untreated controls. In contrast, small intestinal tumors from animals treated for 20 days were not significantly different from untreated controls. Colonic tumors expressed higher levels of Bcl-2 than those from the small intestine and did not show any significant changes in either Bcl-2 or beta-catenin expression after treatment. Results suggest that modulation of aberrant beta-catenin expression occurs during NSAID-induced regression of intestinal adenomas and that Bcl-2 may confer resistance to these effects. | [
{
"begin_idx": "854",
"end_idx": "862",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "1753",
"end_idx": "1761",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "663",
"end_idx": "678",
"entity_id": "D003108",
"entity_type": "Disease",
"text_name": "colonic lesions"
},
{
"begin_idx": "1447",
"end_idx": "1461",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "Colonic tumors"
},
{
"begin_idx": "84",
"end_idx": "101",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "192",
"end_idx": "209",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "579",
"end_idx": "596",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "933",
"end_idx": "950",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "Intestinal tumors"
},
{
"begin_idx": "1218",
"end_idx": "1235",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "1338",
"end_idx": "1355",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "711",
"end_idx": "716",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "16",
"end_idx": "28",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "348",
"end_idx": "360",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "899",
"end_idx": "911",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1064",
"end_idx": "1076",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1150",
"end_idx": "1162",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1591",
"end_idx": "1603",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1676",
"end_idx": "1688",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "251",
"end_idx": "267",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "cyclooxygenase-2"
},
{
"begin_idx": "33",
"end_idx": "38",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "408",
"end_idx": "413",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "915",
"end_idx": "920",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "1081",
"end_idx": "1086",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "1191",
"end_idx": "1196",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "1489",
"end_idx": "1494",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "1582",
"end_idx": "1587",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "1771",
"end_idx": "1776",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
}
] | [
"Yes",
"Yes",
"Yes",
"Yes",
"Yes",
"No",
"No",
"No",
"No",
"No"
] | [
true,
true,
true,
false,
true,
false,
false,
false,
false,
false
] | [
{
"begin_idx": "16",
"end_idx": "28",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "33",
"end_idx": "38",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "16",
"end_idx": "28",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "33",
"end_idx": "38",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "33",
"end_idx": "38",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "348",
"end_idx": "360",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1676",
"end_idx": "1688",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "16",
"end_idx": "28",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1064",
"end_idx": "1076",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1191",
"end_idx": "1196",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
}
] | [
{
"begin_idx": "854",
"end_idx": "862",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "854",
"end_idx": "862",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "84",
"end_idx": "101",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "1447",
"end_idx": "1461",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "Colonic tumors"
},
{
"begin_idx": "84",
"end_idx": "101",
"entity_id": "D007414",
"entity_type": "Disease",
"text_name": "intestinal tumors"
},
{
"begin_idx": "711",
"end_idx": "716",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "663",
"end_idx": "678",
"entity_id": "D003108",
"entity_type": "Disease",
"text_name": "colonic lesions"
},
{
"begin_idx": "663",
"end_idx": "678",
"entity_id": "D003108",
"entity_type": "Disease",
"text_name": "colonic lesions"
},
{
"begin_idx": "1447",
"end_idx": "1461",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "Colonic tumors"
},
{
"begin_idx": "711",
"end_idx": "716",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
}
] | [
"beta-catenin",
"Bcl-2",
"beta-catenin",
"Bcl-2",
"Bcl-2",
"beta-catenin",
"beta-catenin",
"beta-catenin",
"beta-catenin",
"Bcl-2"
] | [
"adenomas",
"adenomas",
"intestinal tumors",
"Colonic tumors",
"intestinal tumors",
"tumor",
"colonic lesions",
"colonic lesions",
"Colonic tumors",
"tumor"
] |
10223196 | High frequency of codon 61 K-ras A-->T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2 years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. | Chloroprene is the 2-chloro analog of 1,3-butadiene, a potent carcinogen in laboratory animals. Following 2 years of inhalation exposure to 12.8, 32 or 80 p.p.m. chloroprene, increased incidences of lung and Harderian gland (HG) neoplasms were observed in B6C3F1 mice at all exposure concentrations. The present study was designed to characterize genetic alterations in the K- and H-ras proto-oncogenes in chloroprene-induced lung and HG neoplasms. K-ras mutations were detected in 80% of chloroprene-induced lung neoplasms (37/46) compared with only 30% in spontaneous lung neoplasms (25/82). Both K- and H-ras codon 61 A-->T transversions were identified in 100% of HG neoplasms (27/27) compared with a frequency of 56% (15/27) in spontaneous HG neoplasms. The predominant mutation in chloroprene-induced lung and HG neoplasms was an A-->T transversion at K-ras codon 61. This mutation has not been detected in spontaneous lung tumors of B6C3F1 mice and was identified in only 7% of spontaneous HG neoplasms. In lung neoplasms, greater percentages (80 and 71%) of A-->T transversions were observed at the lower exposures (12.8 and 32 p.p.m.), respectively, compared with 18% at the high exposure. In HG neoplasms, the percentage of A-->T transversions was the same at all exposure concentrations. The chloroprene-induced ras mutation spectra was similar to that seen with isoprene, where the predominant base change was an A-->T transversion at K-ras codon 61. This differed from 1,3-butadiene, where K-ras codon 13 G-->C transitions and H-ras codon 61 A-->G transitions were the predominant mutations. The major finding of K-ras A-->T transversions in lung and Harderian gland neoplasms suggests that this mutation may be important for tumor induction by this class of carcinogens. | [
{
"begin_idx": "677",
"end_idx": "698",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung and HG neoplasms"
},
{
"begin_idx": "760",
"end_idx": "774",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung neoplasms"
},
{
"begin_idx": "809",
"end_idx": "835",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "spontaneous lung neoplasms"
},
{
"begin_idx": "1058",
"end_idx": "1079",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung and HG neoplasms"
},
{
"begin_idx": "1176",
"end_idx": "1187",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumors"
},
{
"begin_idx": "1265",
"end_idx": "1279",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung neoplasms"
},
{
"begin_idx": "65",
"end_idx": "90",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Harderian gland neoplasms"
},
{
"begin_idx": "459",
"end_idx": "489",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Harderian gland (HG) neoplasms"
},
{
"begin_idx": "919",
"end_idx": "931",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "HG neoplasms"
},
{
"begin_idx": "996",
"end_idx": "1008",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "HG neoplasms"
},
{
"begin_idx": "1248",
"end_idx": "1260",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "HG neoplasms"
},
{
"begin_idx": "1453",
"end_idx": "1465",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "HG neoplasms"
},
{
"begin_idx": "1915",
"end_idx": "1940",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Harderian gland neoplasms"
},
{
"begin_idx": "1990",
"end_idx": "1995",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "27",
"end_idx": "32",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "700",
"end_idx": "705",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1109",
"end_idx": "1114",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1698",
"end_idx": "1703",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1754",
"end_idx": "1759",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1877",
"end_idx": "1882",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "27",
"end_idx": "32",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
},
{
"begin_idx": "1109",
"end_idx": "1114",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "K-ras"
}
] | [
{
"begin_idx": "809",
"end_idx": "835",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "spontaneous lung neoplasms"
},
{
"begin_idx": "459",
"end_idx": "489",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Harderian gland (HG) neoplasms"
}
] | [
"K-ras",
"K-ras"
] | [
"spontaneous lung neoplasms",
"Harderian gland (HG) neoplasms"
] |
10224407 | Promoter polymorphism in the candidate genes, IL-4, IL-9, TGF-beta1, for atopy and asthma. | This paper will review genetic variations in the structure of three important candidate genes with varying effects in atopy and asthma that may have significant overall susceptibility associations in relation to the development of atopy and asthma. The three cytokine genes involved are interleukin (IL)-4, IL-9 and transforming growth factor beta1, and the nature of the polymorphisms may be related to significantly higher outputs of these cytokines in atopy and asthma. | [
{
"begin_idx": "73",
"end_idx": "78",
"entity_id": "C564133",
"entity_type": "Disease",
"text_name": "atopy"
},
{
"begin_idx": "209",
"end_idx": "214",
"entity_id": "C564133",
"entity_type": "Disease",
"text_name": "atopy"
},
{
"begin_idx": "322",
"end_idx": "327",
"entity_id": "C564133",
"entity_type": "Disease",
"text_name": "atopy"
},
{
"begin_idx": "546",
"end_idx": "551",
"entity_id": "C564133",
"entity_type": "Disease",
"text_name": "atopy"
},
{
"begin_idx": "83",
"end_idx": "89",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "219",
"end_idx": "225",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "332",
"end_idx": "338",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "556",
"end_idx": "562",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "46",
"end_idx": "50",
"entity_id": "3565",
"entity_type": "Gene",
"text_name": "IL-4"
},
{
"begin_idx": "52",
"end_idx": "56",
"entity_id": "3578",
"entity_type": "Gene",
"text_name": "IL-9"
},
{
"begin_idx": "398",
"end_idx": "402",
"entity_id": "3578",
"entity_type": "Gene",
"text_name": "IL-9"
},
{
"begin_idx": "434",
"end_idx": "439",
"entity_id": "3779",
"entity_type": "Gene",
"text_name": "beta1"
},
{
"begin_idx": "58",
"end_idx": "67",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGF-beta1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "52",
"end_idx": "56",
"entity_id": "3578",
"entity_type": "Gene",
"text_name": "IL-9"
},
{
"begin_idx": "434",
"end_idx": "439",
"entity_id": "3779",
"entity_type": "Gene",
"text_name": "beta1"
}
] | [
{
"begin_idx": "83",
"end_idx": "89",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "332",
"end_idx": "338",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
}
] | [
"IL-9",
"beta1"
] | [
"asthma",
"asthma"
] |
10227647 | A DLST genotype associated with reduced risk for Alzheimer's disease. | Recent studies suggest that variants of the DLST gene alter the risk of AD. DLST encodes the core subunit of the mitochondrial alpha-ketoglutarate dehydrogenase complex, which is deficient in AD. The authors report that in 247 US white subjects, homozygosity for DLST A19,117, T19,183 was associated with a reduced risk of AD (odds ratio [OR] = 0.35, p = 0.018). The reduced risk was marked in subjects who did not carry the apolipoprotein (APOE)-4 allele (OR = 0.16, p = 0.014). Further study of DLST in AD appears warranted. | [
{
"begin_idx": "49",
"end_idx": "68",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "142",
"end_idx": "144",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "249",
"end_idx": "264",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "deficient in AD"
},
{
"begin_idx": "393",
"end_idx": "395",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "575",
"end_idx": "577",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "2",
"end_idx": "6",
"entity_id": "1743",
"entity_type": "Gene",
"text_name": "DLST"
},
{
"begin_idx": "114",
"end_idx": "118",
"entity_id": "1743",
"entity_type": "Gene",
"text_name": "DLST"
},
{
"begin_idx": "146",
"end_idx": "150",
"entity_id": "1743",
"entity_type": "Gene",
"text_name": "DLST"
},
{
"begin_idx": "333",
"end_idx": "337",
"entity_id": "1743",
"entity_type": "Gene",
"text_name": "DLST"
},
{
"begin_idx": "567",
"end_idx": "571",
"entity_id": "1743",
"entity_type": "Gene",
"text_name": "DLST"
},
{
"begin_idx": "495",
"end_idx": "509",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein"
},
{
"begin_idx": "511",
"end_idx": "515",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "2",
"end_idx": "6",
"entity_id": "1743",
"entity_type": "Gene",
"text_name": "DLST"
},
{
"begin_idx": "495",
"end_idx": "509",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein"
}
] | [
{
"begin_idx": "49",
"end_idx": "68",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "249",
"end_idx": "264",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "deficient in AD"
}
] | [
"DLST",
"apolipoprotein"
] | [
"Alzheimer's disease",
"deficient in AD"
] |
10229804 | CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. | CDw150, a receptor up-regulated on activated T or B lymphocytes, has a key role in regulating B cell proliferation. Patients with X-linked lymphoproliferative disease have mutations in a gene encoding a protein, DSHP/SAP, which interacts with CDw150 and is expressed in B cells. Here we show that CDw150 on B cells associates with two tyrosine-phosphorylated proteins, 59 kDa and 145 kDa in size. The 59-kDa protein was identified as the Src-family kinase Fgr. The 145-kDa protein is the inositol polyphosphate 5'-phosphatase, SH2-containing inositol phosphatase (SHIP). Both Fgr and SHIP interact with phosphorylated tyrosines in CDw150's cytoplasmic tail. Ligation of CDw150 induces the rapid dephosphorylation of both SHIP and CDw150 as well as the association of Lyn and Fgr with SHIP. CD95/Fas-mediated apoptosis is enhanced by signaling via CDw150, and CDw150 ligation can override CD40-induced rescue of CD95-mediated cell death. The ability of CDw150 to regulate cell death does not correlate with serine phosphorylation of the Akt kinase, but does correlate with SHIP tyrosine dephosphorylation. Thus, the CDw150 receptor may function to regulate the fate of activated B cells via SHIP as well as via the DSHP/SAP protein defective in X-linked lymphoproliferative disease patients. | [
{
"begin_idx": "239",
"end_idx": "275",
"entity_id": "D008232",
"entity_type": "Disease",
"text_name": "X-linked lymphoproliferative disease"
},
{
"begin_idx": "1353",
"end_idx": "1389",
"entity_id": "D008232",
"entity_type": "Disease",
"text_name": "X-linked lymphoproliferative disease"
},
{
"begin_idx": "565",
"end_idx": "568",
"entity_id": "2268",
"entity_type": "Gene",
"text_name": "Fgr"
},
{
"begin_idx": "685",
"end_idx": "688",
"entity_id": "2268",
"entity_type": "Gene",
"text_name": "Fgr"
},
{
"begin_idx": "884",
"end_idx": "887",
"entity_id": "2268",
"entity_type": "Gene",
"text_name": "Fgr"
},
{
"begin_idx": "84",
"end_idx": "88",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "CD95"
},
{
"begin_idx": "899",
"end_idx": "903",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "CD95"
},
{
"begin_idx": "1020",
"end_idx": "1024",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "CD95"
},
{
"begin_idx": "636",
"end_idx": "671",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SH2-containing inositol phosphatase"
},
{
"begin_idx": "673",
"end_idx": "677",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SHIP"
},
{
"begin_idx": "693",
"end_idx": "697",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SHIP"
},
{
"begin_idx": "830",
"end_idx": "834",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SHIP"
},
{
"begin_idx": "893",
"end_idx": "897",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SHIP"
},
{
"begin_idx": "1181",
"end_idx": "1185",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SHIP"
},
{
"begin_idx": "1299",
"end_idx": "1303",
"entity_id": "3635",
"entity_type": "Gene",
"text_name": "SHIP"
},
{
"begin_idx": "876",
"end_idx": "879",
"entity_id": "4067",
"entity_type": "Gene",
"text_name": "Lyn"
},
{
"begin_idx": "321",
"end_idx": "325",
"entity_id": "4068",
"entity_type": "Gene",
"text_name": "DSHP"
},
{
"begin_idx": "1323",
"end_idx": "1327",
"entity_id": "4068",
"entity_type": "Gene",
"text_name": "DSHP"
},
{
"begin_idx": "0",
"end_idx": "6",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "109",
"end_idx": "115",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "352",
"end_idx": "358",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "406",
"end_idx": "412",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "740",
"end_idx": "746",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "779",
"end_idx": "785",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "839",
"end_idx": "845",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "956",
"end_idx": "962",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "968",
"end_idx": "974",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "1061",
"end_idx": "1067",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "1224",
"end_idx": "1230",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
},
{
"begin_idx": "997",
"end_idx": "1001",
"entity_id": "958",
"entity_type": "Gene",
"text_name": "CD40"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "321",
"end_idx": "325",
"entity_id": "4068",
"entity_type": "Gene",
"text_name": "DSHP"
},
{
"begin_idx": "839",
"end_idx": "845",
"entity_id": "6504",
"entity_type": "Gene",
"text_name": "CDw150"
}
] | [
{
"begin_idx": "239",
"end_idx": "275",
"entity_id": "D008232",
"entity_type": "Disease",
"text_name": "X-linked lymphoproliferative disease"
},
{
"begin_idx": "1353",
"end_idx": "1389",
"entity_id": "D008232",
"entity_type": "Disease",
"text_name": "X-linked lymphoproliferative disease"
}
] | [
"DSHP",
"CDw150"
] | [
"X-linked lymphoproliferative disease",
"X-linked lymphoproliferative disease"
] |
10231340 | Polymorphisms of the endothelial nitric oxide synthase gene - no consistent association with myocardial infarction in the ECTIM study. | BACKGROUND: Our aim in the present study was to determine whether endothelial NO synthase gene (ecNOS) polymorphisms are associated with myocardial infarction (MI). METHODS: Forty chromosomes from patients with MI were screened for polymorphisms of the ecNOS gene using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis and sequencing. Ten polymorphisms were detected: three in the 5' flanking sequence at positions -1474, -924 and -788, two in coding sequences 774C --> T (silent) and G894 --> T (Glu-298 --> Asp) and five in introns 2, 11, 12, 22 and 23. Five hundred and thirty-one patients with MI and 610 control subjects recruited in France and Northern Ireland in the ECTIM study were genotyped for these polymorphisms. RESULTS: Glu-298 homozygotes were more frequent among patients with MI than in control subjects in the French population [OR = 1.47 (1.03-1.97), P < 0.009], but no such difference was observed in Northern Ireland. No significant difference between cases and control subjects was detected for the other polymorphisms. Our search for a possible association of the combination of ecNOS polymorphisms with MI by logistic regression analysis was also negative. CONCLUSIONS: We have explored a set of polymorphisms of the ecNOS gene in a large case-control study of MI and found that the polymorphisms were not consistently associated with MI. | [
{
"begin_idx": "93",
"end_idx": "114",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "272",
"end_idx": "293",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "295",
"end_idx": "297",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "346",
"end_idx": "348",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "770",
"end_idx": "772",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "966",
"end_idx": "968",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "1300",
"end_idx": "1302",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "1458",
"end_idx": "1460",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "1532",
"end_idx": "1534",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "21",
"end_idx": "54",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "endothelial nitric oxide synthase"
},
{
"begin_idx": "231",
"end_idx": "236",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "ecNOS"
},
{
"begin_idx": "388",
"end_idx": "393",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "ecNOS"
},
{
"begin_idx": "1275",
"end_idx": "1280",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "ecNOS"
},
{
"begin_idx": "1414",
"end_idx": "1419",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "ecNOS"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "21",
"end_idx": "54",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "endothelial nitric oxide synthase"
}
] | [
{
"begin_idx": "93",
"end_idx": "114",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
}
] | [
"endothelial nitric oxide synthase"
] | [
"myocardial infarction"
] |
10231446 | Glucose transporter (GLUT1) allele (XbaI-) associated with nephropathy in non-insulin-dependent diabetes mellitus. | BACKGROUND: Although multiple factors contribute to the initiation and progression of diabetic nephropathy (DN), hyperglycemia and genetic predisposition are two major components implicated in the development of DN. Several pieces of experimental evidence suggest that glucose transporter (GLUT1) activity is an important modulator for the cell hypertrophy and extracellular matrix formation of glomerular mesangial cells. METHODS: To evaluate the role of the GLUT1 gene mutation in the development of DN in Chinese patients with non-insulin-dependent diabetes mellitus (NIDDM), the polymorphic XbaI site of GLUT1 gene was analyzed by polymerase chain reaction in 124 normal subjects and 131 patients with NIDDM, among whom 64 were complicated with DN. DN was defined as persistent albuminuria with or without impaired renal function with no known cause of renal disease other than diabetes. RESULTS: The frequencies of XbaI (+/-) genotype (75 vs. 44%, P < 0.01) and XbaI (-) allele (44 vs. 29%, P < 0.05) were significantly higher in NIDDM patients with DN than those without nephropathy. There were no significant differences for GLUT1 genotype and allele frequency between NIDDM patients without nephropathy and normal subjects. The presence of the XbaI (-) allele appeared to have a strong association with the development of DN. The odds ratio was 1.915, and the 95% confidence interval was 1.044 to 3.514. In addition, no strong association was found between GLUT1 gene polymorphism and retinopathy in NIDDM patients. CONCLUSION: Our results indicate that the XbaI (-) allele of the GLUT1 gene might be a genetic marker of NIDDM with DN, and this genetic susceptibility is independent of its retinopathy in Chinese subjects. | [
{
"begin_idx": "897",
"end_idx": "908",
"entity_id": "D000419",
"entity_type": "Disease",
"text_name": "albuminuria"
},
{
"begin_idx": "997",
"end_idx": "1005",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "74",
"end_idx": "113",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "non-insulin-dependent diabetes mellitus"
},
{
"begin_idx": "645",
"end_idx": "684",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "non-insulin-dependent diabetes mellitus"
},
{
"begin_idx": "686",
"end_idx": "691",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "821",
"end_idx": "826",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1150",
"end_idx": "1155",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1291",
"end_idx": "1296",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1623",
"end_idx": "1628",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1744",
"end_idx": "1749",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "201",
"end_idx": "221",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "diabetic nephropathy"
},
{
"begin_idx": "223",
"end_idx": "225",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "327",
"end_idx": "329",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "617",
"end_idx": "619",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "864",
"end_idx": "866",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "868",
"end_idx": "870",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "1170",
"end_idx": "1172",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "1445",
"end_idx": "1447",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "1755",
"end_idx": "1757",
"entity_id": "D003928",
"entity_type": "Disease",
"text_name": "DN"
},
{
"begin_idx": "228",
"end_idx": "241",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "59",
"end_idx": "70",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "nephropathy"
},
{
"begin_idx": "925",
"end_idx": "948",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "impaired renal function"
},
{
"begin_idx": "972",
"end_idx": "985",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "renal disease"
},
{
"begin_idx": "1192",
"end_idx": "1203",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "nephropathy"
},
{
"begin_idx": "1314",
"end_idx": "1325",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "nephropathy"
},
{
"begin_idx": "1608",
"end_idx": "1619",
"entity_id": "D012164",
"entity_type": "Disease",
"text_name": "retinopathy"
},
{
"begin_idx": "1813",
"end_idx": "1824",
"entity_id": "D012164",
"entity_type": "Disease",
"text_name": "retinopathy"
},
{
"begin_idx": "21",
"end_idx": "26",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "405",
"end_idx": "410",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "575",
"end_idx": "580",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "723",
"end_idx": "728",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "1247",
"end_idx": "1252",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "1580",
"end_idx": "1585",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "1704",
"end_idx": "1709",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "21",
"end_idx": "26",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
},
{
"begin_idx": "1247",
"end_idx": "1252",
"entity_id": "6513",
"entity_type": "Gene",
"text_name": "GLUT1"
}
] | [
{
"begin_idx": "925",
"end_idx": "948",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "impaired renal function"
},
{
"begin_idx": "897",
"end_idx": "908",
"entity_id": "D000419",
"entity_type": "Disease",
"text_name": "albuminuria"
}
] | [
"GLUT1",
"GLUT1"
] | [
"impaired renal function",
"albuminuria"
] |
10231640 | Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. | PURPOSE: Cyclooxygenase, either the cox1 or cox2 isoform, controls synthesis of prostaglandin E2 (PGE2), which regulates expression of matrix metalloprotease-9 (MMP-9). PGE2 and MMP-9 are elevated in aortic aneurysms. The mechanisms and time course of the inhibition of aneurysm expansion with a nonspecific cyclooxygenase inhibitor, indomethacin, were determined in an animal model. METHODS: Rats underwent aortic perfusion with saline (n = 40) as controls or with elastase. Elastase-treated animals received no treatment (n = 82) or received indomethacin (n = 73). Aortic diameters were determined at the time of aortic perfusion and when the rats were killed. The aortas were harvested and used for whole organ culture, substrate gel zymography, or histologic analysis. RESULTS: The control group demonstrated little change in aortic diameter. All the elastase-only animals developed aneurysms (maximal aortic diameter, 5.27 +/- 2.37 mm on day 14). Indomethacin markedly decreased the rate of aortic expansion (maximum aortic diameter, 3.45 +/- 1.11 mm; P <.001 vs the elastase-only group). The enzyme-linked immunosorbent assay of aortic explant culture media showed that PGE2 synthesis paralleled aortic expansion, and indomethacin decreased PGE2 synthesis. Histologically, the aortic elastin architecture was destroyed in the elastase group, but was preserved with indomethacin treatment. In situ, hybridization for cox1 and cox2 showed that cox2, but not cox1, was expressed and was co-localized by immunohistochemistry to macrophages associated with the aortic wall. Decreased levels of MMP-9 activity with indomethacin were shown by means of substrate zymography. MMP-9 was also localized to macrophages. CONCLUSION: Indomethacin attenuates aneurysm growth, and its effects are mediated via inhibition of the cox2 isoform of cyclooxygenase, which decreases PGE2 and MMP-9 synthesis. | [
{
"begin_idx": "389",
"end_idx": "397",
"entity_id": "D000783",
"entity_type": "Disease",
"text_name": "aneurysm"
},
{
"begin_idx": "1006",
"end_idx": "1015",
"entity_id": "D000783",
"entity_type": "Disease",
"text_name": "aneurysms"
},
{
"begin_idx": "1869",
"end_idx": "1877",
"entity_id": "D000783",
"entity_type": "Disease",
"text_name": "aneurysm"
},
{
"begin_idx": "48",
"end_idx": "64",
"entity_id": "D001014",
"entity_type": "Disease",
"text_name": "aortic aneurysms"
},
{
"begin_idx": "319",
"end_idx": "335",
"entity_id": "D001014",
"entity_type": "Disease",
"text_name": "aortic aneurysms"
},
{
"begin_idx": "254",
"end_idx": "278",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "matrix metalloprotease-9"
},
{
"begin_idx": "280",
"end_idx": "285",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "MMP-9"
},
{
"begin_idx": "297",
"end_idx": "302",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "MMP-9"
},
{
"begin_idx": "1714",
"end_idx": "1719",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "MMP-9"
},
{
"begin_idx": "1792",
"end_idx": "1797",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "MMP-9"
},
{
"begin_idx": "1994",
"end_idx": "1999",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "MMP-9"
},
{
"begin_idx": "155",
"end_idx": "159",
"entity_id": "4512",
"entity_type": "Gene",
"text_name": "cox1"
},
{
"begin_idx": "1541",
"end_idx": "1545",
"entity_id": "4512",
"entity_type": "Gene",
"text_name": "cox1"
},
{
"begin_idx": "1581",
"end_idx": "1585",
"entity_id": "4512",
"entity_type": "Gene",
"text_name": "cox1"
},
{
"begin_idx": "87",
"end_idx": "91",
"entity_id": "4513",
"entity_type": "Gene",
"text_name": "cox2"
},
{
"begin_idx": "163",
"end_idx": "167",
"entity_id": "4513",
"entity_type": "Gene",
"text_name": "cox2"
},
{
"begin_idx": "1550",
"end_idx": "1554",
"entity_id": "4513",
"entity_type": "Gene",
"text_name": "cox2"
},
{
"begin_idx": "1567",
"end_idx": "1571",
"entity_id": "4513",
"entity_type": "Gene",
"text_name": "cox2"
},
{
"begin_idx": "1937",
"end_idx": "1941",
"entity_id": "4513",
"entity_type": "Gene",
"text_name": "cox2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "254",
"end_idx": "278",
"entity_id": "4318",
"entity_type": "Gene",
"text_name": "matrix metalloprotease-9"
},
{
"begin_idx": "1567",
"end_idx": "1571",
"entity_id": "4513",
"entity_type": "Gene",
"text_name": "cox2"
}
] | [
{
"begin_idx": "48",
"end_idx": "64",
"entity_id": "D001014",
"entity_type": "Disease",
"text_name": "aortic aneurysms"
},
{
"begin_idx": "319",
"end_idx": "335",
"entity_id": "D001014",
"entity_type": "Disease",
"text_name": "aortic aneurysms"
}
] | [
"matrix metalloprotease-9",
"cox2"
] | [
"aortic aneurysms",
"aortic aneurysms"
] |
10232408 | Squamous cell carcinoma in a family with dominant dystrophic epidermolysis bullosa: a molecular genetic study. | Squamous cell carcinoma in a family with dominant dystrophic epidermolysis bullosa: a molecular genetic study Squamous cell carcinoma (SCC) is a frequent complication in the severe, recessively inherited forms of dystrophic epidermolysis bullosa (RDEB), however, only rarely reported in dominant DEB. Although the SCCs in RDEB are frequently well-differentiated by histopathology, they often have a poor prognosis due to multicentricity, rapid invasiveness, and development of distant metastases. In this study, we sought to determine the molecular basis of DDEB in a family with the unusual occurrence of SCCs. Specifically, a large DDEB family with 2 individuals being affected with SCC was analyzed for potential mutations in the type VII collagen gene (COL7A1) by heteroduplex scanning and direct nucleotide sequencing of PCR amplified segments of the gene. This mutation detection strategy disclosed a G-->A transition at nucleotide position 6,235 which resulted in substitution of a glycine by arginine within the collagenous region of COL7A1. This study establishes, for the first time, the molecular basis in a family with DDEB/SCC. Clinically, this study reemphasizes the importance of vigilance in surveying DEB patients, not only those with recessive but also with dominant inheritance, for SCC. | [
{
"begin_idx": "669",
"end_idx": "673",
"entity_id": "C535956",
"entity_type": "Disease",
"text_name": "DDEB"
},
{
"begin_idx": "745",
"end_idx": "749",
"entity_id": "C535956",
"entity_type": "Disease",
"text_name": "DDEB"
},
{
"begin_idx": "1242",
"end_idx": "1246",
"entity_id": "C535956",
"entity_type": "Disease",
"text_name": "DDEB"
},
{
"begin_idx": "0",
"end_idx": "23",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "Squamous cell carcinoma"
},
{
"begin_idx": "111",
"end_idx": "134",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "Squamous cell carcinoma"
},
{
"begin_idx": "221",
"end_idx": "244",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "Squamous cell carcinoma"
},
{
"begin_idx": "246",
"end_idx": "249",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "SCC"
},
{
"begin_idx": "796",
"end_idx": "799",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "SCC"
},
{
"begin_idx": "1247",
"end_idx": "1250",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "SCC"
},
{
"begin_idx": "1413",
"end_idx": "1416",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "SCC"
},
{
"begin_idx": "41",
"end_idx": "82",
"entity_id": "D016108",
"entity_type": "Disease",
"text_name": "dominant dystrophic epidermolysis bullosa"
},
{
"begin_idx": "152",
"end_idx": "193",
"entity_id": "D016108",
"entity_type": "Disease",
"text_name": "dominant dystrophic epidermolysis bullosa"
},
{
"begin_idx": "324",
"end_idx": "356",
"entity_id": "D016108",
"entity_type": "Disease",
"text_name": "dystrophic epidermolysis bullosa"
},
{
"begin_idx": "358",
"end_idx": "362",
"entity_id": "D016108",
"entity_type": "Disease",
"text_name": "RDEB"
},
{
"begin_idx": "433",
"end_idx": "437",
"entity_id": "D016108",
"entity_type": "Disease",
"text_name": "RDEB"
},
{
"begin_idx": "868",
"end_idx": "874",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "1153",
"end_idx": "1159",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "868",
"end_idx": "874",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "868",
"end_idx": "874",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
}
] | [
{
"begin_idx": "669",
"end_idx": "673",
"entity_id": "C535956",
"entity_type": "Disease",
"text_name": "DDEB"
},
{
"begin_idx": "796",
"end_idx": "799",
"entity_id": "D002294",
"entity_type": "Disease",
"text_name": "SCC"
}
] | [
"COL7A1",
"COL7A1"
] | [
"DDEB",
"SCC"
] |
10233369 | Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation. | A high prevalence of a common mutation in the Hfe gene (C282Y) has recently been reported in patients with the factor V Leiden mutation and a history of thrombosis. The aim of this study was to estimate the relative risk of venous thromboembolism in a large case-control study. 56/481 patients (11.6%) and 57/497 controls (11.5%) were heterozygous for the C282Y allele giving an odds ratio of 1.02 (95%CI 0.69-1.51). 12/81 patients with the factor V Leiden mutation were heterozygous for the C282Y allele compared to 1/13 controls, odds ratio 2.09 (95%CI 0.25-17.6). An analysis of a further group of patients and controls selected for the factor V Leiden mutation did not indicate a higher prevalence of the C282Y allele in symptomatic patients, odds ratio 0.17 (95%CI 0.34-0.81). This study does not support the hypothesis that the C282Y allele is an additional risk factor for venous thrombosis in patients with the factor V Leiden mutation. | [
{
"begin_idx": "266",
"end_idx": "276",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "993",
"end_idx": "1010",
"entity_id": "D019851",
"entity_type": "Disease",
"text_name": "venous thrombosis"
},
{
"begin_idx": "58",
"end_idx": "85",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary haemochromatosis"
},
{
"begin_idx": "8",
"end_idx": "30",
"entity_id": "D054556",
"entity_type": "Disease",
"text_name": "venous thromboembolism"
},
{
"begin_idx": "337",
"end_idx": "359",
"entity_id": "D054556",
"entity_type": "Disease",
"text_name": "venous thromboembolism"
},
{
"begin_idx": "224",
"end_idx": "239",
"entity_id": "2153",
"entity_type": "Gene",
"text_name": "factor V Leiden"
},
{
"begin_idx": "554",
"end_idx": "569",
"entity_id": "2153",
"entity_type": "Gene",
"text_name": "factor V Leiden"
},
{
"begin_idx": "753",
"end_idx": "768",
"entity_id": "2153",
"entity_type": "Gene",
"text_name": "factor V Leiden"
},
{
"begin_idx": "1032",
"end_idx": "1047",
"entity_id": "2153",
"entity_type": "Gene",
"text_name": "factor V Leiden"
},
{
"begin_idx": "86",
"end_idx": "89",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "Hfe"
},
{
"begin_idx": "159",
"end_idx": "162",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "Hfe"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "86",
"end_idx": "89",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "Hfe"
},
{
"begin_idx": "1032",
"end_idx": "1047",
"entity_id": "2153",
"entity_type": "Gene",
"text_name": "factor V Leiden"
}
] | [
{
"begin_idx": "8",
"end_idx": "30",
"entity_id": "D054556",
"entity_type": "Disease",
"text_name": "venous thromboembolism"
},
{
"begin_idx": "58",
"end_idx": "85",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary haemochromatosis"
}
] | [
"Hfe",
"factor V Leiden"
] | [
"venous thromboembolism",
"hereditary haemochromatosis"
] |
10233432 | Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. | Glanzmann's thrombasthenia (GT) arises from a qualitative or quantitative defect in the GPIIb-IIIa complex (integrin alphaIIbbeta3), the mediator of platelet aggregation. We describe a patient in whom clinical and laboratory findings typical of type I GT were found together with a second pathology involving neurological and other complications symptomatic of tuberous sclerosis. Analysis of platelet proteins by Western blotting revealed trace amounts of normally migrating GPIIb and equally small amounts of GPIIIa of slightly slower than normal migration. Flow cytometry confirmed a much decreased binding to platelets of monoclonal antibodies to GPIIb, GPIIIa or GPIIb-IIIa, and an antibody to the alphav subunit also showed decreased binding. Nonradioactive PCR single-strand conformation polymorphism analysis followed by direct sequencing of PCR-amplified DNA fragments showed a homozygous point mutation (T to C) at nucleotide 1722 of GPIIIa cDNA and which led to a Cys542-->Arg substitution in the GPIIIa protein. The mutation gave rise to a HinP1 I restriction site in exon 11 of the GPIIIa gene and allele-specific restriction enzyme analysis of family members confirmed that a single mutated allele was inherited from each parent. This amino acid substitution presumably changes the capacity for disulphide bond formation within the cysteine-rich core region of GPIIIa and its study will provide new information on GPIIb-IIIa and alphavbeta3 structure and biosynthesis. | [
{
"begin_idx": "255",
"end_idx": "275",
"entity_id": "D001791",
"entity_type": "Disease",
"text_name": "platelet aggregation"
},
{
"begin_idx": "78",
"end_idx": "104",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "Glanzmann's thrombasthenia"
},
{
"begin_idx": "106",
"end_idx": "132",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "Glanzmann's thrombasthenia"
},
{
"begin_idx": "134",
"end_idx": "136",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "358",
"end_idx": "360",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "GT"
},
{
"begin_idx": "467",
"end_idx": "485",
"entity_id": "D014402",
"entity_type": "Disease",
"text_name": "tuberous sclerosis"
},
{
"begin_idx": "194",
"end_idx": "199",
"entity_id": "3674",
"entity_type": "Gene",
"text_name": "GPIIb"
},
{
"begin_idx": "582",
"end_idx": "587",
"entity_id": "3674",
"entity_type": "Gene",
"text_name": "GPIIb"
},
{
"begin_idx": "757",
"end_idx": "762",
"entity_id": "3674",
"entity_type": "Gene",
"text_name": "GPIIb"
},
{
"begin_idx": "774",
"end_idx": "779",
"entity_id": "3674",
"entity_type": "Gene",
"text_name": "GPIIb"
},
{
"begin_idx": "1534",
"end_idx": "1539",
"entity_id": "3674",
"entity_type": "Gene",
"text_name": "GPIIb"
},
{
"begin_idx": "40",
"end_idx": "46",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "617",
"end_idx": "623",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "764",
"end_idx": "770",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "1050",
"end_idx": "1056",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "1114",
"end_idx": "1120",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "1201",
"end_idx": "1207",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "1481",
"end_idx": "1487",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "40",
"end_idx": "46",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
},
{
"begin_idx": "1481",
"end_idx": "1487",
"entity_id": "3690",
"entity_type": "Gene",
"text_name": "GPIIIa"
}
] | [
{
"begin_idx": "78",
"end_idx": "104",
"entity_id": "D013915",
"entity_type": "Disease",
"text_name": "Glanzmann's thrombasthenia"
},
{
"begin_idx": "255",
"end_idx": "275",
"entity_id": "D001791",
"entity_type": "Disease",
"text_name": "platelet aggregation"
}
] | [
"GPIIIa",
"GPIIIa"
] | [
"Glanzmann's thrombasthenia",
"platelet aggregation"
] |
10234007 | Altered formation of hemichannels and gap junction channels caused by C-terminal connexin-32 mutations. | Hexamers of connexins (Cxs) form hemichannels that dock tightly in series via their extracellular domains to give rise to gap junction channels. Here we examined the ability of a variety of C-terminal Cx32 mutations, most of which have been identified in X-linked Charcot-Marie-Tooth disease, to form hemichannels and to complete gap junction channels using the Xenopus oocyte system. First, we show that undocked wild-type Cx32 hemichannels at the plasma membrane can be detected as opening channels activated by depolarization. We have been able to estimate the efficiency of assembly of complete channels by measuring the time-dependent incorporation of preformed hemichannels into gap junction channels after cell-to-cell contact. These data offer strong evidence that hemichannels are the direct precursors of gap junction channels. Of 11 Cx32 mutants tested, a group of 5 mutations prevented the formation of functional hemichannels at the cell surface, whereas 4 mutations were fully able to form precursors but reduced the ability of hemichannels to assemble into complete channels, and 2 mutants formed channels normally. The data revealed that a minimum length of human Cx32 including the residue Arg-215 is required for the expression of hemichannels at the cell surface and that the efficiency of hemichannel incorporation into complete channels decreased gradually with the progressive shortening of the cytoplasmic C-terminal domain. | [
{
"begin_idx": "359",
"end_idx": "395",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "X-linked Charcot-Marie-Tooth disease"
},
{
"begin_idx": "81",
"end_idx": "92",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "connexin-32"
},
{
"begin_idx": "528",
"end_idx": "532",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "948",
"end_idx": "952",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "1284",
"end_idx": "1288",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
},
{
"begin_idx": "305",
"end_idx": "309",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "Cx32"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "81",
"end_idx": "92",
"entity_id": "2705",
"entity_type": "Gene",
"text_name": "connexin-32"
}
] | [
{
"begin_idx": "359",
"end_idx": "395",
"entity_id": "C535919",
"entity_type": "Disease",
"text_name": "X-linked Charcot-Marie-Tooth disease"
}
] | [
"connexin-32"
] | [
"X-linked Charcot-Marie-Tooth disease"
] |
10234502 | Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. | Cowden disease (CD) is characterised by multiple hamartomas in a variety of tissues. The pathological hallmark is the presence of a number of trichilemmomas. Several neurological symptoms are also part of CD with megalencephaly and Lhermitte-Duclos disease (LDD) as the most important features. Early recognition of CD patients is important because of the increased risk of developing malignancies. Breast cancer is the most frequent malignancy, but also urogenital, digestive tract, and thyroid cancers are found with higher frequencies. CD was localised to chromosome 10q23 and the PTEN gene (also known as MMAC1 or TEP1) was shown to be involved. Germline mutations were identified in both familial and sporadic CD patients. We identified eight PTEN mutations, of which seven were novel, in 13 CD patients. Combined with previous data we have identified 17 independent CD mutations. Gross DNA alterations in CD patients were not detected. Genotype-phenotype relations are discussed. The only correlation suggested to exist is that missense mutations are not detected in LDD patients. However, larger numbers are needed to confirm this. Association of PTEN mutations and the occurrence of malignant breast disease found in an earlier study cannot be confirmed. Clinical features of five CD patients without a PTEN mutation in the coding sequence do not differ from CD patients with a PTEN mutation. Furthermore, it is likely that we have identified the majority of CD patients in the Netherlands. From this we estimate that CD has a prevalence of about 1 in 250,000 in the Dutch population with a low mutation frequency. | [
{
"begin_idx": "1295",
"end_idx": "1319",
"entity_id": "D001941",
"entity_type": "Disease",
"text_name": "malignant breast disease"
},
{
"begin_idx": "503",
"end_idx": "516",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "Breast cancer"
},
{
"begin_idx": "38",
"end_idx": "52",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Cowden disease"
},
{
"begin_idx": "104",
"end_idx": "118",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Cowden disease"
},
{
"begin_idx": "120",
"end_idx": "122",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "144",
"end_idx": "163",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "multiple hamartomas"
},
{
"begin_idx": "309",
"end_idx": "311",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "336",
"end_idx": "360",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Lhermitte-Duclos disease"
},
{
"begin_idx": "362",
"end_idx": "365",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "LDD"
},
{
"begin_idx": "420",
"end_idx": "422",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "643",
"end_idx": "645",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "797",
"end_idx": "821",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "familial and sporadic CD"
},
{
"begin_idx": "901",
"end_idx": "903",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "976",
"end_idx": "978",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1015",
"end_idx": "1017",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1177",
"end_idx": "1180",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "LDD"
},
{
"begin_idx": "1393",
"end_idx": "1395",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1471",
"end_idx": "1473",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1571",
"end_idx": "1573",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1630",
"end_idx": "1632",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "489",
"end_idx": "501",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "malignancies"
},
{
"begin_idx": "538",
"end_idx": "548",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "malignancy"
},
{
"begin_idx": "270",
"end_idx": "291",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neurological symptoms"
},
{
"begin_idx": "592",
"end_idx": "607",
"entity_id": "D013964",
"entity_type": "Disease",
"text_name": "thyroid cancers"
},
{
"begin_idx": "317",
"end_idx": "331",
"entity_id": "D058627",
"entity_type": "Disease",
"text_name": "megalencephaly"
},
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "688",
"end_idx": "692",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "713",
"end_idx": "718",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "MMAC1"
},
{
"begin_idx": "852",
"end_idx": "856",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "1258",
"end_idx": "1262",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "1415",
"end_idx": "1419",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "1490",
"end_idx": "1494",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "722",
"end_idx": "726",
"entity_id": "7011",
"entity_type": "Gene",
"text_name": "TEP1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "713",
"end_idx": "718",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "MMAC1"
},
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
}
] | [
{
"begin_idx": "336",
"end_idx": "360",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Lhermitte-Duclos disease"
},
{
"begin_idx": "1295",
"end_idx": "1319",
"entity_id": "D001941",
"entity_type": "Disease",
"text_name": "malignant breast disease"
}
] | [
"MMAC1",
"PTEN"
] | [
"Lhermitte-Duclos disease",
"malignant breast disease"
] |
10234611 | Molecular heterogeneity of Krabbe disease. | Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive neurodegenerative disorder that affects both the central and peripheral nervous system due to an enzymatic defect of galactocerebrosidase (GALC). Following its cloning, many mutations in the galactocerebrosidase gene have been reported, but the correlation between phenotype and genotype was not clear in many cases. In this study we further investigated the molecular defects in another 10 patients (6 Japanese and 4 non-Japanese), using cultured skin fibroblasts, and found 10 mutations, of which 8 were novel, including a nonsense mutation (W647X) and 7 missense mutations (G43R, S52F, T262I, Y319C. W410G, R515H, T652R) in the coding region. Some phenotype-specific mutations were found but the other mutations were private. Mutations reported so far have been distributed over the whole GALC gene and it is difficult to speculate on functional domains of the GALC protein and phenotypically specific regions. | [
{
"begin_idx": "27",
"end_idx": "41",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "Krabbe disease"
},
{
"begin_idx": "43",
"end_idx": "57",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "Krabbe disease"
},
{
"begin_idx": "59",
"end_idx": "86",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "globoid cell leukodystrophy"
},
{
"begin_idx": "211",
"end_idx": "251",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "enzymatic defect of galactocerebrosidase"
},
{
"begin_idx": "94",
"end_idx": "140",
"entity_id": "D020271",
"entity_type": "Disease",
"text_name": "autosomal recessive neurodegenerative disorder"
},
{
"begin_idx": "231",
"end_idx": "251",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "galactocerebrosidase"
},
{
"begin_idx": "253",
"end_idx": "257",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
},
{
"begin_idx": "305",
"end_idx": "325",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "galactocerebrosidase"
},
{
"begin_idx": "906",
"end_idx": "910",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
},
{
"begin_idx": "978",
"end_idx": "982",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "231",
"end_idx": "251",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "galactocerebrosidase"
},
{
"begin_idx": "978",
"end_idx": "982",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
}
] | [
{
"begin_idx": "211",
"end_idx": "251",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "enzymatic defect of galactocerebrosidase"
},
{
"begin_idx": "94",
"end_idx": "140",
"entity_id": "D020271",
"entity_type": "Disease",
"text_name": "autosomal recessive neurodegenerative disorder"
}
] | [
"galactocerebrosidase",
"GALC"
] | [
"enzymatic defect of galactocerebrosidase",
"autosomal recessive neurodegenerative disorder"
] |
10319582 | Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. | Gastric cancer is the most common cancer in Korea. Germline mutations of the E-cadherin gene have recently been identified in familial gastric cancer patients. We screened five Korean familial gastric cancer patients to investigate germline mutations of the E-cadherin gene. These patients fulfilled the following criteria: presence of at least two gastric cancer patients within first-degree relatives and one patient diagnosed before the age of 50 years. Abnormal band patterns were found in exons 6 and 10 in two familial gastric cancer patients by polymerase chain reaction-single strand conformation polymorphism analysis (probands from the SNU-G2 and SNU-G1001 families, respectively). DNA sequencing analysis of the E-cadherin gene of these two patients revealed missense mutations in each exon. The SNU-G2 proband harbored a missense mutation from aspartic acid (GAT) to glycine (GGT) at codon 244 in exon 6 of the E-cadherin gene, and the SNU-G1001 proband had a missense mutation from valine (GTG) to alanine (GCG) at codon 487 in exon 10. The SNU-G2 proband was diagnosed with gastric cancer at the age of 38; three brothers and two sisters had died of gastric cancer under the age of 50, and their mother had died of gastric cancer at the age of 63. The SNU-G1001 proband was diagnosed with gastric cancer at the age of 42 and one brother had died of gastric cancer at the age of 49. In summary, we found germline mutations of the E-cadherin gene in two of five Korean familial gastric cancer patients screened. | [
{
"begin_idx": "116",
"end_idx": "122",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "41",
"end_idx": "71",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "Korean familial gastric cancer"
},
{
"begin_idx": "82",
"end_idx": "96",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "Gastric cancer"
},
{
"begin_idx": "208",
"end_idx": "231",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancer"
},
{
"begin_idx": "259",
"end_idx": "289",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "Korean familial gastric cancer"
},
{
"begin_idx": "431",
"end_idx": "445",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "598",
"end_idx": "621",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "familial gastric cancer"
},
{
"begin_idx": "1170",
"end_idx": "1184",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1246",
"end_idx": "1260",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1311",
"end_idx": "1325",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1385",
"end_idx": "1399",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1445",
"end_idx": "1459",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1556",
"end_idx": "1586",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "Korean familial gastric cancer"
},
{
"begin_idx": "1085",
"end_idx": "1088",
"entity_id": "2678",
"entity_type": "Gene",
"text_name": "GTG"
},
{
"begin_idx": "22",
"end_idx": "32",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "159",
"end_idx": "169",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "340",
"end_idx": "350",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "805",
"end_idx": "815",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "1005",
"end_idx": "1015",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "1525",
"end_idx": "1535",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "22",
"end_idx": "32",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
},
{
"begin_idx": "159",
"end_idx": "169",
"entity_id": "999",
"entity_type": "Gene",
"text_name": "E-cadherin"
}
] | [
{
"begin_idx": "41",
"end_idx": "71",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "Korean familial gastric cancer"
},
{
"begin_idx": "116",
"end_idx": "122",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
}
] | [
"E-cadherin",
"E-cadherin"
] | [
"Korean familial gastric cancer",
"cancer"
] |
10319589 | Identification of three novel mutations in the MNK gene in three unrelated Japanese patients with classical Menkes disease. | Menkes disease is an X-linked recessive disorder of the copper membrane transport system caused by mutations to the Menkes (MNK) gene. We identified three novel mutations of the MNK gene in three unrelated Japanese patients with classical Menkes disease by analyzing reverse-transcriptase polymerase chain reaction products and genomic DNA of the MNK gene. Firstly, an insertional mutation was found, 1173 ins A, which led to a premature termination and resulted in a very immature Menkes protein. Secondly, we found a point mutation, T2763G, resulting in a leucine-to-arginine conversion, which we predicted would cause a change in the secondary structure of the Menkes protein. Finally, we identified a splicing mutation, 2317 + 5G > C, which resulted in the skipping of both exons 8 and 9 or exon 9 only, and led to a truncation of the protein. Each of these mutations is hypothesized to destroy copper-ATPase-mediated copper transport. We propose that each of these mutations in the MNK gene plays a causative role in the disease. | [
{
"begin_idx": "47",
"end_idx": "50",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "108",
"end_idx": "122",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "124",
"end_idx": "138",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "240",
"end_idx": "246",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "248",
"end_idx": "251",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "302",
"end_idx": "305",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "363",
"end_idx": "377",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "471",
"end_idx": "474",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "606",
"end_idx": "612",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "788",
"end_idx": "794",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "1111",
"end_idx": "1114",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "145",
"end_idx": "172",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked recessive disorder"
},
{
"begin_idx": "1030",
"end_idx": "1036",
"entity_id": "1769",
"entity_type": "Gene",
"text_name": "ATPase"
},
{
"begin_idx": "47",
"end_idx": "50",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "240",
"end_idx": "246",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "Menkes"
},
{
"begin_idx": "248",
"end_idx": "251",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "302",
"end_idx": "305",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "471",
"end_idx": "474",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "606",
"end_idx": "612",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "Menkes"
},
{
"begin_idx": "788",
"end_idx": "794",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "Menkes"
},
{
"begin_idx": "1111",
"end_idx": "1114",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "240",
"end_idx": "246",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "Menkes"
},
{
"begin_idx": "1030",
"end_idx": "1036",
"entity_id": "1769",
"entity_type": "Gene",
"text_name": "ATPase"
}
] | [
{
"begin_idx": "108",
"end_idx": "122",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "124",
"end_idx": "138",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
}
] | [
"Menkes",
"ATPase"
] | [
"Menkes disease",
"Menkes disease"
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.